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Maturity-onset diabetes of the young (MODY) are monogenic forms of type 2 
diabetes that are characterized by an early disease-onset, autosomal dominant inheritance, 
and defects in insulin secretion. Genetic studies have identified mutations in at least six 
genes associated with different forms of MODY. The majority of the MODY subtypes 
are caused by mutations in transcription factors that include hepatocyte nuclear factor 
(HNF)-4a, HNF-la, PDX-1, HNF-1(3, and NEURO-D1/BETA-2. In addition, genetic 
defects in the glucokinase gene, the glucose sensor of the pancreatic (3-cells, and the 
insulin gene also lead to impaired glucose tolerance. Using molecular and genetic 
approaches, we demonstrated that the MODY genes are functionally related and form an 
integrated transcriptional network that plays an essential role in development and in 
different metabolic pathways. 
C h a p t e r 1: Introduction 
The islets of Langerhans in the pancreas are specialized endocrine micro-organs 
composed of four distinct cell types: insulin-producing (3-cells (65-90%), glucagon 
producing a-cells (5-20%), somatostatin-producing 8-cells (3-10%), and pancreatic 
polypeptide producing (PP) cells (<1%). The precise interplay of these cell types results 
in the fine-tuned release of counterbalanced hormones that are important to maintain 
glucose homeostasis and plays a key role in the etiology of type 1 and type 2 diabetes 
mellitus. Type 1 diabetes is caused by an autoimmune destruction of pancreatic (3-cells. 
Type 2 diabetes accounts for =90% of all diabetes and is characterized by hyperglycemia, 
insulin resistance, and impaired insulin secretion (1, 2). 
Even though there is strong evidence that genetic factors are crucial for the 
development of NIDDM, few predisposing genes are presently known. This is due to the 
fact that the affliction is a multi-factorial polygenic disorder with unknown mode of 
inheritance. To better elucidate the molecular causes of NIDDM, a paradigm for genetic 
studies should be utilized. Maturity-onset diabetes of the young (MODY) is one such 
paradigm since the disease is monogenic (the disease is caused mutation in a single single 
gene) with high penetrance and a well-defined mode of inheritance (autosomal dominant) 
(3). Such characteristics allow for the collection of multigenerational pedigrees to 
confirm the linkage of susceptibility gene to disease. The information gathered from the 
study of MODY should also be applicable to NIDDM, allowing for a better 
understanding of its pathophysiology, risk assessment, and for the development of novel 
predictive and therapeutic approaches. 
The findings that mutations in the transcription factors, hepatocyte nuclear factor 
(HNF)-la, -1(3, -4a, pancreatic and duodenal homeobox gene-1 (PDX-1), and neurogenic 
differentiation 1 (NEUROD1) are genes that cause MODY, suggest that MODY is a 
disorder of gene expression (4-9). These transcription factors belong to a network that 
plays important roles in (3-cell development and function, and thus its impairment leads to 
islet cell dysfunction and causes MODY. In addition, this transcriptional network also 
plays a central role in regulating gene expression in the liver, kidney, and intestine, 
suggesting that patients with MODY may exhibit abnormal extra-pancreatic function. 
The identification of extra-pancreatic abnormalities in MODY patients might provide 
surrogate markers for the diagnosis of this disorder. 
The introduction will review the pathophysiology of the two major types of 
diabetes and then focusing on the function and molecular defects of different MODY 
genes and the transcriptional network that they form. In the subsequent chapters, 
molecular and genetic studies will be presented that shows the involvement of this 
transcription factor network in the different metabolic pathways of pancreatic (Chapters 
2-5) and extra-pancreatic (Chapters 6 and 7) tissues. 
Diabetes Mellitus: 
Diabetes mellitus refers to a variety of metabolic syndromes with a common 
feature of elevated plasma glucose levels (1, 2). There are 3 ways to diagnose diabetes 
and must be reconfirmed on a different day by any one of the 3 methods (10): 1) 
Symptoms of diabetes (polyuria, polydipsia, and unexplained weight loss) in addition to 
casual plasma glucose level > 200mg/dl. Casual is defined as any time of the day. 2) 
Fasting plasma glucose (no caloric intake for at least 8 hours) > 126 mg/dl. 3) 2 hour 
postload glucose > 200 mg/dl. There are 2 major categories of the disease, types 1 and 2. 
Type 1 diabetes, also known as insulin-dependent diabetes mellitus (IDDM), is a 
multifactorial autoimmune disease which results from the selective destruction of 
pancreatic (3-cells by autoreactive T cells (11). Both CD4 (class II MHC restricted) and 
CD8 (class I MHC restricted) T cells are involved in its pathogenesis. Extensive studies 
have not yet identified the origins of the autoreactivity in IDDM, however a number of 
candidate autoantigens have been described including insulin, glutamic acid 
decarboxylase (GAD), tyrosine phosphatase (IA-2), and heat shock protein 60 (11, 12). 
Overt diabetes develops when over 90% of pancreatic (3-cell are destroyed. Treatment of 
Type 1 diabetes is mostly based on daily self injection of insulin, but the long term 
diabetic complications including retinopathy, nephropathy, and neuropathy are not 
prevented. Transplantation of insulin producing islet cells may represent a cure, however 
lack of sufficient donor organs limits its potential. A novel way to generate a renewable 
souorce of functional islets-like structures to restore endocrine pancreatic function in type 
1 diabetic patients is described in chapter 5. 
Type 2 diabetes (NIDDM) is a clinically heterogeneous disorder for which 
susceptibility is determined by both environmental and genetic factors. The mechanisms 
leading to hyperglycemia and its complications remain largely unknown. Consequently, 
the usual treatments often fail to induce adequate glucose control and is a major public 
health problem affecting about 6-7% of the population and is the sixth leading cause of 
death in the US in 1997 (13). Diabetes occurs in all populations and age groups but is 
increasing in prevalence in the elderly, African Americans, Hispanics, Native Americans, 
and Asians (14). The diabetic complications including retinopathy, nephropathy, 
neuropathy, and cardiovascular disease cause enormous human suffering. While the cost 
of human suffering is immeasurable, the health care cost due to NIDDM reaches 105 
billion dollars annually, involves 10% of all US health care spending and 25% of 
Medicare dollars (15). 
In a non-diabetic individual, plasma glucose levels are maintained in a very 
narrow range (80-120 mg/dL) despite variations in nutrient uptake. Normal glucose 
homeostasis depends on four factors (16): 1) insulin sensitivity: the ability of cells to take 
up glucose in the presence of insulin; 2) glucose sensitivity: the ability of cells to take up 
glucose in the absence of insulin; 3) first and second phase insulin secretion: the ability of 
the pancreatic (3-cells to elicit both first and second phase insulin release. First phase 
insulin secretion lasts approximately 10 minutes with the maximum insulin release at 3-5 
minutes after glucose load. Second phase insulin release is more prolonged and lasts as 
long as glucose levels remain elevated; 4) counter-regulatory hormones: counter-
regulatory hormones such as glucagon must balance the anabolic effects of insulin to 
achieve glucose homeostasis. 
Pathophysiologically, insulin resistance and insulin deficiency are the two major 
defects that cause diabetes. Insulin resistance, the decreased response of peripheral 
tissues to insulin, usually precedes overt diabetes. Reduced capacity of insulin stimulated 
glucose uptake in muscle and in fat appears to be the primary defect. Insulin resistance in 
fat results in increased lipolysis and elevated plasma fatty acid levels, which further 
accelerates the progression of insulin resistance by reducing glucose uptake in muscle 
and liver. To cope with insulin resistance, (3-cell mass increases to provide sufficient 
insulin to maintain glucose homeostasis. At some point, the (3-cells can no longer 
compensate, failing to respond appropriately to elevated glucose levels. This presumably 
reflects a reduced capacity to adequately maintain or expand 3-cell mass to meet the 
progressively worsening of insulin resistance. In this situation, first phase insulin 
secretion is lost, but the second phase insulin release is partially preserved. Eventually, 3-
cells severely decompensate, leading to the deterioration of glucose homeostasis, loss of 
both first and second phase insulin secretion, and complete metabolic decompensation 
with severe hyperglycemia and ketosis (17). The different metabolic stages of type 2 
diabetes is diagrammed in figure 1-1. 
Since insulin resistance and impaired insulin secretion are the key metabolic 
defects in type 2 diabetes, identification of the genetic components involved in insulin 
signaling, insulin secretion, and 3-cell development are necessary towards a molecular 
understanding of the disease. However, because type 2 diabetes is clinically 
heterogeneous with a complex inheritance pattern, few predisposing genes to type 2 
diabetes are presently known. Specific genetic defects have been identified for several 
uncommon monogenic subtypes of NIDDM including MODY. 
Maturity-Onset Diabetes of the Young (MODY) 
Although in most cases, type 2 diabetes appears to be a multi-factorial polygenic 
disorder, monogenic forms such as maturity-onset diabetes of the young (MODY) have 
been identified. MODY is a clinically heterogeneous disease that is characterized by an 
autosomal dominant inheritance and an early disease onset, usually before 25 years of age 
(3). In contrast to late-onset forms of type 2 diabetes in which 3-cell defects develop as a 
result of insulin resistance, MODY is caused by a primary defect in pancreatic 3-cell 
function and impaired glucose-stimulated insulin secretion (GSIS) (3). Using genetic 
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linkage and candidate gene approaches, mutations in genes on chromosome 2, 7, 12. 13, 
19, and 20 have been linked to MODY and collectively may represent up to 5% of all 
patients with type 2 diabetes (18, 19). The gene on chromosome 7 (MODY2) encodes 
the glycolytic enzyme glucokinase (Gck) which plays a key role in generating the 
metabolic signal for insulin secretion and integrating hepatic glucose uptake (20). The 
genes on chromosome 20 (MODY1), 12 (MODY3), 19 (MODY5), 13 (MODY4), and 2 
(MODY6) are caused by mutations in transcription factors HNF-4a, HNF-1 a, HNF-1 p, 
PDX-1, and NeuroDl respectively (4-6, 8, 9, 21). In addition to their expression in 
pancreatic (3-cells, these genes are also expressed in the liver, kidney, and intestine. 
Therefore, abnormalities in extra-pancreatic might also be appreciated in some forms of 
MODY. The molecular basis as well as the clinical features of MODY genes are 
summarized in table 1-1 and described further below. 
MODY1 (Hepatocyte Nuclear Factor-4a) 
HNF-4a is a member of the superfamily of ligand-dependent transcription factors. 
It contains a zinc finger region (amino acids 48 to 128) and binds DNA as a homodimer. 
HNF-4cc contains two transactivation domains, designated AF-1 and AF-2. AF-1 of 
transcription. The AF2 transactivation domain of HNF-4a, spanning amino acid residues 
128-366, include the dimerization interface and a putative ligand binding domain. An 
HNF-4a promoter region named P2 is the major regulatory site for islet specific HNF-4a 
transcription. This enhancer element is located approximately 46 kb upstream of the 
previously identified PI promoter of the HNF-4a gene and contains binding elements for 
HNF-la and PDX-1 (22, 23). 
HNF-4a plays a critical role in development, cell differentiation, metabolism and 
is essential for the normal function of visceral endoderm, liver, intestine, kidney, and 
pancreatic islets (24, 25). The MODY1 locus was mapped to chromosome 20q (20ql2-
ql3.1) and includes the gene encoding HNF-4a. Clinical studies demonstrated that loss-
of-function mutation in HNF-4a cause MODY by compromising (3-cell function. 
Prediabetic subjects with HNF-4ot mutations have normal sensitivity to insulin and first-
phase insulin responses to intravenous glucose (26). However, compared with normal 
subjects, MODY1 patients exhibit a decrease in absolute amplitude of insulin secretory 
oscillations and reduced insulin secretion rates in response to intravenous glucose 
infusions as blood glucose levels increase above 7mmol/l (26). Furthermore, HNF-4a 
haploinsufficiency leads to diminished glucagon secretory responses to arginine, 
suggesting a role of the MODY1 gene in cc-cell function (27). Clinically, MODY1 
patients frequently develop severe diabetes and complications, including micro- and 
macro-vascular angiopathy and peripheral neuropathy. About 30% of cases with MODY1 
require insulin therapy and the remainder are treated with oral anti-diabetic drugs. 
Molecular studies indicate that HNF-4a deficiency lead to abnormal pancreatic islet gene 
expression which results in an impairment of insulin secretion. Several genes of the GSIS 
pathway in pancreatic (3-cells are regulated by HNF-4a. They include the glucose 
transporter-2 (GLUT-2) and several enzymes of glycolysis (aldolase B, glyceraldehyde-
3-phosphate dehydrogenase, L-pyruvate kinase) (Table 1-1). Furthermore, HNF-4a is an 
upstream transcriptional regulator of HNF-la (the MODY3 gene) which itself is a 
transcriptional activator of the insulin gene (25). Together, these data suggest that 
diminished HNF-4a activity can impair GSIS by decreasing glucose entry and 
metabolism in pancreatic (3-cells as well as insulin regulated gene transcription (25). 
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Since HNF-4a is not only expressed in pancreatic (3-cells but also plays a key role in 
hepatocyte differentiation, mutations in this gene could be expected to result in 
pleiotropic phenotypes. Indeed, we show in chapter 7 that subjects with HNF-4a 
haploinsufficiency have diminished serum apolipoprotein (apo)AII, apoCIII, Lp(a) and 
triglyceride levels compared to normal controls or patients with other forms of early-
onset diabetes (28). 
MODY2 (Glucokinase) 
The phosphorylation of glucose at the sixth carbon position is the first step in 
glycolysis and is catalyzed by a family of enzymes called hexokinases. Glucokinase 
(GCK), expressed mainly in the liver and endocrine pancreas, is a unique member of this 
family. In contrast to hexokinases 1, 2, and 3, GCK (hexokinase 4) is characterized by a 
high substrate specificity for glucose, a high Km of about lOmM (versus 0.1-0.001mM 
for the other hexokinases), and a lack of inhibition by metabolites such as glucose 6-
phosphate or glucose 1,6 bisphosphate. These unique biochemical properties allow GCK 
to serve as the glucose sensor of the pancreatic (3-cell by integrating glucose metabolism 
and insulin secretion (20). Impairment in the enzymatic activity of mutant GCK leads to 
decreased glycolytic flux in pancreatic (3-cells (29). This translates in vivo as a rightward 
shift in the dose response curve relating blood glucose and insulin secretion rates (ISR) 
obtained during a graded intravenous glucose infusion. Average ISRs over a glucose 
range between 5 and 9 mM are 61% lower in MODY2 subjects than in control subjects 
(29). The release of insulin in response to arginine is preserved, indicating that the insulin 
secretion defect in MODY2 patients is due to glucose sensing. Complete loss of GCK 
activity in subjects with homozygous mutations in the GCK gene (T228M and M210K) 
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cause neonatal diabetes, a rare form of diabetes that requires insulin therapy within the 
first month of life (30). An activating GCK mutation (V455M) that causes a leftward 
shift of the dose-response curve relating blood glucose and insulin secretion rates has 
been reported to cause autosomal dominant familial hyperinsulinism (31). These genetic 
findings confirm the importance of GCK as a critical regulator for insulin secretion in 
pancreatic (3-cells. 
Gck-deficient mice are an excellent animal model to study the genetic defect in 
humans. Mice that lack Gck activity die perinatally with severe hyperglycemia and 
phenotypically resemble rare forms of neonatal diabetes. Heterozygous mice have 
elevated blood glucose levels and reduced insulin secretion. Expression of Gck in (3-cells 
in the absence of expression in the liver can rescue Gck null mice, providing strong 
evidence for the critical need of (3-cells Gck in glucose sensing and for maintaining 
normal glucose levels (32). 13C nuclear magnetic resonance spectroscopy studies have 
revealed that a hepatic glucose cycling defect also contributes to the molecular etiologies 
of the MODY2 phenotype. MODY 2 patients have decreased net accumulation of hepatic 
glycogen and augmented hepatic gluconeogenesis after meals (33). These results suggest 
that in addition to the altered (3-cell function, abnormalities in liver glycogen metabolism 
play an important role in the pathogenesis of hyperglycemia in patients with GCK-
deficient diabetes (Table 1-1) (33). 
Fetal insulin secretion in response to maternal glycemia is an important 
determinant for intrauterine growth. Glucose sensing defects in pancreatic (3-cells, caused 
by a heterozygous mutation in the GCK gene, reduce fetal growth and birth weight in 
addition to causing hyperglycemia after birth (34). The inheritance of a GCK mutation by 
the fetus results in a reduction of birth weight of 521 g (p - 0.0002) compared to 
unaffected sibs (34). Maternal hyperglycemia due to a GCK mutations results in a mean 
increase in birth weight of 601 g (P = 0.001) (34). Since glucose, but not insulin crosses 
the placenta, it is likely that these changes in birth weight reflect changes in fetal insulin 
secretion that are influenced directly by the fetal genotype and indirectly, through 
maternal hyperglycemia, by the maternal GCAT-genotype (34). 
In contrast to MODY1 and MODY3 patients who frequently develop diabetes at 
the time of puberty, hyperglycemia in subjects with GCK mutation frequently manifest in 
the neonatal period and invariably develops before adolescence (Table 1-1) (34, 35). 
GCK deficiency is not associated with an increased incidence of diabetic complications, 
including retinopathy, neuropathy, or proteinuria, and other manifestations of the 
metabolic syndrome such as hypertension, obesity, or dyslipidemia (Table 1-1) (18, 35). 
This finding is also consistent with the low frequency of coronary heart disease seen in 
MODY2 patients. 
MODY3 (Hepatocyte Nuclear Factor-la) 
HNF-la is a homeodomain transcription factor composed of an N-terminal 
dimerization domain, a POU-homeobox DNA binding domain, and a C-terminal 
transactivation domain. HNF-la is expressed in liver, kidney, intestine, and pancreatic 
islets where it directs tissue-specific gene expression. Mice with targeted inactivation of 
the hnf-la gene have been shown to have NIDDM, dwarfism, renal Fanconi-like 
syndrome, glycogen storage disease lb and defects in bile acid and plasma HDL-
cholesterol metabolism (Chapter 6) (36-39). Pancreatic islets from Hnf-la deficient mice 
have impaired (3-cell glycolytic signaling proximal to mitochondrial oxidation (40, 41). In 
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chapter 3, we provide evidence that the glycolytic signaling impairment primarily results 
from abnormal gene expression caused by HNF-la deficiency (42) 
The gene encoding HNF-la is located on the long arm of chromosome 12 
(12q24.2) and was identified as the MODY3 gene through a combination of genetic 
linkage analysis and positional cloning (5). Mutations in the HNF-1 a gene (MODY3) are 
the most common cause of MODY and depending on the population, may account 
between 21%-73% of all MODY (43, 44). The clinical features of MODY3 are similar to 
MODY1 since HNF-la and HNF-4a regulate each other's expression. HNF-1 a 
mutations lead to (3-cell dysfunction and result in elevated fasting glycemia and glucose 
stimulated insulin secretion (GSIS) (45). Other clinical features of MODY3 include 
increased responsiveness to sulfonylureas and lower body mass index (BMI) (35, 45, 46). 
In addition to its effects on (3-cell function, HNF-la deficiency lead to decreased renal 
reabsorption of glucose (47, 48). HNF-la mutations are highly penetrant, with 63% of 
MODY3 diagnosed by the age of 25 years, 78.6% by 35 years, and 95.5% by 55 years 
(49). Subjects with HNF-la mutations have a more rapid deterioration in (3-cell function 
than MODY2 subjects (Table 1-1) (35). MODY3 patients frequently require treatment 
with oral hypoglycemic agents or insulin (35). 
MODY4 (Pancreatic and duodenal homeobox gene-1) 
Pancreatic and duodenal homeobox gene-1 (PDX-1, IPF-1) is a homeodomain 
transcription factor that was originally isolated as a regulator of the insulin and 
somatostatin genes (50-52) . PDX-1 binds as a heterodimer with the ubiquitously 
expressed homeodomain protein PBX to target sites containing a consensus TGATTAAT 
motif (53). During development, PDX-1 is initially expressed at 8.5 dpc in the dorsal and 
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ventral gut epithelium that will later develop into a pancreas. At 9.5 dpc, PDX-1 
expression marks the dorsal and ventral pancreatic buds of the gut and later is restricted 
to differentiating insulin producing (3-cells and somatostatin producing 8-cell (50-52). 
Targeted disruption of the pdx-1 gene results in a failure of the pancreas to develop (54, 
55). Furthermore, (3-cell-specific inactivation of the murine pdx-1 gene indicates that 
Pdx-1 in the adult islet is required for maintenance of the (3-cell phenotype, including 
expression of Nkx6.1, insulin, Glut-2, and Gck (56). Together, Pdx-1 appears to be a key 
regulator in early pancreas formation and later in maintaining islet pattern of hormone 
expression and normoglycemia. 
Understanding the regulation of the PDX-1 gene is of paramount importance since 
PDX-1 is an essential regulator of pancreas development and (3-cell differentiation. 
Expression of PDX-1 in the adult islet is regulated by the feed forward loop formed by 
the transcription factor HNF-la and HNF-4a as well as by the winged helix transcription 
factor HNF-3(3 (FOXA2) (Fig. 1-2) (42, 57-59). Recently, PDX-1 was found to be 
required for the expression of the fibroblast growth factor receptor-1 (FGFR1), an 
important signaling component in (3-cells, indicating that PDX-1 acts upstream of FGFR1 
signaling in (3-cells to maintain proper glucose sensing, insulin processing, and glucose 
homeostasis (60). 
The link between HNF-4a and PDX-1 is also found in humans by analyzing the 
promoter of HNF-4a. A mutation (-146T-C) in the HNF-40P2 promoter of a large 
MODY family was identified where a mutated PDX-1 binding site in the P2 promoter 
cosegregates with diabetes (LOD score of 3.25) (22). This mutation lead to decreased 
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binding activity of PDX-1 to this site and reduced transcriptional activity. These data 
suggest that PDX-1 is an important activator of HNF-4a expression in pancreatic (3-cells. 
PDX-1 mutations are rare and most of the clinical findings of MODY4 are based 
on studies of a single family. Stoffers et al. (1997) identified a single nucleotide deletion 
within codon 63 (Pro63fsdelC) of the human PDX-1 gene in a patient with pancreatic 
agenesis. This patient inherited the mutant allele from his parents who were heterozygous 
for the same mutation (6). Heterozygous family members have early-onset diabetes 
(range, 17 to 67 years) (7). The point deletion leads to an out-of-frame protein 
downstream of the PDX-1 transactivation domain, resulting in a non-functional protein 
lacking the homeodomain that is essential for DNA binding (6). Expression studies of the 
mutant PDXl(Pro63fsdelC) protein in eukaryotic cells revealed a second PDX-1 isoform 
that resulted from an internal translation initiating at an out-of-frame AUG (21). The 
reading frame crosses over to the wildtype PDX-1 reading frame at the site of the point 
deletion just carboxy-proximal to the transactivation domain, resulting in a second PDX1 
isoform that contains the COOH-terminal DNA-binding domain but lacks the amino-
terminal transactivation domain (21). This terminal domain PDX-1 isoform may inhibit 
the transactivation functions of wildtype PDX-1, suggesting that a dominant negative 
mechanism may contribute to the development of diabetes in individuals with this 
mutation. Six affected members in this pedigree had severe impairment of insulin 
secretion during a hyperglycemic clamp study (61). However, none of the family 
members carrying the PDX-1 (Pro63fsdelC) mutation showed ketosis or other indications 
of severe insulin deficiency (7). 
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M O D Y 5 (Hepatocyte Nuclear Factor-l(3) 
HNF-la and -1(3 are homologous proteins belonging to a large superfamily of 
homeodomain-containing transcription factors. As such, HNF-1(3 is structurally similar to 
HNF-la with an N-terminal dimerization domain, a POU-homeobox DNA binding 
domain, and a C-terminal transactivation domain (62). HNF-la and -1(3 bind to DNA as 
homo- and/or heterodimers. The HNF-1 genes have an overlapping tissue distribution but 
HNF-la/HNFl(3 ratios differ from one organ to another with HNF-la being the 
predominant form in the liver and HNF-1(3 the major form in the kidney. Inactivation of 
the hnf-1 /3 gene in mice results in early embryonic lethality by day 7.5 of development. 
Hnf-1 (3-deficient embryos exhibit an abnormal extraembryonic region, poorly organized 
ectoderm, and no discernible visceral endoderm (62, 63). 
The gene encoding HNF-1(3 maps to chromosome 17q (17cen-q21.3) and genetic 
variation in this gene is responsible for several human disorders including MODY5, 
familial hypoplastic glomerulocystic kidney disease (renal cysts), and female genital 
abnormalities (vaginal aplasia with rudimentary uterus and bicornuate uterus) (8, 64-68). 
In contrast to other MODY types, patients with mutations in the HNF-1 fi gene have early 
and rapidly progressing familial hypoplastic glomerulocystic kidney disease different 
from the diabetic nephropathy in type 1 or type 2 diabetes. HNF-1 (3 mutations are rare 
causes of MODY and only six MODY5 families have so far been reported. MODY5 
develops early in life (range 10-25 years) and ultimately require insulin replacement 
therapy to control hyperglycemia (Table 1-1). 
MODY6 (neurogenic differentiation-1) 
NEUROD1/BETA2 belongs to the basic helix-loop-helix (bHLH) family of 
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transcription factors that is involved in determining cell type during development (69). 
NeuroDl is composed of a bHLH DNA binding domain and a C-terminal transactivation 
domain that interacts with the cellular co-activator p300 and CBP. It was first isolated on 
the basis of its ability to activate the transcription of the insulin gene (69, 70). NEUROD1 
is expressed in pancreatic islets, intestine, and the brain (69). Mice deficient for Neuro-
Dl function have abnormal islet morphology, overt diabetes, and die shortly after birth 
(71). 
Mutations in the NEUROD1 gene have recently been reported as being associated 
with diabetes in two families with autosomal dominant inheritance (9). The first family 
carries a missense mutation (G to T transversion) causing a substitution of Arg to Leu 
(R111L) in the proximal bHLH domain and thereby, abolishes its DNA binding activity 
(9). The second mutation in the NEUROD1 gene consists of an insertion of a cytosine 
residue in a polyC tract in codon 206 (206+C) (9). NeuroD(H206fsinsC) gives rise to a 
truncated polypeptide lacking the C-terminal transactivation domain, a region that 
associates with the co-activators CBP and p300 (72, 73). This mutant retains its ability to 
bind to DNA, however, it has lost its ability to activate transcription through the deletion 
of the protein domain that interacts with co-activator p300 (9). The clinical profile of 
patients with this truncated protein is more severe and shares clinical features of MODY 
such as non-obese diabetes, low endogenous insulin secretion ((3-cell dysfunction) and 
early age of onset (range 17-56 years) (9). Therefore, mutations in NEUROD1 may result 
in another subtype of MODY. 
MODY-X 
Mutations in GCK and in islet enriched transcription factors indicate that MODY 
is the result of abnormal gene expression involving effectors of glucose homeostasis. 
Additional MODY genes (MODY-X) may exist since there are families in which MODY 
does not co-segregate with markers tightly linked any of the known MODY loci. MODY-
X may account for approximately 15% of Europeans and up to 80% of Japanese patients 
with the clinical diagnosis of MODY (15). Several mutations in genes involved in 
glucose metabolism including islet-brain-1 (IB-1, an inhibitor of JNK pathway for 
optimal insulin secretion), islet-1 (ISL-1, an islet enriched transcription factor required 
for (3-cell development and function), and insulin were found to segregate with early-
onset diabetes (74, 75) (76). However, these genes must be further characterized both 
genetically and clinically to determine their etiologies and assess if they might be the 
cause of MODY-X. Identification of genes responsible for MODY-X will enable a better 
understanding of the causes and pathophysiology of MODY and maybe type 2 diabetes. 
The Transcriptional Network of the Pancreatic Islet 
Numerous studies have shown that the HNFs as well as other islet enriched 
transcription factors fall into a regulatory network (Fig. 1-2). Identification of these 
transcription factors as diabetes susceptibility genes and MODY highlights their 
importance in the normal function of the endocrine pancreas. This transcription network 
is also present in extra-pancreatic organs such as the liver, and is involved in their 
differentiation and as well as in various metabolic pathways. 
In vitro studies have shown that the forkhead transcription factor HNF-3(3 is a 
transcriptional activator of PDX-1, HNF-4a, HNF-la, and HNF-3a, suggesting that 
HNF-3(3 is a master regulator of this transcriptional hierarchy (57, 59, 77). The highly 
conserved DNA binding domain of the HNF-3 proteins is similar to that of linker 
HNF-1 (3 
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Figure 1-2. Proposed model for a hierarchical transcriptional network. This 
diagram shows the transcriptional regulation of transcriptional factors essential for 
endocrine pancreatic function. Arrows show positive transcriptional regulation. Bars 
show transcriptional repression. Black color indicates the transcriptional regulation in 
the liver and/or pancreatic islets. Red color indicates the transcriptional regulation that 
has only been found in the endocrine pancreas. Abbreviations: HNF: hepatocyte 
nuclear factor, GCK: glucokinase, IAPP: islet amyloid polypeptide, GLUT-2: glucose 
transporter-2, INS: Insulin, PDX-1: pancreatic and duodenal homeobox gene-1, SHP: 
small heterodimer protein, NEURO-D1: neurogenic differentiation-1, ALDO-B: 
aldolase B, L-PK: pyruvate kinase liver isoform, PCD: pterin-4-alpha-carbinolamine 
dehydratase. 
histones HI and H5. However, unlike the linker histones that compact D N A chromatin 
and repress gene expression, HNF-3(3 have been shown to decompact DNA from the 
nucleosome and is associated with transcriptionally active chromatin (78) (79). HNF-1(3 
also occupies a preeminent position in the transcriptional network. It was shown that in 
hnf-1 ft1' visceral endoderm, the expression of Hnf-4a and Hnf-la are either markedly 
reduced or absent (62, 63). In the liver, HNF-4a regulates the expression of HNF-la, 
whereas in pancreatic (3-cells, HNF-4a and HNF-la form an auto-regulatory loop in 
which HNF-la also regulate the expression levels of HNF-4a (42, 80, 81). The 
regulatory feed-forward loop is further demonstrated with the recent identification and 
characterization of the major regulatory site (P2) for islet-specific HNF-4a expression 
which revealed a functional binding site for HNF-la (22) (82). These data suggest that a 
defect in the autoregulatory loop between HNF-4a and HNF-la may be responsible for 
the similar clinical features between MODY1 and MODY3. In addition, a functional 
PDX-1 binding site was also found in the P2 promoter, indicating that PDX-1 is a 
transcriptional activator of HNF-4a (22). Strong evidence showing that this functional 
hierarchy is also important in pancreatic (3-cells came from the finding that MODY could 
be caused by a mutation in the PDX-1 binding site of the HNF-4aP2 promoter (22). 
Recent in vitro studies demonstrated that HNF-la can bind to an evolutionarily 
conserved HNF-la binding site in the PDX-1 promoter and activate its transcription (57). 
In addition, Pdx-1 expression levels are reduced in isolated Hnf-la deficient islets, 
indicating that Hnf-la is required for normal Pdx-1 expression in pancreatic (3-cells (42). 
The importance of this transcriptional hierarchy in islet function and glucose homeostasis 
is further investigated in chapter 4 by studying the epistatic relationship between different 
transcriptional components of the network. 
A negative regulator that may be important to down-tune the activity of the 
network has been identified. Small dimerization partner (SHP-1) is an orphan nuclear 
factor of the steroid hormone superfamily that contains an AP2 domain but lacks the N-
terminal DNA binding domain (83). SHP-1 can heterodimerize with various nuclear 
hormone receptors, including HNF-4a, and inhibit their transactivation activity (84). A 
recent study showed that the expression of Shp-1 is diminished in islets of hnf-la null 
mice and this decrease is mediated secondarily by reduced expression of Hnf-4a in these 
islets (42). This report demonstrate that SHP-1 can regulate its own expression by 
inhibiting the function of its transcriptional activator HNF-4a, thus forming a negative 
feedback loop. SHP-1 may therefore serve as an important checkpoint to balance the 
activity of the islet transcriptional network (Fig. 1-2). However, additional studies are 
required to determine the physiological significance of this negative regulation. 
This transcription factor network plays an important role in glucose homeostasis 
in pancreatic (3-cells by coupling nutrient metabolism, insulin synthesis and secretion 
with electrical activity. After a meal, elevation of blood glucose leads to glucose transport 
into (3-cells by glucose transporter-2 (GLUT-2), where it enters glycolysis and is broken 
down into pyruvate. The GCK and pyruvate kinase (PK) genes encode two glycolytic 
enzymes that catalyze the rate limiting and irreversible steps in glycolysis. Pyruvate then 
enters the mitochondria and undergoes oxidative phosphorylation, leading to an increase 
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(KIR6.2). The change in membrane potential activates voltage-gated calcium channels 
and results in a rise in cytosolic calcium levels that trigger insulin release (Fig. 1-3). 
The islet enriched transcription factors controls GSIS from (3-cells at the 
following steps: 1) The transcription network regulate the entry of glucose into the (3-
cells by controlling the expression of GLUT-2, the major glucose transporter in the (3-
cells; 2) This network regulates the flux of glucose through glycolysis by regulating the 
expression of glucokinase, aldolase B, glyceraldehyde-3-phosphate dehydrogenase (1,3 
BGD) and the liver pyruvate kinase isoform (L-PK); 3) Finally, this transcription network 
activates the transcription of the insulin gene itself. The combinatorial control of (3-cell 
function by the islet enriched transcription factors generates both diversity and stringency 
for glucose homeostasis. 
Summary 
Type 2 diabetes among youth, is an emerging public health problem. Increasing 
evidence indicates that type 2 diabetes is a complex genetic disorder in which defects in 
insulin action (insulin resistance) and secretion contribute to the clinical features of the 
disease. Islet enriched transcription factors play a vital role in the normal development 
and function of the endocrine pancreas in animal models. The importance of this network 
is further underscored by its involvement in early-onset type 2 diabetes. Studying the 
pathophysiology of MODY and other early-onset diabetes of known etiology have 
provided important insights on glucose homeostasis and may provide novel insights into 
the etiology of (3-cell dysfunction in more complex, late-onset type 2 diabetes. 
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C h a p t e r 2: I m p a i r e d G l u c o s e H o m e o s t a s i s a n d N e o n a t a l 
Mortality in Hepatocyte Nuclear Factor-3oc Deficient Mice 
Introduction 
The hepatocyte nuclear factor 3 (HNF-3/FOXA) family of transcription factors in 
mammals are encoded by 3 unlinked genes designated HNF-3a, HNF-3(3, and HNF-3y. 
They all have in common a highly conserved 100 amino acid DNA-binding domain, 
which is centrally located in the HNF-3 proteins (85). The DNA-binding domain is made 
up of 3 a-helices and 2 characteristic loops (wings), resulting in the designation of this 
DNA-binding motif as the winged helix DNA binding domain that is responsible for 
monomeric recognition of specific DNA target sites (85). The structure of the highly 
conserved DNA binding domain of the HNF-3 proteins is similar to that of linker 
histones HI and H5 (85). However, unlike linker histones that compact DNA in 
chromatin and repress gene expression, HNF-3 proteins have been shown to exhibit 
nucleosome-binding properties, decompact DNA from the nucleosome and are associated 
with transcriptionally active chromatin (78, 79). In addition to its DNA-binding domain, 
HNF-3 contain 4 trans-activation domains (86) (domains II-V). 
HNF-3 transcription factors were discovered by their ability to bind to the 
promoters of the genes encoding a 1-antitrypsin and transthyretin (87). Subsequently, 
HNF-3 binding sites have been discovered in numerous genes encoding hepatic and 
pancreatic enzymes, serum proteins and hormones (88). Based on their multiple targets in 
the liver and pancreas, an important role for HNF-3 proteins in metabolism has been 
suggested. In the adult, hnf-3 genes have overlapping patterns of tissue expression 
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including gut, central nervous system, neuroendocrine cells, lung, and the liver (87, 89, 
90). During development, HNF-3(3 is expressed first, followed by sequential expression 
of HNF-3a, and HNF-3y in the definite endoderm, notochord, and floor plate of the 
neural tube (91-94). These observations suggest that in addition to their regulatory roles 
in metabolism in the adult, the HNF-3 proteins may play critical roles in the development 
of endodermal derived tissues (e.g. liver, pancreas). 
The functional significance of the HNF-3 proteins in vivo was analyzed by gene 
targeting in mice. Targeted disruption of the hnf-3(S in mice produces an embryonic lethal 
phenotype that lacks a notochord and exhibits defects in foregut and neural tube 
development (93, 95). Because of the early lethality of the homozygous mutant embryos, 
the role of Hnf-3(3 in the development of the gut, pancreas, and liver could not be 
characterized in detail. Tissue-specific deletion of hnf-3(5 in the liver during late fetal 
development (using Cre recombinase under the control of albumin promoter) have no 
effect on liver function and gene expression (96). This suggests that the main role of Hnf-
33 is to set up a developmental program, and once such a transcriptional program is 
established, the function of HNF-3(3 in the liver seems dispensable. The function of Hnf-
3(3 in pancreatic (3-cell function was addressed by tissue specific deletion of hnf-3(3 using 
the Cre-loxP recombination system. Mice that lack Hnf-3(3 specifically in pancreatic (3-
cells resemble several pathophysiological aspects of familial hyperinsulinism such as 
dysregulated insulin secretion in response to both glucose and amino acids (97). The 
inappropriate hypersecretion of insulin is due to reduced expression of ATP-sensitive 
potassium channel (Kir6.2 and Surl). the most common genes linked to familial 
hyperinsulinism (97). In addition, hnf-3/3~'' mice may also exhibit an a-cell defect since 
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the plasma glucagon levels are inappropriately low (97). Together these data show that 
HNF-3J3 is required in pancreatic islets to maintain proper circulating levels of insulin 
and glucagon for glucose homeostasis. 
In contrast to the hnf-3(3 null mice, hnf-3y deficient embryos develop normally 
and show no obvious metabolic defects. The mild phenotype of hnf-3y'~ mice can be 
explained in part by an upregulation of Hnf-3a and Hnf-3(3 (98). The role of Hnf-3a was 
analyzed in visceral endoderm derived from hnf-3a null embryonic stem (ES) cells (77). 
In this system, lack of Hnf-3a lead to an increase in the expression levels of several 
apolipoproteins and glycolytic enzymes including apolipoprotein (Apo)-Al, -All, -AIV, 
B, -CII, glucose transporter (glut)-2, aldolase B, and liver pyruvate kinase (77). In 
addition, Hnf-3a regulate the expression of early-onset diabetes genes HNF-la 
(MODY3) and HNF-4a (MODY1). Together, these data show that Hnf-3a is upstream of 
the liver and islet enriched transcription factor network that is required for both liver and 
pancreatic islet function. To test the function of Hnf-3a in vivo, we have generated mice 
lacking hnf-3a by gene targeting. We show that hnf-3a deficient mice develop a complex 
metabolic syndrome characterized by neonatal persistent hypoglycemia, hormonal 
insufficiencies, pancreatic a- and (3-cell dysfunction, and increased expression of Hnf-3a 
target genes. 
Results 
Generation of hnf-3alSu\\ Mice. 
The hnf-3a gene was disrupted in ES cells by homologous recombination using a 
targeting vector in which most of exon 2 of the hnf-3a gene was deleted and fused in 
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ES cell clone that carried the targeted allele was used to generate chimeric male animals 
that passed the mutant allele to the offspring (Fig. 2-IB). Hnf-3a heterozygous mice 
were phenotypically indistinguishable from wildtype (wt) mice and were inbred to 
produce hnf-3a'' mice. No hnf-3a mRNA could be detected in hnf-3a'1' mice by RT-
PCR analysis (Fig. 2-1C). 
Phenotypes of hnf-3 a1' Mice 
Heterozygous hnf-3a mice, indistinguishable from wt animals, were intercrossed 
to generate offsprings with genotypes of Mendelian expectations. A total of over 1000 
mice were generated and studied. The gross and histological morphologies of the gut, 
liver, and pancreas in hnf-3a'' neonates are phenotypically indistinguishable from their 
littermates suggesting normal embryonic development. The mutant newborn mice are as 
active as their littermates, exhibit normal suckling behavior and have milk in their 
stomach. However, Hnf-3oc is required for postnatal life since over 99% of hnf 3a'' mice 
die between postnatal days 2-14 (only 1 out of over 200 hnf-3a'' animals survived to 3 
month of age). 1 to 2 days postnatally, hnf-3a'' mice show signs of growth retardation 
(Fig. 2-2A, B). Although milk could be detected in the stomach throughout the life of 
hnf-3a''' mice, milk volume in the stomach was drastically decreased after postnatal day 1 
(Fig. 2-2C). Blood glucose and triglyceride levels were reduced 20-60%, whereas serum 
cholesterol was normal in 2- to 3-day old mutant mice compared with wt littermates (Fig. 
2-2D, E). 
Physiological Analysis of Hypoglycemia in hnf-3a1' Mice 
To investigate the physiological basis for postnatal persistent hypoglycemia and 
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D a y s after birth 
Figure 2-2: Phenotypes of hnf-3cd- mice 
(A) A typical litter from a cross between 
/?n/-3o;+'-mice on postnatal day 3. (B) 
Growth curves of littermate wildtype (+/+), 
heterozygous (+/-), and homozygous (-/-) 
hnf-3a mice. (C) Stomach and duodenum 
of 2 day old wildtype (+/+) and hnf-3a null (-
/-) mice. There is less milk content in the 
stomach of mutant mice after day 2 
postnatally. (D) Plasma glucose 
concentrations in newborn (0), 3-, and 5-
day old mice. Values are means±standard 
deviation. Numbers in brackets indicate 
number of animals studied. *, P<0.05, **, 
PO.005, ***, P<0.0005. 
+/ + +/- -/• 
glucagon, Cortisol, growth hormone, catecholemine (epinephrine and norepinephrine), 
and leptin that are known to regulate blood glucose concentrations. Serum insulin levels 
in mutant mice were reduced to approximately 50%, which is that found in wt mice after 
24 hours of starvation (Fig. 2-3A). Plasma Cortisol, growth hormone and catecholemine 
levels are significantly higher in hnf-3a1' mice compared to their control littermates (Fig. 
2-3B-D). These data suggest that the counter-regulatory responses to hypoglycemia of the 
pituitary gland, adrenal gland, and pancreatic (3-cells that stimulate growth hormone, 
release of corticosteroid and catecholemine, and inhibition of insulin secretion, 
respectively, appeared normal. We found that the plasma leptin levels to be significantly 
lower in the hnf-3a null mice (Fig. 2-4E). Lowered plasma leptin level may be a 
secondary phenotype, due to the fact that hnf-3a deficient mice have very little adipose 
tissue. Lastly, we found that the plasma glucagon levels were decreased approximately 
50% when compared with wt littermates (Fig. 2-3F). The paradoxical reduction in 
glucagon levels is further evident when compared to wt or heterozygous littermates that 
have been starved for 24 hours (Fig. 2-3F). 
There are several mechanisms that could account for the reduced plasma glucagon 
levels in hnf-3a''mice including abnormalities in glucagon secretion and/or synthesis. To 
test if there is a defect in pancreatic cc-cell secretory machinery, we performed in vivo 
glucagon secretion assay. Alanine, the principle endogenous aminogenic glucose 
precursor, is a potent stimulus of glucagon secretion and is used to evaluation cc-cell 
function (99-103). Increased blood glucose levels due to glucagon can be used to assay 
for the integrity of glucagon secretory machinery. Alanine (0.25g/kg) was injected 
subcutaneously into 10 day old control mice and the peak alanine response as assayed by 
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the rise in plasma glucose levels was determined to be 30 minutes post treatment (Fig. 2-
4A). Once the time interval of alanine response is determined, we treated wt, hnf-3a+/', 
and hnf-3a'' mice with alanine and measured glucose levels at 0, 15, and 30 minutes post 
treatment. We found that the rate of glucose increase is similar between mice of various 
genotypes (Fig. 2-4B). Since alanine is a gluconeogenic substrate, the rise in blood 
glucose levels may be secondary due to increased alanine concentration and not to 
increased glucagon secretion. To determine if alanine stimulated glucagon secretion 
directly, we measured plasma glucagon levels at 0 and 30 minutes post alanine treatment. 
We found that plasma glucagon levels increased at similar rate between wt and hnf-3a'' 
mice (Fig. 2-4C). These data indicate that the reduced plasma glucagon levels in hnf-3a''' 
mice are not due a defect in glucagon secretion. Furthermore, these data also suggest that 
the downstream effects of glucagon to increase blood glucose levels are not affected by 
hnf-3a deficiency. 
Gene Expression Profiles in hnf-3 a Null Mice 
To study the molecular mechanisms that are responsible for the complex 
metabolic abnormalities in hnf-3a'1' mice, we analyzed steady state mRNA levels in the 
brain, liver, gut, and pancreas of newborn (<12 hours), 3, 5, and 7 day old mice. Gene 
expression of wt, heterozygous, and null mice were assayed by using reverse 
transcriptase (RT)-PCR. Each sample contained similar amounts of mRNA, as shown by 
the equal amplification of hypoxanthine phosphoribosyl transferase (HPRT) message. 
We analyzed the expression of 126 genes that were either reported to be regulated by 
Hnf-3 transcription factors or are known to affect glucose and energy homeostasis with 
similar expression pattern as Hnf-3cc. Genes tested in the expression screen included 
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the rise in plasma glucose levels was determined to be 30 minutes post treatment (Fig. 2-
4A). Once the time interval of alanine response is determined, we treated wt, hnf-3a+'~, 
and hnf-3a'' mice with alanine and measured glucose levels at 0, 15, and 30 minutes post 
treatment. We found that the rate of glucose increase is similar between mice of various 
genotypes (Fig. 2-4B). Since alanine is a gluconeogenic substrate, the rise in blood 
glucose levels may be secondary due to increased alanine concentration and not to 
increased glucagon secretion. To determine if alanine stimulated glucagon secretion 
directly, we measured plasma glucagon levels at 0 and 30 minutes post alanine treatment. 
We found that plasma glucagon levels increased at similar rate between wt and hnf-3a'' 
mice (Fig. 2-4C). These data indicate that the reduced plasma glucagon levels in hnf-3a'' 
mice are not due a defect in glucagon secretion. Furthermore, these data also suggest that 
the downstream effects of glucagon to increase blood glucose levels are not affected by 
hnf-3a deficiency. 
Gene Expression Profiles in hnf-3a Null Mice 
To study the molecular mechanisms that are responsible for the complex 
metabolic abnormalities in hnf-3a'1' mice, we analyzed steady state mRNA levels in the 
brain, liver, gut, and pancreas of newborn (<12 hours), 3, 5, and 7 day old mice. Gene 
expression of wt, heterozygous, and null mice were assayed by using reverse 
transcriptase (RT)-PCR. Each sample contained similar amounts of mRNA, as shown by 
the equal amplification of hypoxanthine phosphoribosyl transferase (HPRT) message. 
We analyzed the expression of 126 genes that were either reported to be regulated by 
Hnf-3 transcription factors or are known to affect glucose and energy homeostasis with 
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hormones, peptide neurotransmitters and their receptors, glucose, amino acid and peptide 
transporters, transcription factors regulating metabolic pathways, enzymes of glycolysis, 
gluconeogenesis, glycogen synthesis and degradation, urea cycle, cholesterol and fatty 
acid synthesis and metabolism, intracellular storage proteins, and serum factors (the list 
of genes that were tested is in the appendix). No abnormalities in gene expression were 
detected in 3 day old mutant mice that would indicate primary defects in 
gluconeogenesis, glycogen metabolism, or fatty acid metabolism (data not shown). Thus, 
postnatal induction of mRNAs encoding gluconeogenic enzymes, glycogen breakdown, 
and fatty acid degradation enzymes are not impaired and cannot explain the 
hypoglycemia observed in these animals. 
Consistent with the plasma hormone measurements, proglucagon mRNA was 
reduced = 50% in the pancreas of hnf-3a1' mice and remained low throughout life (Fig. 2-
5A, data not shown). Hormones belonging to the same gene family such as secretin, 
gastric inhibitory peptide, vasoactive intestinal peptide, and cholecystokinin were 
unchanged. Surprising, proglucagon mRNA levels in the gut were indistinguishable in wt 
and hnf-3a''' mice, suggesting that Hnf-3cc is not required for expression of proglucagon 
transcription in intestinal L cells (Fig. 2-5B). Steady-state mRNA levels of neuropeptide 
Y (NPY) were also reduced by = 50% shortly after birth, suggesting that Hnf-3oc is 
required for transcriptional regulation of this gene. However, in contrast to pancreatic 
proglucagon mRNA levels, NPY transcription levels normalized after postnatal day 3 
(Fig. 2-6), suggesting that other transcription factors can up-regulate NPY expression in 
hnf-3a'' mice. In addition, steady-state mRNA levels of three genes not previously 
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insulin growth factor binding protein-1 were significantly increased in 5 day old mutant 
animals, and phosphofructo-2-kinase/fructose-2,6-bisphophatase (PFK-2/FBase) was 
increased 2 fold in 7 day old hnf-3a'' mice (Fig. 2-6). 
The finding of reduced glucagon mRNA transcripts in hnf-3a'' mice implies a 
previously unrecognized role for Hnf-3a in the regulation of glucagon gene expression. 
A conserved Hnf-3 binding site has been identified in the G2 element in the glucagon 
promoter (104). Hnf-3 (3 was shown to bind to the G2 site, but it repressed the activity of 
the glucagon promoter construct in transient transfection experiments. In contrast to the 
postulated negative role of Hnf-3(3 on glucagon expression, deletion of the G2 binding 
site leads to a major loss of basal glucagon reporter activity in an islet cell line, implying 
that another member of the Hnf-3 family may activate glucagon expression through the 
G2 enhancer (104). To test if Hnf-3cc can activate directly glucagon expression, we 
cloned a 1 kb rat glucagon promoter containing the G2 site and fused it upstream of a 
luciferase reporter gene (Fig. 2-5C). Transient co-transfections of Hnf-3cc with the 
glucagon reporter construct lead to a dose-dependent 6-fold activation of luciferase 
activity (Fig. 2-5C). Together, these data indicate that Hnf-3oc is a potent activator of 
glucagon transcription in vitro and in vivo. 
To determine if the glucagon insufficiency in hnf-3a null mice is caused by 
reduced glucagon levels in pancreatic a-cells, we measured total intracellular glucagon 
contents from pancreas of wt and mutant animals. Total pancreatic glucagon content of 
hnf-3 a null mice was also reduced 50% compared with wt littermates (3.2 vs. 6.4 u.g/g 
pancreas, respectively). These results suggest that a decrease in pancreatic glucagon 
content in the pancreas is the primary defect of hypoglucagonemia in hnf-3a'' mice. 
38 
The reduced total intracellular glucagon content in hnf-3 a'' mice may be caused 
by a block in pancreatic a-cell development. Pancreatic cell lineage allocation was 
assessed by looking for the presence of a- and (3-endocrine cell types using 
immunohistochemistry. Islet structure and the number of glucagon and insulin-expressing 
cells are similar in wt and mutant pancreas (Fig. 2-7). These results indicate that the 
differentiation of the endocrine pancreas is normal in mice lacking Hnf-3cc and that the 
reduced intracellular glucagon content is not due to decreased a-cell mass. 
In several knockout mouse models, targeted mutation of one transcription factor 
lead to an up-regulation of other transcription factors belonging to the same gene family 
(98, 105). In addition, we previously showed that Hnf-3cc negatively regulates the 
expression of the MODY genes Hnf-la and Hnf-4a in embryoid bodies derived from ES 
cells lacking Hnf-3a (77). In this system, we also showed that the expression of genes 
required for normal metabolism, including apolipoproteins, aldolase B, and L-pyruvate 
kinase are increased. To test whether this is true in the liver, gut, and pancreas of hnf-3a 
null mice, we measured steady-state mRNA levels of these genes. Consistent with our 
previous findings, mRNA levels of Hnf-3(3 and Hnf-3y were unchanged (data not shown). 
In contrast to the situation in embryoid bodies, there is no change in the transcript levels 
of Hnf-la and Hnf-4a or other members of the HNF- transcription network (data not 
shown). Similarly, the mRNA levels for apolipoproteins (apo -AI, -All, -AIV, -B, and 
-CII) were not affected by hnf-3 a deficiency (data not shown). 
Glucagon Signaling and Kidney Function in hnf-3a~ Mice. 
Since Hnf-3a is expressed in the liver, intestine, and kidney in addition to its 
expression in the pancreas, abnormalities in the function of these extra-pancreatic organs 
39 








Figure 2-7. Normal pancreatic morphology in hnf-3cclm Mice. Pancreatic 
tissue sections showing representative islets from 3-day old pancreata of 
wildtype and hnf-3a mutant mice. Sections were stained with antibodies against 
glucagon and insulin as described in Materials and Methods. Glucagon and 
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may contribute to hypoglycemia in hnf-3 a''mice. Glucagon is the primary hormone used 
in the neonatal period to maintain glucose homeostasis. To determine if the glucagon 
signaling pathway is intact in peripheral tissues such as the liver, we injected exogenous 
glucagon into 10 day old wt and hnf-3 a''mice and measured plasma glucose levels at 0 
and 30 minutes post treatment. We found that glucagon but not PBS increased plasma 
glucose concentration and that the rate of increase in glucose levels between wt and hnf-
3cev"mice are similar (Fig. 2-8). These data are consistant with the alanine response 
results and indicate that Hnf-3a deficiency does not impair glucagon signaling in extra-
pancreatic tissues. 
Liver glycogen is important for newborn pups as an energy source and later in life 
for glucose homeostasis (106). To investigate whether glycogen synthesis or degradation 
was impaired in the livers of hnf-3a''' animals, total liver glycogen contents were 
measured in fasted states. We determined that glycogen content was similar overall in 
mutant and wt mice, suggesting that there was no intrinsic defect in glycogen metabolism 
(data not shown). Furthermore, mutant hnf-3a mice were able to increase their hepatic 
glycogen stores after intraperitoneal glucose administration, providing further support 
that glycogen synthesis in hnf-3a''' mice is functional (data not shown). Finally, no 
differences were detected in the steady state mRNA of enzymes involved in 
gluconeogenesis (pyruvate carboxylase, phosphoenolpyruvate carboxylase, Fructose 1,6-
bisphosphatase, and glucose 6 phosphatase), and glycogen metabolism (glycogen 
phosphorylase, phosphoglucomutase, UDP-glucose pyrophosphorylase, glycogen 
synthetase). These data further validate that hnf-3a deficiency does not diminish 
downstream effects of glucagon to increase blood glucose levels including 
42 
gluconeogenesis and glycogenolysis. 
Ketone bodies are produced by the liver from free fatty acids at times of 
hypoglycemia, low insulin, and high serum glucagon concentrations. We therefore 
measured (3-hydroxybutyrate plasma concentrations to study whether hnf-3 a'1' mice 
maintain the ability to metabolically adapt to hypoglycemia by increasing fatty acid 
degradation. As expected, (3-hydroxybutyrate concentrations were moderately elevated in 
the plasma of hnf-3 a deficient mice and reached levels that were comparable to wt mice 
that had been starved for 24 hours (data not shown). 
Hnf-la null mice develop a Fanconi-like syndrome characterized by excessive 
loss of glucose and amino acids in their urine (36, 37). We therefore investigated whether 
a defect in renal reabsorption of glucose contributes to hypoglycemia in hnf-3a'' mice by 
performing a quantitative urinalysis of glucose and amino acids. No glucose was detected 
in the urine of mutant hnf-3a'' mice, and amino acid concentrations were similar to 
littermate control animals (Table 2-1). These results indicate that hypoglycemia and 
wasting of hnf-3 a'' mice cannot be explained by loss of glucose or amino acids in the 
urine. 
Exocrine pancreas insufficiency due to decreased synthesis and/or secretion of 
amylase, proteinase, and lipases can lead to chronic malabsorption and hypoglycemia. 
We therefore test whether hypoglycemia in hnf-3a'' mice might be caused by exocrine 
insufficiency. We assay the enzymatic activities of amylase, trypsin, chymotrypsin, and 
phospholipase from gut homogenate of wt and mutant mice. No significant differences 
were noted in these activities, suggesting that wasting is not caused by malabsorption due 
to decreased capacity to hydrolyze nutrients in the intestine. 
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A m i n o Acid 
T h r 
S e r 
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G l y 
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V a l 
M e t 
H e 
L e u 
T y r 
P h e 
His 
L y s 
A r g 
W i l d t y p e 































Table 2-1. Quantitative Urinalysis on Wildtype and hnfSa'- Mice. Amino acid 
was quantitated from the urine of wildtype and hnf-3a/- mice. W e found that the 
amino acid contents were similar between urine obtained from wildtype and hnf-3a 
deficient mice. The 3 letter amino acid code are shown. 
Pancreatic (3-cell Function in hnf-3 a'' Mice 
Hnf-3a is highly expressed in pancreatic (3-cells and may be a part of a 
transcriptional network that is essential for normal pancreatic (3-cell function (77). To 
assess pancreatic (3-cell function in hnf-3a'' mice, we challenged normal and mutant mice 
with glucose by parenteral administration. Three-day-old mice were given an 
intraperitoneal glucose infusion of 2 mg glucose/g total body weight and glucose and 
insulin levels were measured after 1 hour. Glucose levels were significantly elevated and 
insulin levels were markedly reduced in hnf-3 a'1' mice as compared to wt and 
heterozygous littermates (Fig. 2-9A). Because hypoglycemia and starvation can have 
adverse effects on glucose-stimulated insulin secretion, we also performed intraperitoneal 
glucose tolerance in 4- to 6-week old wt and heterozygous hnf-3a mice that have 
indistinguishable body weight from wt mice and normal blood glucose levels. We 
observe that hnf-3 et1' mice had significantly higher blood glucose levels 30 minutes after 
glucose challenge and reduced plasma insulin concentrations at 60 and 120 minutes after 
glucose challenge (Fig. 2-9B, C). These data indicate that hnf-3a haploinsufficiency 
causes a mild insulin-secretory defect and that Hnf-3a is also critical for normal 
pancreatic (3-cell function. 
Discussion 
We have used a genetic approach to study the function of Hnf-3a by generating 
mutant mice with a loss-of-function mutation in the hnf-3 a gene. Mice that lack Hnf-3a 
expression develop neonatal persistent hypoglycemia. Persistent low blood-glucose levels 
can be caused by conditions of extreme malabsorption, underproduction of glucose (liver 
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abnormalities), and overutilization of glucose because of hyperinsulinemia. The 
paradoxical reduction in circulating glucagon levels is most likely the cause of 
hypoglycemia. However, other mechanisms may contribute to the wasting syndrome 
because parenteral glucose and glucagon administration twice daily did not lead to weight 
gain or prolonged survival in hnf-3 a null mice. One of the most dramatic phenotypes in 
hnf-3a''' mice is an altered feeding behavior, as evidenced by reduced milk intake that is 
followed by malnutrition. The molecular and physiological mechanisms by which Hnf-
3a regulates food intake and participates in glucose sensing are currently not understood. 
The hypothalamus plays a major role in normal control of appetite behavior, sensing 
hypoglycemia and mediating counter-regulatory responses (107). We have found Hnf-3a 
to be highly expressed in lateral and posterior part of the hypothalamus, and thus, cannot 
rule out that the abnormal feeding behavior is caused by a central nervous system defect. 
However, we have tested the expression of hypothalamic modulators of food intake such 
as galanin, orexin, peptide YY, cholecystokinin, and proopiomelanocortin and found the 
mRNA levels to be indistinguishable between mutant and WT neonates. Interestingly, 
expression of the orexigenic peptide NPY was normal in the hypothalamus but was 
significantly reduced in the pancreas and gut of newborn and 3 day old hnf-3 a null mice. 
NPY transcripts increased after day 3 to normal levels, suggesting that elevated serum 
glucocorticoid levels and hypoinsulinemia, both known to increase NPY gene expression 
in the rat, can compensate for the transcriptional defect in NPY expression (108). 
Hypoglycemia inhibits insulin secretion and stimulates rapid increases in the 
secretion of several hormones including glucagon, growth hormone, Cortisol, and 
catechcolamines, that act in concert to increase plasma glucose concentrations (109). 
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Hnf-3a''' mice fail to respond to low blood glucose by increasing glucagon secretion. The 
glucagon gene is expressed as a prohormone in a-cells of the endocrine pancreas, L cells 
of the intestine, and in the brain stem (110). Proglucagon is then processed differentially 
to generate glucagon and glucagon-like peptide-1, which are known to be the main 
biologically active hormones of the pancreas and intestine, respectively (111). Several 
mechanisms could account for this relative glucagon insufficiency in the hnf-3a'' mice, 
including abnormalities in glucagon synthesis, glucagon secretion, and/or reduced 
number of a-cells. Hnf-3(3, a related member of the Hnf-3 forkhead transcription factor 
family, was recently shown to regulate insulin secretion (97). Hnf-3a may have a similar 
action on pancreatic a-cells to regulate glucagon secretion. Impairment in glucagon 
secretion was ruled out since Hnf-3a deficient mice could secrete glucagon in response to 
a glucagon secretagogue (alanine). Recent gene targeting experiments of other islet 
enriched transcription factors such as Pdx-1 have revealed their importance in the 
development of the endocrine pancreas. Loss of Pdx-1 expression leads to pancreatic 
agenesis and (3-cell specific abolition indicates that the Pdx-1 is required for late 
differentiation or maturation of the pancreatic (3-cells (54-56). To rule out the possibility 
that hnf-3a deficiency impairs islet a-cell development, we assessed islet cell type 
composition by immunostaining with markers for a- and (3- cells. Insulin producing (3-
cells, the predominant cell type in the islet, formed the core of the islets, whereas the less 
abundant glucagon expressing a-cells are distributed in the islet periphery. No 
differences in the ratio of a- to (3-cells were observed between wt and hnf-3 a'' mice, 
thereby ruling out a developmental effect of Hnf-3a on the endocrine pancreas. 
48 
L o w plasma glucagon levels in hnf-3a'' mice most likely reflect a defect in 
transcriptional activation of the proglucagon gene in a-cells, because mRNA levels are 
reduced shortly after birth. The results of our transient transfection analysis on the 
glucagon promoter further validate our claim. Together, our results indicate that Hnf-3a 
is an essential regulator of glucagon transcription both in vitro and in vivo. Surprisingly, 
we did not find decreased pro-glucagon mRNA levels in the intestine of hnf-3a'' mice, 
indicating that Hnf-3a is not required for transcriptional activation of proglucagon in 
intestinal L cells. 
To determine if there may be a defect in glucagon signaling in peripheral tissues 
such as the liver that is masked by glucagon insufficiency, we performed glucagon 
challenge assays. We determined that blood glucose levels raised at similar rates in both 
wt and hnf-3 a''' mice, indicating that Hnf-3a deficiency does not impair glucagon 
signaling. 
Hnf-3a is also expressed at high levels in insulin secreting pancreatic (3-cells (92, 
112, 113). To study pancreatic (3-cell function in hnf-3a null mice, we performed glucose 
tolerance tests by intraperitoneal glucose administration. Hnf-3a'' mice have markedly 
elevated glucose levels after 1 hour and significantly reduced insulin levels compared 
with littermate control mice. These results indicated that there might be an insulin 
secretory defect in pancreatic (3-cells of hnf-3 a deficient mice that is only revealed after a 
glucose challenge. Alternatively, impaired (3-cell function could be caused by an indirect 
mechanism, since continuous exposure of pancreatic islets to low glucose can impair 
insulin secretion (114). To address this, we subjected adult wt and heterozygous 
littermates that have indistinguishable fasting blood-glucose levels to an intraperitoneal 
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glucose tolerance test. Blood glucose concentrations were significantly increased, 
whereas serum insulin levels were reduced in hnf-3a+/' animals compared with wt mice 
after a glucose challenge, providing further evidence that Hnf-3a is also important for 
normal pancreatic (3-cell function. 
We have identified three genes, hexokinase-1, phosphofructo-2-kinase/fructose-
2,6-bisphosphatase, and insulin growth factor binding protein-1, that are up-regulated in 
hnf-3 a mutant mice, suggesting an inhibitory role of Hnf-3a on transcription. 
Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and insulin growth factor binding 
protien-1 were shown to contain functional Hnf-3 DNA-binding consensus sequences in 
their promoter/enhancer (115). However, changes in steady-state mRNA levels of these 
genes were only elevated after postnatal day 5, suggesting up-regulation of these 3 genes 
could be adaptive mechanisms for maximal absorption of glucose by maintaining an 
optimal glucose gradient across the intestinal epithelium. 
We did not detect alterations in gene expression in the majority of Hnf-3 target 
genes that have previously been shown to be regulated by Hnf-3a and Hnf-3(3 in visceral 
endoderm of embryoid bodies (77). We believe that transcription of these genes is 
predominately regulated by Hnf-4a and Hnf-la, which are targets of Hnf-3a in 
embryoid bodies. However, in hnf-3 a null mice, no differences in Hnf-4a and Hnf-la 
expression are observed (Fig. 2-10). Therefore, targets of Hnf-4a/Hnf-1 a are not 
affected. In addition, it is also possible that Hnf-3(3 and Hnf-3y, which are still present at 
wt levels in the hnf-3 a'' mice, can compensate for the loss of Hnf-3a without gross 
alterations in gene expression of most Hnf-3 target genes. We are currently testing this 
hypothesis by generating mice with combined allelic inactivation of Hnf-3a and Hnf-3(3. 
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Mutations in hepatocyte nuclear factors-la, -1(3, and -4a have been associated 
with pancreatic (3-cell defects resulting in maturity-onset diabetes of the young 3, 5, and 1 
respectively. In this study, we have shown that another member of this transcriptional 
network, Hnf-3a, is essential for glucose homeostasis. In contrast to the other MODY 
genes, Hnf-3a regulates glucose homeostasis by controlling glucagon expression in 
pancreatic a-cells. No mutations have been described in HNF-3a gene in humans; 
however, Hnf-3a deficient mice share remarkable similarities to several reports of 
patients with neonatal persistent hypoglycemia and glucagon deficiency (101, 116). 
Sequencing the HNF-3a gene in a patient with severe neonatal hypoglycemia did not 
reveal any functional mutations (116, 117). This result does not preclude an involvement 
of HNF-3a as a cause of other cases of persistent neonatal hypoglycemia and HNF-3a 
may still be a candidate gene for human congenital glucagon deficiency syndromes. 
C h a p t e r 3: H n f - l a Deficiency in M i c e L e a d s to A b n o r m a l 
Expression of G e n e s Involved in Pancreatic Islet D e v e l o p m e n t 
a n d M e t a b o l i s m 
Introduction 
HNF-la is a homeodomain transcription factor composed of an N-terminal 
dimerization domain, a POU-homeobox D N A binding domain, and a C-terminal 
transactivation domain (118). HNF-la is expressed in liver, kidney, intestine, and 
pancreatic islets (119). Clinical studies in humans have shown that heterozygous 
mutations in HNF-la are associated with impaired pancreatic (3-cell function that is 
characterized by impaired insulin secretion (45, 120). Surprisingly, although HNF-la is 
expressed in extra-pancreatic tissues, the majority of phenotypic abnormalities identified 
to date in M O D Y 3 patients involve pancreatic (3-cell defects (45, 120). This suggests that 
HNF-la plays an essential tissue-restricted role in pancreatic (3-cells to maintain glucose 
homeostasis. 
Mice with heterozygous mutations in hnf-la gene are phenotypically normal. 
However, analogous to the M O D Y 3 phenotype, hnf-la'' mice have severely blunted 
glucose-stimulated insulin secretion and develop overt diabetes (36, 37, 39). Previous 
physiological studies using pancreatic islets from hnf-1 cc-deficient mice showed that (3-
cell dysfuction in these animals is likely to result from its defective glycolytic signaling 
proximal to mitochondrial oxidation (40, 41). This conclusion is based on the following 
findings: (i) insulin secretion and intracellular calcium responses to glucose and 
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glyceraldehyde are reduced, (ii) glucose flux through glycolysis and the generation of 
ATP and NADH are reduced, (iii) ATP-sensitive K+-currents (KATP) in (3-cells from hnf-
la'~ mice are not suppressed by glucose but are sensitive to ATP, and (iv) mitochondrial 
substrates can suppress KATP and correct the insulin secretion defect of hnf-1 a~'~ islets. 
The results are also supported by recent studies showing reduced expression of liver 
pyruvate kinase (L-Pk) and glucose transporter 2 (Glut2) in islets of hnf-1 a'~ mice and 
downregulation of Glut-2, L-Pk and insulin in cell lines that express a dominant-negative 
form of HNF-la (81, 121). In contrast to the above reports, a recent in vitro study has 
suggested that a mitochondrial abnormalities may contribute to the (3-cell defect in HNF-
la-deficient diabetes (122). In this report, a dominant negative HNF-la, HNFla-
P291fsinsC, was expressed in insulinoma INS-1 cells and resulted in reduced expression 
levels of mitochondrial 2-oxoglutarate dehydrogenase (Ogdh) El subunit and increased 
expression of uncoupling protein 2 (Ucp2), thereby leading to impaired mitochondrial 
oxidation and consequently defective insulin secretory response (122). These inconsistent 
findings have yet to be resolved. In addition, the transcriptional control of (3-cell genes by 
HNF-la are still poorly understood. 
In this study, the molecular basis by which Hnf-la deficiency causes pancreatic 
(3-cell dysfunction was explored. We compared pancreatic islet gene expression profiles 
from wt and hnf-1 a~'~ mice instead of relying exclusively on cell culture systems. We 
found that hnf-1 a deficiency results in a pleiotrophic defect that includes dysregulation of 
glycolytic genes as well as other transcription factors of the islet transcription factor 
network. Our results localize the transcriptional defect in islets of hnf-la'~ mice to 
nutrient entry and the glycolytic pathway, and provide evidence for a wider role of Hnf-
la in the regulation of islet-enriched transcription factors that are critical for (3-cell 
differentiation than has previously been anticipated. In addition, the liver steady-state 
mRNA levels of genes that we found to be regulated by Hnf-la in the islet are 
determined. Interestingly, Hnf-la target genes in the islet including Glut-2, L-PK, neutral 
and basic amino acid transporter (NBAT) and Hnf-4a are not regulated by Hnf-la in the 
liver. Together, these results suggest that the selective pancreatic (3-cell dysfunction in 
MODY3 may stem from the tissue specific requirement for HNF-la function in 
pancreatic islets. 
Results 
Pancreatic Islet Gene Expression in hnf-la1' Mice 
In keeping with previously reported data, insulin secretory responses to glucose 
are markedly reduced in hnf-la"'" mice compared to littermate controls (40, 41). 
Methylpyruvate, an insulin secretagogue that freely permeates the mitochondrial 
membrane, can suppress ATP-dependent K+-channel activity in hnf-1 a~'~ pancreatic islets 
suggesting that the defect in glucose metabolism is upstream of mitochondria (40). To 
test which genes involved in glucose metabolism was affected by the disruption of hnf-
la, we measured the mRNA levels of glucose transporters, amino-acid transporters, and 
all glycolytic enzymes. We also measured the proximal rate limiting enzymes of 
oxidative phosphorylation, including components of the pyruvate dehydrogenase 
complex (pyruvate decarboxylase, dihydrolipoyl dehydrogenase), aconitase, isocitrate 
dehydrogenase and a-ketoglutarate dehydrogenase complex (2-oxoglutarate 
dehydrogenase, dihydrolipoyl succinyl-transferase, dihydrolipoyl dehydrogenase) as well 
as uncoupling protein-2 (Ucp-2). Furthermore, we determined the mRNA levels of the 
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sulphonylurea receptor-1 (Sur-1), ATP-dependent K+-channel (Kir6.2), prohormone 
convertase-2 and -3 (Pc2, Pc3), insulin, glucagon, somatostatin, and pancreatic peptide 
(PP). 
Hypoxanthine phosporibosyltransferase (Hprt) expression levels were determined 
to show that each sample contained equivalent amounts of mRNA. No products were 
amplified in the absence of reverse transcriptase (Hprt-RT), indicating the absence of 
genomic DNA in the mRNA samples. The cDNA of each sample was derived from one 
animal, and 5-6 animals of each genotype (hnf-1 a+/+, hnf-la*'', hnf-1 a'~) were studied. 
We first assess the expression levels of the proximal steps of nutrient stimulated insulin 
secretion, mainly entry of nutrients into pancreatic (3-cells and its breakdown by 
glycolysis. We found that the expression of genes encoding the liver isoform of pyruvate 
kinase (L-Pk), glucokinase (Gck), Glut-2, and neutral and basic amino acid transporter 
(Nbat) were significantly reduced (Fig. 3-1A). The absence of Glut-2 protein in mice that 
lack Hnf-la was also confirmed by immunohistochemistry of pancreatic sections (Fig.3-
2). The expression of other glucose (Glut-1) and amino acid (neutral amino acid 
transporter, Naat) transporters remain unchanged (Fig. 3-1 A). The expression of the 
remaining glycolytic enzymes including phosphoglucose isomerase (Gpi), 
phosphofructokinase (Pfk), aldolase B (Aldo-B), triosephosphate isomerase (Tpi), 
glyceraldehyde 3-phosphate dehydrogenase (G3PD), phosphoglycerate kinase (Pgk), 
phosphoglycerate mutase (Pgaml and 2), 2,3-bisphosphoglycerate mutase (Bpgm), a, (3 
and y-enolases were also similar in islets of hnf-1 a+/+ and hnf-1 a~'~ animals (Fig. 3-1B). 
We next sought to determine if hnf-la deficiency affect the expression of 
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all the genes involved in the tricarboxylic acid (TCA) cycle including Ogdh were similar 
between wt and hnf-la'' mice. Finally, we checked genes involved in insulin secretion 
that are distal to the TCA cycle such as the exocytotic machinery and the systems for 
processing peptide hormones. We did not detect any expression differences between 
insulin processing enzymes (PC2, PC3) or ATP-sensitive potassium channels (Kir 6.2, 
Sur-l)(Fig. 3-3A). 
To confirm that impaired insulin secretion in hnf-la'' mice is not caused by a 
change in insulin steady-state mRNA levels or a change in the endocrine cell lineage 
allocation, we assessed islet composition quantitatively by determining the islet hormone 
expression levels. Consistent with the previous staining of islets with markers for a-, (3-, 
5-, and PP-cells (41), expression of different islet cell types markers such as Iapp, 
somatostatin, pancreatic polypeptide and total insulin (insulin 1 and 2) did not differ. 
Together these results suggest that the various islet cell types contributed equally in wt 
and hnf-1 a'~ animals (Fig. 3-3B). However, we found decreased expression levels of 
insulin 1 and glucagon. Decreased expression level of insulin 1 is probably due to a 
consensus Hnf-1 binding site in -410 in the promoter of insulin 1 but not insulin 2. 
Decreased glucagon expression is probably due to hyperglycemia in hnf-1 a'~ mice. To 
rule out a possible glucagon secretion defect that may be masked by hyperglycemia, we 
performed an in vivo glucagon secretion test using alanine as the glucagon secretagogue 
(99-103, 123). We found that there is no difference in glucagon secretion rate between wt 
and hnf-la'' mice (Fig. 3-4A, B). 
Since hyperglycemia and hypoinsulinemia in hnf-1 ex"'" animals can lead to 
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Figure 3-4: Analysis of pancreatic a-cell function and pyruvate kinase 
activity. Alanine (0.25 g/kg) (A) or PBS (B) is injected intraperitoneal^ into 
wildtype, and hnf-1 a'- mice. Glucagon is measured before and 30 minutes after 
alanine treatment. Plasma glucagon levels increased at similar rates in both 
wildtype and hnf-1 a'- mice. (C) Pyruvate kinase enzyme activity was measured in 
extracts of isolated islets. Pyruvate kinase activity is correlated to NADH 
consumption. The rates of consumption of NADH were similar in WT (n=4) and 
hnf-1'cr'- (n=4) mice. PEP, phosphoenolpyruvate 
genes were also studied in pancreata of newborn animals that had not been exposed to 
chronic hyperglycemia. We found that the expression of Glut-2, L-Pk, and Ins-1 was 
already decreased shortly after birth (Fig. 3-1A, 3-3B), suggesting that hnf-1 a deficiency 
lead to the reduced expression of these genes. In contrast, glucagon and Gck mRNA 
levels were not altered in newborn pancreata (Fig. 3-1 A, 3-3B), demonstrating that the 
decrease expression in hnf-la~'~ adult islets is likely due to hyperglycemia or 
hypoinsulinemia in these mice. Finally, we found that the expression of L-Pk was 
markedly reduced in islets of adult and newborn hnf-la"'" animals. This transcriptional 
defect was specific for the liver isoform of pyruvate kinase (L-Pk) and expression levels 
of the muscle isoform (M2Pk) were unchanged in hnf-la"'" mice (Fig. 3-1 A). To estimate 
the effect of the reduced L-Pk expression on overall pyruvate kinase activity, we 
measured total pyruvate kinase activity in islets of hnf-la+/+ and hnf-1 a"'~ mice (Fig 3-
4C). Interestingly, no differences were detected in total pyruvate kinase activity, thus 
supporting previous findings that M2-Pk is the major pyruvate kinase isoform in 
pancreatic islets (125, 126). 
Expression Analysis of Islet Enriched Transcription Factors in hnf-1 a'Mice 
Hnf-la belongs to a transcription network that controls the appropriate expression 
of (3-cell genes to maintain glucose homeostasis (Fig. 1-3). Components of the islet 
enriched transcription network have been shown in the liver and extra-embryonic tissues 
to regulate the expression of other transcription factors in the same network (Fig. 1-2) 
(77, 80). To assess the effects of hnf-la deficiency on the transcriptional regulatory 
network, we investigated the expression levels of islet-enriched transcriptional factors 
that are important for either pancreas development or glucose metabolism in hnf-la''' 
mice. 
W e found that steady-state m R N A levels of Hnf-4a, an upstream regulator of 
Hnf-la, was reduced in islets of hnf-la"'' mice suggesting Hnf-la is critical for the 
normal expression of Hnf-4a in pancreatic islets (Fig. 3-5). We also determined that the 
expression levels of several other islet-enriched transcription factors, including pancreatic 
and duodenal homeobox (Pdx)-l, neurogenic differentiation (NeuroD)-l, NK homeobox 
gene (Nkx) 2.2, Nkx6.1, dimerization cofactor of Hnf-la (Dcoh) and small heterodimer 
partner (Shp)-l, were reduced approximately 1.4 to 11-fold in islets of hnf-la~'~ mice 
(Fig. 3-5). In contrast, the expression levels of Hnf-1(3, -3a, -3(3, -Ay, -6, Paired 
homeobox gene (Pax)-4, Pax-6, Islet-1, and caudal-type homeobox gene (Cdx) 2/3 did 
not differ between wt and hnf-la'' mice (Fig. 3-5 and data not shown). Steady state 
mRNA levels of Dcoh, Pdx-1, NeuroDl, Nkx2.2, and Nkx6.1 were also measured and 
found to be reduced in pancreata of newborn mice (Fig. 3-5). Our data indicate that Hnf-
la deficiency rather than nonspecific effects due to hyperglycemia compromised several 
components in the islet-enriched transcription network. These transcription factors may 
act together to impair nutrient stimulated insulin secretion by reducing glucose flux 
through glycolysis. 
Liver Gene Expression Profiles in hnf-1 a+/+ and hnf-1 a~'~ Mice 
Similar to the endocrine pancreas, the liver is an important organ for glucose 
metabolism. In addition, Hnf-la as well as its target genes are expressed in the liver. To 
test if the changes in gene expression profiles of pancreatic islets are also present in the 
liver of hnf-la"'" animals, we measured mRNA concentrations of all the above-mentioned 
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Figure 3-5. Analysis of islet enriched transcription factors in hnf-1ar'- mice. Steady-state m R N A s of 
islet enriched transcription factors were analyzed by R T - P C R by using [a-32P]dCTP P C R products were 
separated by P A G E , and bands were visualized by autoradiography. W e found that the expression of 
Hnf-4a, Shp, Dcoh, Pdx-1, NeuroDl, Nk box (Nkx) 2.2, Nkx6.1 are decreased in the absence of Hnf-1a. 
genes in hnf-la null, heterozygous and wt mice. Insulin growth factor 1 (Igf-1) was 
previously found to be reduced in hnf-la'' livers and is used as an expression control 
(37). We first tested all the glycolytic and TCA cycle enzymes involved in nutrient 
stimulated insulin secretion. Consistent with Hnf-la regulation in the islets, the 
expression of Nbat was decreased in Hnf-la deficient livers. In contrast to pancreatic 
endocrine pancreas, the liver is an important organ for glucose metabolism. In addition, 
Hnf-la as well as its target genes are expressed in the liver. To test if the changes in gene 
expression profiles of pancreatic islets are also present in the liver of hnf-1 a~'~ animals, 
we measured mRNA concentrations of all the above-mentioned genes in hnf-la null, 
heterozygous and wt mice. Insulin growth factor 1 (Igf-1) was previously found to be 
reduced in hnf-la'' livers and is used as an expression control (37). We first tested all the 
glycolytic and TCA cycle enzymes involved in nutrient stimulated insulin secretion. 
Consistent with Hnf-la regulation in the islets, the expression of Nbat was decreased in 
Hnf-la deficient livers. In contrast to pancreatic islets, the expression of Glut-1, Glut-2, 
Naat, and L-Pk was increased in hnf-la~'~ mice (Fig. 3-6). The expression of the 
remaining glycolytic and mitochondrial genes was similar in mice of different Hnf-la 
genotypes (data not shown). These results show that Hnf-la is required for expression of 
Glut-1, Glut-2, and L-Pk in insulin producing cells but not in other tissues which also co-
express these genes. 
We next assessed whether tissue-specific dependence on Hnf-la can be extended 
to its interactions with other components of the transcription factor network. Consistent 
with the expression profile in the islets, transcript levels of DCoH were reduced in Hnf-
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Figure 3-6. Steady state m R N A levels of Hnf-1 a target g e n e s in the liver. 
R T - P C R w a s performed from three separate R N A samples of each genotype as 
described in Methods. W T / M u t indicates the ratio of expression levels of the 
m e a n s of wildtype and hnf-1'or*-mice. ":p <0.05; **: p <0.01; "*:p <0.005. 
Differences in L-Pk and Glut-2 expression in wildtype vs. mutant livers reached 
marginal significance (p = 0.06). 
were unchanged in the liver of hnf-la'' mice. In analogy to the expression results 
obtained for Glut-1 and Naat, we found that Hnf-1(3 mRNA levels were significantly 
increased in the liver but not in pancreatic islets. Finally, Hnf-6 message was reduced in 
the liver but not in the pancreas (Fig. 3-6). The expression of other transcription factors 
including Hnf-3a, -3(3 and -Ay were unchanged in the liver (Fig. 3-6). 
In summary, these data demonstrate that differences exist in the gene expression 
profiles of islets vs. liver in hnf-la"'" mice. Therefore, in the liver other mechanisms may 
be operative that can activate Hnf-la target genes, such as Glut-2 and L-Pk. These 
compensatory mechanisms may include elevated expression of Hnf-1(3 (which shares the 
same DNA binding sites as Hnf-la) and/or unaltered expression levels of Hnf-4a. 
Regulation of Small Heterodimer Partner in hnf-la'' Mice 
The orphan nuclear receptor, small heterodimer partner (Shp), is one of only a 
few negative regulators of the islet and liver enriched transcription factor network. Shp 
can heterodimerize with various nuclear hormone receptors, including Hnf-4a, and 
inhibit their function (83, 84). These interesting properties in addition to our study which 
indicate that Hnf-la may regulate Shp expression made it a fascinating candidate to 
analyze its promoter. Surprisingly, the promoter regions of both the human and murine 
Shp promoter did not contain any Hnf-1 binding sites (127). In contrast, a putative Hnf-
4a consensus binding sequence was identified at position -551 to -570 bp in the human 
SHP promoter. This binding site was also evolutionary conserved at a similar location in 
the murine shp promoter (Fig. 3-7A) (Genbank accession numbers for murine and human 
sequences are AF044315 and AF044316, respectively). We therefore hypothesized that 
the downregulation of Shp may be due to the reduced Hnf-4a message in hnf-la"'" mice. 
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Figure 3-7. Analysis of the SHP-1 promoter. (A) Comparison between the human and murine 
SHP-1 promoter that shows 9 0 % homology in the HNF-4 binding site. The wildtype and mutant 
sequences of the HNF-4 binding site is shown. (B) EMSA analysis of the HNF-4 binding site in the 
SHP-1 promoter. The DNA binding activity was measured using a 32P-labeled double stranded 
oligonucleotide containing the HNF-4 binding site as a probe and nuclear extracts of HIT-T15 cells 
that were transfected with pCMV-pHNF4a. Competition was carried out with a 20-fold excess of cold 
probe (lane 3), and supershifts were performed with a polyclonal a-HNF-4a antiserum or an oc-Stat-1 
control antiserum (lanes 4 and 5, respectively). No binding activity was detected with a probe 
containing a mutated HNF-4 binding site (Lane 7). Free probe on the bottom of the gel is not shown. 
Electrophoretic mobility shift assays (EMSA) were performed to investigate if 
Hnf-4a can bind to the putative HNF-4 binding site in the SHP promoter. A major 
DNA/protein complex was detected with a 32P-labeled oligonucleotide that contained the 
HNF-4 binding site (Fig. 3-7B, lane 2). This binding activity could be competed by an 
unlabeled excess of cold Hnf-4 binding oligonucleotide (Fig. 3-7B, lane 3). Furthermore, 
a supershift of the complex was observed after pre-incubation of extract with a 
monospecific anti-Hnf-4a antiserum (a-445), but not with anti-STAT-1 antibodies (Fig. 
3-7B, lanes 4 and 5) demonstrating that Hnf-4a can bind to the HNF4 site in the SHP 
promoter. As expected, Hnf-4a was not able to bind to the mutated Hnf-4 site (Fig. 3-7B, 
lane 7). 
Next, we addressed the question of whether Hnf-4a can act as a direct 
transcriptional activator in co-transfection assays by cloning a 582 bp of the 5'- human 
SHP promoter containing the putative HNF-4 binding site and linked it to a luciferase 
reporter gene (pGL2-pSHP). Co-transfection of pGL2-pSHP with a Hnf-4a expression 
vector (pcDNA3-pHNF-4a) showed an approximately 2- to 5- fold dose-dependent 
activation of the SHP promoter in three different cell lines, Cos7 (kidney), HepG2 (liver) 
and HIT-T15 (islet) cells (Fig. 3-8A to C). In contrast, Hnf-la expression did not result 
in the transcriptional activation of this reporter construct (Fig. 3-8A to C). To confirm 
that Hnf-4a can directly activate the SHP promoter, we mutated one hexamer half of the 
HNF-4 binding site in the reporter plasmid pGL2-pSHP (Fig. 3-1 A). Transcriptional 
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abolished (Fig. 3-8D-F), indicating that the HNF-4 binding site in the SHP promoter is 
functionally important for its expression. 
In order to test if SHP can down-regulate its own transcriptional activation by 
inhibiting the function of HNF-4a, we co-transfected SHP expression vector pcDNA3-
pSHP with constant quantities of pcDNA3-pHNF-4a and pGL2-pSHP into Cos7, HIT-
T15 and HepG2 cells. Luciferase activity decreased in a dose-dependent manner when 
increasing amounts of pcDNA3-pSHP vector were co-expressed with constant amount of 
HNF-4a (Fig. 3-8G-I). These data suggest that SHP can inhibit its own transcription 
through a negative transcriptional feedback loop that is mediated by HNF-4a (Fig. 1-2). 
Discussion 
Nutrient metabolism starts with glycolysis and mitochondrial substrate oxidation 
in pancreatic (3-cells to generate ATP. Mitochondrial ATP generation closes ATP-
sensitive potassium channels and depolarizes the plasma membrane. Depolarization of 
the plasma membrane opens the voltage-dependent calcium channels which increase 
intracellular calcium concentration and consequently, insulin exocytosis. Previous studies 
have demonstrated that the insulin secretory responses to glucose are impaired in Hnf-
la'" mice (41). Physiological studies have shown that ATP-sensitive K+-currents (KATP) 
in (3-cells of mutant mice are insensitive to suppression by glucose or glyceraldehyde but 
are normally sensitive to ATP Flux of glucose through glycolysis in islets of mutant 
mice is reduced but mitochondrial substrates, such as methylpyruvate, can inhibit KATP, 
elevate [Ca2+], and restore the insulin secretion defect (40, 41). These results indicate that 
insulin secretion is impaired by a defect proximal to mitochondrial metabolism in the (3-
cell glycolytic signaling pathway. However, a recent in vitro study showed that 
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expressing a dominant negative form of Hnf-la, HNFla-P291fsinsC, in insulinoma INS-
1 cells affects mitochondrial function by reducing the expression of Ogdh and increasing 
the expression of Ucp-2 (122). The net result of these expressing alterations is to impair 
mitochondrial function such as oxidation and ATP generation, and to dissipate the 
mitochondrial membrane potential, leading to decreased glucose stimulated insulin 
secretion. These inconsistent findings have not been resolved. In addition, the molecular 
basis by which hnf-1 a deficiency causes impaired nutrient stimulated insulin secretion is 
poorly understood. 
In this study, we investigated the transcriptional defects resulting from hnf-
la deficiency. We studied steady state mRNA levels in adult and newborn islets of genes 
that are critical (3-cell function in the islets of hnf-1 a+/+ and hnf-1 a~'~ littermates. Gene 
transcript levels were also measured in the pancreata of newborn animals to control for 
secondary effects that hyperglycemia may have on gene expression profiles in hnf-la"1" 
mice. Newborn hnf-1 a~'~ mice are normoglycemic (87 vs. 90 mg/dl in hnf-la+/+ and hnf-
la'" newborn mice, respectively) and blood glucose levels of hnf-1 a+'~ females are 
indistinguishable from hnf-1 a/'+ female animals during the last week of pregnancy (118 
vs. 121 mg/dl in hnf-la/'* and hnf-la/''pregnant mice, respectively). This indicates that 
newborn islets of hnf-1 a'"mice were not exposed to chronic hyperglycemia. We found 
reduced expression of three genes involved in the glycolytic signaling pathway, namely 
Glut-2, Gck, and L-Pk in hnf-la'~ mice (Fig. 3-1A). In addition, we also found 
diminished expression of Nbat, an amino acid transporter that transports both neutral and 
basic amino acids into the cell (Fig. 3-1A). Reduced expression of Glut-2, Gck and Nbat 
are likely to contribute to the defect in nutrient stimulated insulin secretion since mutant 
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mice lacking Glut-2 or Gck are hyperglycemic and hypoinsulinemic due to impaired 
glucose stiumlated insulin secretion (32, 128). The downregulation of Nbat may reduce 
the transport of basic and neutral amino acids into the (3-cell and offers a molecular 
explanation for decreased cellular ATP production in response to leucine (122). In 
contrast, it is unlikely that decreased L-Pk expression levels contribute significantly to 
the (3-cell defect in hnf-la"'" mice because we did not observe a significant reduction in 
the overall enzyme activity of islet pyruvate kinase in hnf-la~'~ mice (Fig. 3-4C). 
Therefore, our findings agree with previous studies that indicated M2-Pk is the major 
pyruvate kinase isoform in pancreatic islets (125, 126). Our data suggest then, that the 
lack of Glut-2, Gck, and Nbat, which was not compensated for by increased expression 
levels of other glucose and amino acid transporters, may contribute to the diminished 
glucose or amino acid-stimulated insulin secretion rates in hnf-1 a'~ animals. 
To determine if hnf-la deficiency also impairs the expression of genes that are 
critical for mitochondrial function, we measured mRNA levels of numerous 
mitochondrial genes including Ogdh and Ucp-2. Ogdh constitutes the rate-limiting 
enzyme in the mitochondrial TCA cycle and Ucp-2 uncouples respiration from oxidative 
phosphorylation and inhibits the efficiency of ATP synthesis. In contrast to a previous 
report (122), the expression of Ogdh and Ucp-2 were not changed in the absence of Hnf-
la (Fig. 3-3A). We also did not find the expression of other mitochondrial enzymes 
involved in the TCA cycle to be affected by Hnf-la deficiency (Fig. 3-3A). Several 
reasons may account for these discrepancies. First, the previous study investigated the 
consequences of Hnf-la deficiency by using a deoxycycline inducible dominant negative 
Hnf-la. Doxycycline has been shown to be cytotoxic and thus, may alter gene expression 
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in treated cells (129, 130). Second, since Hnf-la can either homodimerize, or 
heterodimerize with Hnf-1(3, the dominant negative Hnf-la used in the previous study 
may inhibit the function of both Hnf-la and Hnf-1(3 (131). As a result, reduced Ogdh 
and increased Ucp-2 expression may also be due to impaired Hnf-13 function and not 
solely to Hnf-la deficiency. Finally, the previous study was done in a transformed 
insulinoma cell line (INS-1) and differences between INS-1 cell line (132) and islets 
(used in the present study) exist that may explain the differences in Hnf-la regulated 
genes in the mitochondria. 
In addition to the transcriptional defect in genes regulating (3-cell glycolytic 
signaling, we found the expression levels of several other transcription factors to be 
significantly reduced in mice with Hnf-la deficiency. The steady-state mRNAs of Hnf-
4a, Pdx-1, Nkx2.2, Nkx6.1, and Neuro-Dl/Beta-2, as well as the dimerization cofactor 
Dcoh were reduced shortly after birth in islets of hnf-1 a'~ mice, suggesting that these 
changes are caused by hnf-la deficiency and are likely to contribute to the molecular 
defects in hnf-1 a~'~ islets. Decreased expression of several of these genes may be 
mediated directly by Hnf-la. For instance, a functional Hnf-1 binding site has recently 
been identified in the HNF-4a promoter P2 that is located =46kb upstream of the hepatic 
(PI) promoter. Transcription from the P2 promoter is responsible for the expression of 
the most abundant HNF-4a isoform in pancreatic (3-cells and HNF-la is a potent 
activator of HNF-4a transcription from the P2 promoter in vitro (22). Our finding 
suggests that in pancreatic islets, Hnf-la and Hnf-4a form an autoregulatory loop, and 
that a haploinsufficiency in either of these transcription factors causes an expression 
disequilibrium (see model proposed, Fig. 1-2). Mutations in HNF-4a in humans result in 
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a very similar (3-cell phenotype to M 0 D Y 3 patients (26, 28, 120), supporting the 
possibility that both are indeed involved in a common regulatory circuit that is present in 
pancreatic (3-cells. 
Interestingly, the expression of Pdx-1 was reduced in a dose-dependent manner in 
hnf-la/"', hnf-1 a/'~ and hnf-1 ex~'~ mice (Fig. 3-5). Pdx-1 is an essential transcription 
factor for pancreas development and (3-cell function, and loss-of-function mutation in this 
gene causes MODY4 (7, 21, 54, 56). Expression levels of Pdx-1 in hnf-1 ex1" islets were 
reduced 30-50% (Fig. 3-5). Since Pdx-1 is a transcriptional regulator of Gck, Glut-2, and 
insulin (56, 133-135), their down-regulation may also be due to diminished Pdx-1 
expression levels in hnf-la''' mice. Functional Hnf-la as well as Hnf-4a binding sites 
have been reported in evolutionarily conserved enhancer elements of the Pdx-1 promoter 
(57, 59). Therefore, decreased Pdx-1 expression in hnf-la'~ islets may also be the result 
of reduced hnf-1 a and hnf-4 a gene expression. We also found that the mRNA levels of 
Neuro-Dl, a helix-loop-helix transcription factor that can activate insulin gene 
transcription in vitro (136), were reduced 80% in hnf-1a~'~ mice. Despite the reduced 
expression of Pdx-1 and Neuro-Dl, mRNA levels of Ins-2 were indistinguishable in islets 
of in hnf-la*'* and hnf-1 a~'~ mice (Fig. 3-3B). This finding is in agreement with other 
reports (40, 41) that did not find significantly reduced insulin mRNA levels in hnf-la"'" 
mice and may be explained by compensation through other transcriptional activators of 
the insulin gene, such as Hnf-1(3, Cdx2/3, Isl-1 and Pax4. In contrast, we found that Ins-1 
expression was reduced =50% in islets of in hnf-la"'" mice (Fig. 3-3B). This reduction is 
most likely a direct effect of Hnf-la deficiency, mediated by an Hnf-1 binding element in 
the ins-1 promoter that is lacking in the murine Ins-2 promoter (137). 
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It is worth noting that expression levels of other islet transcription factors that are 
important for (3-cell metabolism, differentiation and insulin gene transcription, including 
Hnf-1(3, -3a, -3(3, -4y, -6, Cdx-2, Isl-1, Pax4 and Pax6, were unchanged in hnf-1 a"'" mice. 
Interestingly, the transcriptional control of this network and the regulation of downstream 
target genes are distinct in pancreatic islets and in the liver. For instance, the expression 
of Glut-2, Gck and L-Pk was normal or increased in the liver but significantly decreased 
in islets of hnf-la"1' compared to wt littermates. These differences may be explained by 
compensatory upregulation of transcriptional regulators (e.g. Hnf-l(3}n the 
liver, reduced expression of liver-enriched transcription factors absent in adult pancreatic 
islets (e.g. Hnf-6) or through differential regulation of transcription factors and 
downstream targets through tissue-specific promoters (e.g. Hnf-4a, Gck). These data 
indicate that the impairment in nutrient stimulated insulin release in hnf-la'' mice is 
likely to result from multiple pancreatic (3-cell expression defects and support our 
hypothesis that loss of Hnf-la function causes a pleiotrophic, but distinct defect in the (3-
cell transcriptional network that is essential to maintain glucose homeostasis. In addition, 
the observations that different Hnf-la target genes have distinct tissue-specific 
requirement for Hnf-la may be an explanation for MODY3 phenotype of pancreatic (3-
cell dysfunction without major extra-pancreatic abnormalities. 
Finally, in vitro studies have suggested that Shp may heterodimerize with Hnf-4a 
and inhibit its transcriptional activity (84). Mutations in SHP have also been identified in 
humans and may be associated with mild obesity in Japanese subjects (138). Shp 
expression was markedly reduced in islets of hnf-1 a~'~ mice, suggesting that it may be 
regulated by Hnf-la, Hnf-4a, Pdx-1, Nkx2.2, Nkx6.1 or Neuro-D. To better understand 
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the molecular basis of shp gene regulation, we studied its promoter. The 5'-regulatory 
sequence of SHP lacked binding sites for Hnf-la, Pdx-1 and Neuro-D but contained a 
conserved and functional Hnf-4 site. The biochemical characterization of this site and in 
vitro transactivation studies indicate that Hnf-4a is a transcriptional activator of the Shp 
gene. The reduced Shp mRNA levels in pancreatic islets of hnf-1 a~'~ mice are likely due 
to the reduced expression of Hnf-4a in Hnf-la-deficient islets. Furthermore, our data 
indicate that Shp may regulate its own expression by inhibiting Hnf-4a function, thus 
forming a negative feedback loop and indirectly (through Hnf-4a) regulate the activity of 
Hnf-la, Pdx-1 and Neuro-D (Fig. 1-3). Shp may therefore serve as an important 
checkpoint to balance the activity of the islet transcriptional network. Further studies, 
including targeted mutagenesis of the shp gene in mice, are needed to shed light on the 
biological role of Shp in pancreatic islet function. 
In summary, we have used a null mutant animal model as opposed to studies 
based solely on tissue culture systems to study impaired nutrient stimulated insulin 
secretion observed in MODY3 patients. We found that Hnf-la mediates a distinct genetic 
program involving islet enriched transcription factors in pancreatic (3-cells to decrease 
nutrient entry and reduce flux through glycolysis. Thus, the selective pancreatic (3-cell 
dysfunction in the islets of hnf-la'' mice may be a molecular mechanism why human (3-
cells is particularly vulnerable to hnf-la haploinsufficiency. However, it remains to be 
established whether the same tissue specific requirement for Hnf-la function exists in 
MODY3 patients. 
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C h a p t e r 4: Pancreatic (3-Cell Defects in M i c e with C o m b i n e d 
M u t a t i o n s in the G e n e s E n c o d i n g P d x - 1 , H n f - l a a n d Hnf-3(3 
Introduction 
Type 2 diabetes (NIDDM) is a genetically determined metabolic disorder, 
affecting over 5 % of the population in western countries (13). Numerous studies indicate 
that N I D D M is a polygenic disease, associated with peripheral insulin resistance and 
impaired pancreatic (3-cell function. Although a majority of type 2 diabetic patients have 
insulin resistance in the muscle and the fat (tissues that are responsible for 9 0 % of 
glucose disposal following a carbohydrate load) (139, 140), mice with muscle or adipose 
tissue specific deficiencies of the insulin receptor suggest that insulin resistance in these 
tissue alone is not enough to develop overt diabetes (141, 142). O n the other hand, 
animals with targeted disruption of genes that impair insulin secretion in pancreatic (3-
cells invariably become diabetic, suggesting that impaired (3-cell function by itself may 
be sufficient to develop clinical diabetes. 
Genetic and biochemical studies in humans and mice have identified many key 
transcription factors that are involved in controlling pancreas development and (3-cell 
function in the adult islet. Heterozygous mutations in a subset of these genes, including 
hepatocyte nuclear factor (HNF)-4a, HNF-la, PDX-1, HNF-1 (3, and BETA2, axe 
specifically associated with a form of type 2 diabetes, termed maturity-onset diabetes of 
the young ( M O D Y ) , that is characterized by an early disease onset (usually <25 years) 
and a primary defect in insulin secretion. Interestingly, in contrast to humans, only 
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heterozygous pdx-1 mutants but not hnf-4a, hnf-la, hnf-1 fl, or beta2 induce a diabetic 
phenotype in mice, presumably due to the direct importance of Pdx-1 in regulating 
glucose transporter-2 (Glut-2), glucokinase (Gck), and insulin expression. There is 
increasing evidence that these and other islet-enriched transcription factors (e.g. Nkx2.2, 
Nkx6.1, Pax-4, and Pax-6) form an integrated regulatory network in the (3-cell that is 
critical for normal glucose-stimulated insulin secretion (143, 144). 
The (3-cell transcriptional network is organized in a hierarchical manner (Fig. 1-
2). The upstream regulator of the network may be Hnf-3(3, a protein in the forkhead 
transcription factor family. Although little is known about how Hnf-3(3 activates 
transcription in pancreatic (3-cell development and function, it may promote transcription 
in a manner similar to its action in liver and initiate the opening of the chromatin and 
transcription complex assembly (79, 145). Hnf-3(3 and Hnf-1(3 regulates hnf-4a and hnf-
la gene expression in extra-pancreatic tissues (62, 63, 77), but it is unclear if this is also 
true in the pancreas. In (3-cells, Hnf-3(3 and Hnf-la may directly regulate pdx-1 gene 
transcription (57-59, 146). In addition, HNF-la and HNF-4a autoregulate each other's 
expression (25, 42). Collectively, Hnf-la, Hnf-1(3, Hif-3(3, Hnf-4a and Pdx-1 form 
crucial links in the cascade of transcription factors that control the appropriate expression 
of a number of key genes involved in glucose metabolism in the (3-cell, including glut-2, 
gck, the liver pyruvate kinase isoform (T-pk), aldolase B (aldo-B), and insulin (147). 
In spite of numerous gene targeting studies that characterized single gene 
mutations in islet enriched transcription factors, the effects of combined mutations on (3-
cell function has not been studied so far. To analyze the complex epistatic interactions 
between different components of the islet-enriched transcription factor network, we 
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created combined allelic mutations in genes encoding Pdx-1, Hnf-la, Hnf-3a, Hnf-3(3 
and Hnf-4a. Using this genetic approach, we show that Pdx-1 acts in concert with Hnf-
la and Hnf-3 (3 to mediate a transcriptional program that control whole body glucose 
levels and maintain normal islet morphology. 
Results 
Generation of Mutant Mice 
Mice carrying heterozygous mutations in of hnf-la, hnf-3 a, hnf-3 f/>, hnf-4 a, and 
pdx-1 were bred into C57/B16 strain for at least 7 generations (2 years of breeding) and 
maintained in C57/B16 genetic background. The combined heterozygous hnf-la*'~/hnf-
4a*'", hnf-3p'-/]mf-4a*'", pdx-l*'"/hnf-3i3*'-, pdx-l*'"/}mf-4a*'", and pdx-1*'"/Imf-la*'" 
mutant mice were generated by intercrossing mice heterozygous for each mutation. 
Except for pdx-1'*'~/lv\f-3f5*'~, differentiation combination of the 5 mutations are born with 
expected Mendalian frequency with no significant difference between mouse growth 
rates. Pdx-l*'~/hnf-3i3*'~ mice at weaning were less frequent than expected (16% actual 
versus 25% actual, n=126). This suggests that either a percentage of pdx-l*'~/}inf-3f3*'~ are 
embryonic lethal or are dead before weaning. To differentiate between these possibilities, 
we determined the distributions of different genotypes during embryonic development 
and perinatal period. We found that pdx-1*'''/hnf-3'f3*'~ were born at expected frequency 
but a proportion (6% of all pdx-l*'~/hnf-3i6*'~, n=103) died by 7 days after birth. The 
cause of death for these mice are unknown. However, the pdx-l*'~/hnf-3f/>*'~ mice that 
survived to weaning showed similar growth rates as mice with other mutations. 
Development of Diabetes in pdx-1*''/hnf-3 f3*'~ and pdx-1*1"/hnf-1 a*'~ Mice 
We first examined the metabolic consequences of mice carrying different 
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mutation combination by measuring glucose levels in the fasted and random-fed states. 
The effect of the combined mutants on serum glucose homeostasis was compared to pdx-
1*'~ to show the worsening of the pdx-1*'' diabetic phenotype. Only the pdx-1 *'~/fmf-3 ft*'" 
and pdx-1 *'~/\v\f-la*'~ mice exhibited progressive elevation in fasting and random-fed 
plasma glucose levels. Pdx-l*'"/]\nf-la*'" mice developed higher fasting and ad lib 
feeding serum glucose levels than pdx-1*'" mice at three month of age (136±11 and 
188+10 vs. 94±4 and 167±5 mg/dl, p=0.04 and 0.03, respectively) (Fig. 4-1A, B). Pdx-
V'~/hnf-3f3*'~ mice develop significant elevation in fasting and random-fed glucose levels 
after 4 month (Fig. 4-1C, D). 
Intraperitoneal glucose tolerance tests (IPGTT) were performed on both male and 
female mice of the various genetic groups. Mice with combined allelic mutations in pdx-
l*'"/Jmf-4a*'", hnf-la*'"/lmf-4a*'~, and hnf-3p*'"/lmf-4a*'" had indistinguishable blood 
glucose levels from the single haploinsufficienct mice over a six month interval (data not 
shown). Pdx-l*'~/lvxf-la*'~ mice showed reduced glucose clearance levels when compared 
to the pdx-1*'" (Fig. 4-2). In addition, the IPGTT profile of pdx-1*'/hnf-la*'" mice 
deteriorated over time, whereas the pdx-1*'' mutants was non-progressing (Fig. 4-2). 
Male and female pdx-l*'~/hnf-3f3*'~ mutant mice were phenotypically indistinguishable 
from pdx-1*'" animals at one month of age but developed a progressively decreased 
ability to clear glucose by 3 and 4 months (Fig. 4-3). 
Eventhough a mutant hnf-3 fl allele worsens the diabetic phenotype of pdx-1*1' 
mice, their metabolic abnormalities are less severe than observed in pdx-l*'~/linf-la*'~ 
mice. The glucose tolerance profile of pdx-l*'~/hnf-3(3*'~ mice are milder and deteriorate 
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of elevated fasting and ad lib plasma glucose levels than pdx-r'~/hnf-3p*'" animals. 
Despite the variability in the severity of the diabetic phenotype, both pdx-1*'-/hnf-3 ^'~ 
and pdx-1'*'"/hnf-1 a*'~ mice exhibit an age-dependent progressive impairment in their 
ability to dispose of a glucose load. The worsening of the pdx-l*'~phenotype suggest that 
significant synergistic effects exist between Hnf-la and Hnf-3 (3 with Pdx-1, and that 
their interactions regulate glucose homeostasis. 
Insulin Secretion Defects in pdx-l*'~/hnf-3(¥'" and pdx-l*'~lhnf-la*'~ Mice 
To further evaluate the synergistic interaction between Hnf-la and Hnf-3(3 with 
Pdx-1, insulin release was measured in response to stimulation with glucose. Glucose-
stimulated insulin release from pdx-r'~/tinf-la*'~ and pdx-l*'~/hnf-3f/>*'- mice was 
compared to the pdx-1*1' animals to better assess the worsening of the diabetic phenotype. 
In both male and female controls (wt, hnf-3 fl*'', and hnf-la*''), a three to six-fold 
increases in insulin levels were observed within two minutes after an intraperitoneal (IP) 
glucose injection (Fig. 4-4 and 4-5). Serum insulin levels in control mice remained higher 
than baseline values for up to 60 minutes, indicating an effective second phase insulin 
secretion response (Fig. 4-4 and 4-5). The pdx-l*'~ mice exhibited a markedly impaired 
acute 1S1 and 2nd phase insulin secretion response. In spite of the secretion defect in Pdx-
1*'~ mice, insulin levels gradually rose, and by 120 minutes after glucose load, the insulin 
levels were not significantly different between pdx-1 *'" and control mice. In contrast, the 
acute insulin response was virtually absent in pdx-1*'"/hnf-1 a*'" mice, and insulin 
secretion was reduced throughout the IPGTT when compared to pdx-1*'' mice (Fig. 4-4). 
Similarly, pdx-1*'~/hnf-3 \°>*'~ mice also lost the first phase insulin response. However, 
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Figure 4-4: Insulin secretion defects in pdx-1+/Vhnf-1<x+/- mice. Glucose (3 g/kg 
body weight) was injected intraperitonally to 5 month old male (A, B) and female (C, D) 
mice. The left panel (A, C) shows acute insulin secretion responses, the right panel (B, 
D) displays insulin levels after glucose challenge over a 2 hour period. The data of the 
left and right panels were collected independently and mice were allowed to recover 
for one week. Male and female pdx-1+//hnf-1'a/-'- mice show a complete loss of first 
phase insulin response and a blunted second phase insulin response compared to 
pdx-1+/~littermates. *: P<0.05, **: p<0.01, ***: p<0.005, ****: p<0.0001. 
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Figure 4-5: Insulin secretion defects in pdx-1 +/-/hnf-3j3+/- mice. Glucose (3 g/kg body 
weight) was injected intraperitonally to 5 month old male (A, B) and female (C, D) mice. 
The left panel (A, C) shows acute insulin secretion responses, the right panel (B, D) 
displays insulin levels after glucose challenge over a 2 hour period. The data of the left 
and right panels were collected independently and mice were allowed to recover for one 
week. A significantly blunted first phase insulin secretion response was observed in 
male and female pdx-1+/-/hnf-3p+/' mice as compared to compared to pdx-1+/~ 
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(Fig. 4-5). These results suggest that synergistic interactions between Hnf-la, Hnf-
3(3, and Pdx-1 profoundly affect insulin secretion and glucose homeostasis in mice. 
Since Hnf-la, Hnf-3(3, and Hnf-4a are also expressed in liver and pancreatic a-
cells, we investigated the levels of surrogate markers produced in these tissues that can 
influence glucose homeostasis. Serum glucagon, fatty acid, glycerol, cholesterol and bile 
acid levels in single and combined heterozygous mutant mice were indistinguishable 
from wt mice (Table 4-1). These data further support the notion that impaired glucose 
homeostasis in pdx-l*'"/lxnf-la*'~ and pdx-l*'~/hnf-3j3*'~ mice is primarily due to a 
pancreatic (3-cell defect. 
Morphological Analysis of Pancreatic Islets 
Several mechanisms could account for the observed deterioration of pdx-1*'' 
diabetic phenotype in pdx-1'*'~/linf-la*'~ and pdx- l*'~/hnf-3(3*'~ mice including changes in 
islet cell lineage allocation, alterations in islet architecture, and/or abnormalities in the 
expression of genes that mediate insulin secretion. Epistatic interactions between Hnf-la 
and Hnf-3(3 with Pdx-1 could result in a decrease in insulin-producing (3, thus reducing (3-
cell mass and altering a- to (3- cell ratio. This possibility is relevant in light of recent Pdx-
1 gene targeting experiment. Loss of Pdx-1 expression leads to pancreatic agenesis and (3-
cell specific abolition indicates that the Pdx-1 is required for late differentiation or 
maturation of the pancreatic (3-cells (54-56). Therefore reducing the amount of Hnf-la 
and Hnf-3b in Pdx-1 haploinsufficient state may lead to decreased (3-cell mass. 
To evaluate whether the alterations in islet function were associated with any 
changes in morphology, we carried out immunofluorescent analysis of pancreata from wt, 
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composition was assessed quantitatively by immunostaining with insulin and glucagon 
antibodies to visualize (3- and a-cells, respectively. Morphometric analysis of pancreatic 
sections showed no apparent difference in total pancreatic islet area or in a- to (3-cells 
ratio between wt and mutant islets (Table 4-2). Thus, it is unlikely that a reduction of (3-
cell size/number leads to the diabetic phenotype in double-mutant mice. 
Wildtype, pdx-1*'', hnf-la*'', and hnf-3f}*'~ mice display characteristic islet 
architecture where (3-cells, the predominant cell type in the islets, form the core of the 
normal islet and are surrounded by a-cells which are confined to the periphery (Fig. 4-6A 
to D). In contrast, the characteristic islet architecture, specifically the confinement of a-
cells to the periphery of islet, was disorganized in pdx-1*'-/linf-3(1*'- and pdx-l*'~/Jmf-la*'~ 
mice (Fig. 4-6E, F). Even though the islet topology was disturbed, there was no 
inappropriate coexpression of islet hormones in any endocrine cells examined (i.e. no 
yellow cells were observed in the merged images), suggesting that islet cell lineage 
allocation was not impaired. These results indicate that the abnormal islet morphology 
could contribute to the phenotype of the combined heterozygous mutant mice. 
Pancreatic Gene Expression 
To determine more precisely why (3-cell function was compromised in pdx-
l*'~/hnf-3fl*'~ and pdx-r'~/hnf-la*'~ mice, steady-state mRNA profiles of transcription 
factors, hormones, and components of the glucose-stimulated insulin secretion pathway 
that are essential for (3-cell activity were generated by RT-PCR from wt and mutant islet 
RNA. Significant changes in expression from genes present in each effector category 
were identified in the combined heterozygous mutant mice (Fig. 4-7, Table 4-3). 
Pdx-1 mRNA levels were moderately reduced in hnf-3(5*'" mice (24%) and 
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Figure 4-7. Pancreatic islet gene expression analysis. Steady-state m R N A levels of 
pancreatic islet enriched genes of wildtype, pdx-1*'-, hnf-3ji+/-, hnf-1 a+/~, pdx-1+/-/hnf-3(3+/-
and pdx-1+/~/hnf-1a+/- mutant mice. The housekeeping gene hypoxanthine 
phosphoribosyltransferase (Hprt) w a s amplified to show that each sample contained similar 
amounts of m R N A . A lack of any amplification signal in reactions without reverse 
transcriptase (-RT) shows that genomic D N A did not contaminate the samples. Transcript 
levels were measured in 3 animals for each genotype by R T - P C R using [ct-32P]dCTP. P C R 
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decreased in pdx-1*'', hnf-la*'', pdx-1*'-/imf-la*'" and pdx-r''/]inf-3 f5*'" animals by 38%, 
41%, 65%, and 51%, respectively (Fig. 4-7, Table 4-3). These results are consistent with 
previous reports suggesting that Hnf-3(3 and Hnf-la are regulators of Pdx-1 gene 
expression (57-59, 146). Hnf-la mRNA levels were only reduced in hnf-1 a*'~ and pdx-
l*'"/lxnf-la*'" mice whereas Hnf-la mRNA levels were similar in all different genotypes 
(Fig. 4-7, Table 4-3). Hnf-4a expression levels were marginally reduced in hnf-la*'" and 
pdx-l*'-/hnf-la*'" mice, indicating that the MODY1 gene may be regulated by Hnf-la. 
Interestingly, Nkx6.1 expression was reduced in pdx-1*'' and hnf-3(l*'~ mice as well as in 
combined heterozygous pdx-1 *'~/lmf-3(3*'~ and pdx-1*'~/hnf-1 a*'- mice, but not in hnf-la*'' 
animals, suggesting Nkx6.1 is regulated by Hnf-3(3, Pdx-1 (Fig. 4-7, Table 4-3). 
Expression levels of Nkx2.2 were diminished in pdx-l*'~ and in double heterozygous 
mutant mice, indicating that reduced Nkx2.2 expression is mainly mediated by Pdx-1 
(Fig. 4-7, Table 4-3). Islet glucagon mRNA levels were similar in all mutants studied, 
supporting our immunohistological findings that indicated normal a-cell differentiation 
and similar a-cell to (3-cell ratios between islets of wt and various mutants. 
Decreased insulin transcript levels (11%) and 46%), respectively) were detected in 
pdx-1*'''/hnf-3'fi*'" and pdx-l*'-/linf-la*'- mutants compared with pdx-1*'' (Fig. 4-7, Table 
4-3), indicating that a reduction in insulin gene transcription may contribute to the insulin 
secretion defect in these mice. In addition, we found a number of changes in the 
expression of genes that are responsible for glucose-stimulated insulin secretion. The 
expression of Glut-2 was reduced in pdx-l*'~ (35%, p<0.05), hnf-la*'" (55%, p<0.0l), 
pdx-r'-/hnf-3p'- (31%,p<0.05) and pdx-1*''/Jinf-la*'' (83%,/?<0.001) compared with wt 
animals, indicating that both Pdx-1 and Hnf-la, but not Hnf-3(3, are important regulators 
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of Glut-2 expression (Fig. 4-7, Table 4-3). There was a synergistic effect on Glut-2 
expression in mice that were haploinsufficient for both pdx-1 and hnf-la genes. Liver 
pyruvate kinase mRNA levels were reduced in hnf-la*'" animals and hnf-1 a*'~/pdx-l*'~ 
mice and the expression pattern correlates best with this gene being under the 
transcriptional control of Hnf-la. Expression levels of the gene encoding Gck, which 
operates at the rate-limiting step of glycolysis, were reduced in double heterozygous 
mutants compared with pdx-1*'' mice (56% and 52% for pdx-l*'~/hnf-3fl*'~ and pdx-
1*'~/hnf-la*'", respectively) (Fig. 4-7, Table 4-3). 
To identify genes that may contribute to the abnormal islet morphology in the 
double heterozygous mice, we also investigated the expression levels of E-cadherin, a 
transmembrane domain glycoprotein that mediates cell-cell adhesion in the 
gastrointestinal tract and endocrine pancreas (148). Interestingly, expression levels of E-
cadherin were significantly reduced in pdx-1*'~/hnf-1 a*'~ and pdx-l*'~fhnf-3/3*'~ animals 
(44% and 48%, respectively) (Fig. 4-7, Table 4-3), suggesting a possible role for E-
cadherin in islet architecture of these mice. 
As described above, compound heterozygous of pdx-1 *'~/lmf-4a*'", hnf-3f3*'"/hnf-
4a*'~ and hnf-la*''/hnf-4a*'~ mice do not have a worsened phenotype than is seen in 
single-mutant mice alone. These findings were surprising since heterozygous inactivation 
of HNF-4a, like HNF-la, in humans is associated with the development of MODY. To 
study the possible mechanism(s) that confer(s) relative protection to the development of 
diabetes on an hnf-4a*'~ genetic background we assayed gene expression in pancreatic 
islets of mice with one or two functional hnf-4a alleles. We did not detect a significant 
down regulation in the expression of any transcription factor including Hnf-4a, or gene 
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that is involved in glucose-stimulated insulin secretion, such as Glut2, Gck, L-Pk and 
aldolase B (Fig. 4-8). Moreover, known target genes of Hnf-4a such as aldolase B and 
Hnf-la were not reduced in hnf-4a*'~ mice compared to wt animals. This is in contrast to 
our findings in hnf-la*'" mice, which displays reduced levels of Glut-2, L-Pk, Hnf-4a, 
Hnf-la and Pdx-1 mRNA. Our results therefore suggest that, in mice, Hnf-4a can 
compensate for allelic loss by up-regulating the expression of its remaining functional 
allele. 
Discussion 
Type 2 diabetes is a polygenic disease and genetic predisposition to this condition 
is likely due to changes in expression and/or activity of proteins important in insulin 
sensitivity and normal pancreatic islet function. However, a mutation in a susceptibility 
gene often does not result in diabetes unless present in combination with another, which 
together result in impaired glucose homeostasis. Such gene-gene interactions within the 
insulin-signaling pathway have been shown upon combining specific inactivating gene 
mutations in mice that are predisposed to insulin resistance (149-151). For instance, 
plasma insulin levels increased by almost 50-fold in mice with combined 
haploinsufficiencies in the insulin receptor (ir) and insulin receptor substrate-1 (irs-1) 
genes, with approximately 40% of the ir*''lirs-l*'' mice becoming overtly diabetic at 4-6 
months of age (149). Interestingly, islet mass was greatly expanded in these diabetic mice 
as means of producing more insulin to aid in glucose clearance. Although the islet has 
clearly been shown to have a central role in regulating glucose homeostasis, little is 
known about how this process is influenced by epistatic interactions between factors 
critical for pancreatic (3-cell function. In this study, we have shown that a combination of 
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heterozygous deletions in certain subsets of the islet transcription factor network can act 
synergistically to cause diabetes. 
Allelic loss of hnf-la and hnf-3ft, athough having no effect on glucose 
homeostasis as single mutants, markedly worsened the diabetic phenotype in pdx-1*'' 
mice. Pdx-1 is a key effector of glucose sensing due to its action on Glut-2, insulin, and 
Gck expression. Insulin secretion and blood glucose levels were compromised in both 
female and male double mutant mice. These results are consistent with recent findings 
showing that Hnf-3(3 and Hnf-la directly activate pdx-1 transcription (39, 57-59, 146). In 
contrast, allelic loss of function of Hnf-3a or Hnf-4a with Pdx-1 haploinsufficiency 
revealed no synergism between these genes and did not alter the phenotype of pdx-l*'~ 
mice. Furthermore, hnf-1 a*'~/lwf-4a*'~ and hnf-3(3*'"/}inf-4a*'~ mutant mice have similar 
blood glucose levels as littermates with single mutations. Together, our in vivo data 
suggest that Hnf-3(3, Hnf-la and Pdx-1 are key components of a common pathway that is 
essential for normal glucose-induced insulin secretion. 
To gain insight into the molecular mechanisms by which (3-cell function was 
impaired in pdx-l*''/]xnf-la*'~ and pdx-l*'~/hnf-3i3*'' mice, pancreatic islet gene 
expression profiles were generated in the individual and combined mutants. Target genes 
of Hnf-la and Pdx-1, such as glut-2, were significantly reduced in the individual 
mutants. L-pk, a target gene of Hnf-la, was also reduced in hnf-la*'' mice. In addition, 
there was a modest reduction in Pdx-1 expression levels in the phenotypically normal 
hnf-3(3*'' and hnf-la*'' mice. Interestingly, the pdx-1 *'~/fnxf-la*'' and pdx-1 *'~/hnf-3/3*'' 
mice exhibited decreased mRNA expression of specific factors involved in regulated islet 
gene transcription (Pdx-1, Nkx2.2, and Nkx6.1) and glucose-stimulated insulin secretion 
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signaling (Glut-1, Gck, L-Pk, and aldol-B) (Fig. 4-7). Insulin message was also 
significantly decreased in the double-heterozygous mutant mice in which Pdx-1 mice was 
reduced by > 50%. A reduction in Pdx-1 expression of > 50%) seems to be a critical 
threshold for causing a decrease in insulin gene mRNA levels. The insulin mRNA levels 
found in pdx-1*'' islets (i.e. normal) and islets wherein Pdx-1 was selectively removed 
also support our data (56). Together our findings illustrate that significant synergism 
exists between the Hnf-3(3, Hnf-la, and Pdx-1 transcription factors in regulating insulin 
gene transcription and expression of genes involved in glucose-stimulated insulin 
secretion. 
Expression profiling of different mutants revealed that cooperative interactions 
exist between Hnf-3(3 and Hnf-la with Pdx-1 to maintain the genetic program for proper 
glucose homeostasis. Particularly important are their regulation on islet enriched 
transccription factors and GSIS signaling components. The islet transcription factors 
Nkx2.2, Nkx6.1, and Pdx-1 were previously shown to be important for pancreatic (3-cell 
function and their inactivation all lead to severe diabetes in mice (54-56, 144, 152). The 
components of glucose stimulated insulin secretion regulate various functions of (3-cells 
such as glucose sensing, stimulus-secretion coupling, insulin biosynthesis and processing, 
and exocytotic machinery. We found that glucose sensing is further impaired when Hnf-
3(3 or Hnf-la haploinsufficiencies are combined with pdx-1*1' mice. Particularly 
important for glucose sensing are Gck and Glut-2. The low affinity, high capacity glucose 
transporter Glut-2 transport glucose with the Michaelis-Menten constant (Km) of 18 mM 
(153). The low affinity Gck then phosphorylates glucose with a Km of 10 mM (153). 
The physiological ranges of glucose are 5-7 mM. Since Km is defined as the substrate 
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concentration at which the reaction velocity is half-maximal, the K m of Glut-2 and Gck 
would enable glucose uptake and phosphorylation when blood glucose is elevated (after a 
meal), thus serve as glucose sensor of the pancreatic (3-cells. However the maximal 
reaction velocity (Vmax) is dependent on the concentration of the catalysts (Glut-2, and 
Gck). As a result, if the expression of Glut-2 and Gck are decreased, then the Vmax for 
the eventual ATP generation would also be decreased, thus compromising glucose 
sensing and GSIS in pdx-1*''/hnf-1 a*'" and pdx-l*'-/hnf-3/3*'- mice. 
To begin to address why (3-cell function was not compromised in pdx-l*'~/hnf-
4a*'~, hnf-4a*'~/lxnf-la*'~, or hnf-4a*'"/hnf-3p*'- mice, gene expression profiles were 
generated with islet RNA from wt and hnf-4a*'~ mice. Interestingly, in contrast to the hnf-
la, hnf-3 fi or pdx-1 haploinsufficiency, the loss of an hnf-4a allele did not significantly 
affect Hnf-4a mRNA expression levels as compared to the wt. In addition, we did not 
find reduced expression of Pdx-1 or known targets of Hnf-4a (e.g. L-Pk, Hnf-la, and 
Aldo-B). These results suggest that mechanism(s) exist(s), possibly through an 
autoregulatory feedback loop that can compensate for the loss of one hnf-4a allele. 
Furthermore, our results also suggest that factors that do not significantly reduce Pdx-1 
gene expression, like hnf-4a*'~/hnf-la*'~ and hnf-3fi*'~/hnf-4a*'~ (data not shown), are less 
likely to affect (3-cell activity. 
To study if allelic variation in pdx-1, hnf-3fl and hnf-la affected islet 
development, a detailed morphological analysis was performed. We did not detect 
differences in islet size although marked alterations in architecture were revealed by 
immunohistological analysis, with a-cells no longer confined to the islet periphery. 
However, the a-cells in double heterozygous mutant mice appeared to be functional (no 
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differences in plasma glucagon levels were observed in mice of various genotypes) and 
present at the same relative ratio to 3-cells as in wt. As a change in islet morphology has 
also been noted in nkx2.2, nkx6.1 and hnf-3fl-deficient mice (97, 144, 152), the reduced 
expression levels of these genes in pdx-1*'-/hnf-3fi*'- and pdx-1*'''/hnf-la*'' mice may 
therefore contribute to this phenotype. In addition, the double heterozygous mice had 
reduced expression of E-cadherin. E-cadherin is important to regulate adhesion between 
all pancreatic endocrine cells and to maintain correct islet topology (148, 154). 
Furthermore, the cell-to-cell contacts mediated by E-cadherin have been shown to be 
required for insulin secretion in response to nutrient stimuli (155). Therefore, the reduced 
E-cadherin levels observed in the islets of double mutant mice may not only lead to 
disorganized islets, but may also contribute to impaired glucose tolerance. 
In conclusion, we have created novel polygenic models for progressive pancreatic 
3-cell failure. Our results provide new molecular insights of how subclinical, genetically 
predisposing defects in the pancreatic islet transcription network can synergize to develop 
progressive 3-cell failure. Furthermore, these mutant mice provide unique models to 
dissect the epistatic interactions among different genes in complex pathways that regulate 
islet morphology and function, and to design specific therapeutic approaches that prevent 
3-cell failure. 
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C h a p t e r 5: T h e Role of Islet-Enriched Transcription Factors in 
the D e v e l o p m e n t of Pancreatic (3-Cells in vitro 
Introduction 
Both type 1 and type 2 diabetes mellitus result from an insufficient pancreatic 3-
cell mass. Type 1 diabetes mellitus (IDDM) is caused by a polygenic autoimmune 
disease that leads to the self-destruction of insulin producing pancreatic 3-cells. In type 2 
diabetes mellitus ( N I D D M ) , the inadequate functional 3-cell mass is due to impaired islet 
function and/or increased insulin demand often caused by insulin resistance. Strict 
glycemic control through intensive drug (glitazones, sulphonylureas) and/or insulin 
therapy can significantly retard the morbidity and mortality associated with diabetes (156, 
157). However, patient compliance to strict treatment regimen is often poor and thus 
normoglycemia is not maintained in the majority of cases. In principle, diabetes should 
be curable by maintaining sufficient 3-cell mass through reduction of autoimmune 
destruction, transplantation of exogenous 3-cells, and/or regeneration of islet cells. 
However, the success of these approaches are limited by the following obstacles: (1) 
immunosuppressive therapy used to treat autoimmune disease and to reduce graft 
rejection often themselves lead to diabetogenic side effects (158); (2) prolonged 
treatment with immunosuppressive agents are associated with several undesirable 
complications such as development of malignancies and susceptibility to infections; (3) 
islet transplantation is further limited by the shortage of purified islets from cadaveric 
donors; (4) the neogenic factor(s) necessary for in vivo islet regeneration remained to be 
identified. 
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The limitations of the above approaches along with the increased epidemic of 
diabetes demand a search for alternative source of islet cells. A promising approach to 
increase functional 3-cell mass is to use pluripotent embryonic stem (ES) cells to 
generate an unlimited supply of insulin producing cells. ES cells are non-transformed 
cells with normal karyotype, are capable of unlimited, undifferentiated proliferation in 
vitro, have the capacity to regenerate themselves, and can differentiate to generate all of 
the cell types in an organism (159). ES cells have also been used to study the 
differentiation of various cell types and tissues in vitro, such as neuronal cells (160, 161), 
hematopoietic lineages (162), and cardiomyocytes (163). Furthermore, these cells have 
been successfully transplanted into animals, where morphological and functional 
integration was demonstrated (163, 164). Recently, promising results have been reported 
for the generation of insulin producing cells from undifferentiated ES cells (165, 166). 
However, these initial advances suffer from several shortcomings that remain to be 
conquered. One major limitation is that the current stem cell differentiation protocol 
resulted in a mixture of cell types and that the percentage of cells expressing insulin at 
best reached 15% (165, 166). A recent report used cell trapping strategy to increase the 
functional consistency in the differentiated ES cells (167). However, this method resulted 
in possibility transformed cells that may have malignant potential. Despite the 
limitations, these results demonstrated that ES cells can give rise to different cell types of 
the endocrine pancreas. Furthermore, pure populations of insulin producing cells with the 
desired phenotypes may be obtained with more elaborate selection and differentiation 
schemes that are compatible with normal 3-cell development. This will most likely 
require similar patterning, inductive, and cell intrinsic signals that are important for in 
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vivo pancreas development. 
The endocrine and exocrine pancreas are derived from the endodermal cells of the 
upper duodenal region of the foregut (fig. 5-1) (168). The gut epithelium that will become 
the future dorsal pancreatic bud is initially in direct contact with the notochord (169). At 
the 13-somite stage around embryonic day 8.5 (E8.5), the notochord secretes a variety of 
potent signaling molecules such as the TGF-3 family member activin-3 and fibroblast 
growth factor (FGF)-2. These two inductive factors have been implicated in the 
repression of two members of the hedgehog family of signaling molecules, sonic 
hedgehog (Shh) and indian hedgehog (Ihh), in the presumptive dorsal pancreatic 
endoderm and thus, allow the formation of the dorsal pancreatic bud and expression of 
pancreatic marker pdx-1 (170-172). In contrast, the exclusion of Shh and Ihh expression 
from the ventral pancreatic epithelium may be achieved by a notochord-independent 
mechanism. The budding of the dorsal and ventral pancreas occurs on E9 and E10.5 
respectively (173). The growth, morphogenesis, and differentiation of the dorsal 
pancreatic bud require the function of two homeobox transcription factors, pancreatic and 
duodena] homeobox gene-1 (Pdx-1) and homeobox gen-9 (Hlxb9), whereas the function 
of Hlxb9 is dispensable for the ventral bud (54, 55, 174). A few insulin-expressing cells 
appear within a day after bud formation, and these early insulin-expressing cells often co-
express glucagon (175). Fully differentiated 3-cells first appear around E13 at the start of 
a massive wave of 3-cell proliferation and differentiation named the secondary transition 
(176). Fusion of the dorsal and ventral pancreatic bud occurs around E16/17 (177). The 
specification of endocrine and exocrine fate utilizes the Notch signaling pathway and 
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Figure 5-1. Proposed model for pancreatic cell differentiation. This diagram shows the cell extrinsic 
and intrinsic factors that are vital for pancreatic development. The numbers on the left (E8-P1) indicate 
the approximate time in the requirement of these factors. 
with active Notch-signaling express the b H L H class transcription factor P48, which is 
required for the generation of exocrine pancreas. In contrast, cells that lack Notch-
signaling express the transcriptional factor neurogenin (Ngn) 3 and adopt an endocrine 
fate (178, 180, 181). The endocrine cells subsequently migrate to the adjacent 
mesenchyme where they aggregate and form typical architecture of mature islets with 
insulin expressing cell in the center and non-insulin-producing cells in the periphery at 
about E18.5 (175). In late embryogenesis and early postnatal life, as the wave of 3-cell 
neogenesis that initiated with the secondary transition starts to wane, the proliferation of 
pre-existing 3-cells produce a further increase in 3-cell number (182). The endocrine 
pancreas develops the ability to sense glucose and regulate insulin secretion only after 
birth (175, 183). 
Mouse genetic studies have uncovered an emerging developmental pathway 
controlled by several transcription factors that are essential for the development of the 
endocrine and exocrine pancreas (184). The transcription factors Pdx-1, hepatocyte 
nuclear factor (Hnf)-33, Ngn3, and Hlxb9 are required for the early stages of pancreas 
development (fig. 5-1). For example, mice that are deficient for the Pdx-1 lack a pancreas 
(54, 55, 174). Hnf-33 is temporally expressed earlier than Pdx-1 and has been shown to 
bind to conserved regulatory elements in the mouse and human pdx-1 promoters and 
activate their transcription (57, 59). Ngn3 null mice fail to generate any pancreatic 
endocrine cells and die postnatally from diabetes (181). Finally, Hlxb9 deficient mice 
selectively ablate the dorsal pancreas (185, 186). In addition to the above transcription 
factors, late pancreatic differentiation requires the function of islet 1 (Isll), NK 
homeobox (Nkx) 2.2, Nkx6.1, paired box gene (Pax) 4, Pax6, neurogenic differentiation 
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1 (NeuroDl), Hnf-la, and Hnf-3a (36, 37, 42, 71, 123, 144, 152, 187-190). Disruption of 
these transcription factors affect the differentiation state, proportion, and/or function of 
the different endocrine cell types, indicating that they act in various combinations to 
ensure the correct endocrine differentiation during late pancreatic ontology. 
The development of the pancreas shares many similarities to neuronal cells. 
Analogous to the central nervous system (CNS), the process of lateral specification 
mediated by the Notch signaling pathway specifies endocrine and exocrine cell fate from 
a homogenous field of cells. Furthermore, the pancreas and the CNS share many cell 
intrinsic factors that are vital for their proper differentiation such as Isll, NeuroDl, Pax4, 
Pax6, Nkx2.2, and Hnf-33- In mis study, we describe a differentiation scheme that would 
direct the differentiation of ES cells into pancreatic endocrine cells based on the 
similarities between islet and neuronal cell development. We also establish the use of 
fluorescence-activated cell-sorting (FACS) to quantitate the proportion of endocrine 
precursors that were generated at various stages of the differentiation protocol and to 
isolate these precursors to over 90% purity. In addition, the function of different cell 
intrinsic factors in pancreatic development were studied by generating pdx-T1' ES cells 
and differentiating these cells along with hnf-3 a, hnf-3 fi, and hnf-4 a null ES cells. The 
roles of these transcription factors in development were analyzed by gene expression 
profiling and by their ability to secrete insulin in response to glucose and other 
secretagogues. Finally, a mouse transgene was constructed in which enhanced green 
fluorescent protein (EGFP) is driven by the Pdx-1 promoter. We determined that mice 
carrying this transgene express EGFP in insulin producing 3-cells and in islet periductal 
cells (putative adult pancreatic stem cells). This transgenic mouse will be used in future 
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studies to study pancreatic development, 3-cell neogenesis, and expansion and 
transdifferentiation of pancreatic duct cells in vivo. 
Results: 
Differentiation of ES Cells into Pancreatic Endocrine Cells 
The differentiation protocol was divided into 4 stages (Fig. 5-2). In stage 1, ES 
cells were grown on gelatin-coated plates in the absence of mouse embryonic fibroblasts 
(MEF) and leukemia inhibitory factor (LIF). This stage is to initiate differentiation and to 
reduce the number of MEF in the culture. To induce embryoid bodies (EB) formation 
(stage 2), ES cells were grown in suspension on non-adherent petri dishes. Generation of 
EB is important because they provide many of the conditions (polarized cell contact, 
production of growth factors, cell-cell interactions, etc..) necessary to produce cells of 
different lineages. Cells at the end of stage 1 and 2 were stained with primary anti-insulin 
and anti-glucagon antibodies, however, no insulin or glucagon positive cells were 
detected (data not shown). 
Recent studies have shown that nestin, an intermediate filament protein, is a 
marker for precursor cells of certain lineages including neuronal cells and hormone 
negative pancreatic endocrine precursors (160, 191-193). Nestin expressing cells were 
selected by growing EB in serum free medium supplemented with insulin, transferrin, 
selenium, and fibronectin (ITSF) supplement (stage 3). The nestin positive cells were 
then expanded by using 2 mitogens, basic fibroblast growth factor (bFGF) and nerve 
growth factor (3NGF), that were shown to maintain the expression of pdx-1 and promote 
the development of pancreas (60, 170, 194-197). Cells at the end of this stage are 
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extensions, and grow as separated cells (Fig. 5-3A, B). Occasionally w e observed a few 
neurons in the culture express glucagon (Fig. 5-3B, C). Many smaller and rounded cells 
are also present and aggregate into clusters (Fig. 5-3A and Fig. 5-4A, B). To determine if 
these cell aggregates express any of the pancreatic hormones, we stained them using 
primary anti-insulin (red) and anti-glucagon (green) antibodies to visualize (3- and a-cells 
respectively. We found that both hormones were generated in the clusters and that 
numerous cells co-express insulin and glucagon (yellow) (Fig. 5-4E, F arrow). In 
addition, cells in these clusters appeared to be polarized with the majority of insulin or 
double positive cells surrounded by glucagon expressing cells (Fig. 5-4E, F). This is 
reminiscent of pancreatic islet morphology. 
In stage 4 of the differentiation protocol, these endocrine cells were grown under 
low glucose with the addition of nicotinamide and B27. The cells continued to aggregate 
themselves into clusters (Fig. 5-5A, B). These hormone positive clusters proceed to 
organize into pancreatic islet like topology with a majority of glucagon producing cells 
forming a mantle around insulin and double positive cells (Fig. 5-5E, F). At the end of 
this stage, fewer cells were stained with both insulin and glucagon (Fig. 5-5E, F). In 
addition, we observed that insulin positive cells were increased and glucagon positive 
cells were decreased relative to stage 3 differentiation (compare Fig. 5-5E, F with Fig. 5-
4E, F). These results show that the differentiation protocol generates cells that express 
pancreatic hormones and that they organize into islet like cell clusters. 
Role of Pdx-1 in pancreatic endocrine development in vitro 
The phenotypes observed in the (3-cell specific and complete inactivation of the 
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well as in (3-cell differentiation and function. To study the role of pdx-1 in differentiating 
ES cells, we generated three independent pdx-1 null ES cell lines by culturing the pdx-T' 
ES cells (pdx-1 is disrupted by a lacZ knockin) in high concentrations of G418 medium 
(55). The frequency in generating pdx-1 null ES cells were: 0/200 at 1.0 mg/ml G418, 
2/200 at 1.5 mg/ml G418, and 1/200 at 2.0 mg/ml G418. The genotypes of these clones 
were analyzed by Southern blot analysis, which confirmed the precise targeting of the 
remaining pdx-1 allele without DNA rearrangement and gene duplication (Fig. 5-6A). 
They were also additionally confirmed by Western blot analysis showing that no 
functional PDX were produced in pdx-1 null ES cells (Fig. 5-6B). 
The different pdx-T1' ES cell lines were differentiated and analyzed by 
immunofluorescent staining for insulin and glucagon at the end of stage 1, 3, and 4. 
Similar to the WT, we did not detect insulin or glucagon positive cells at stage 1 and 2 
(data not shown). The pdx-1 null ES cells also begin to aggregate in stage 3 (Fig. 5-4C, 
D). However, these pancreatic precursors contained much less hormone positive cells 
than WT and that majority of these cells were localized to the periphery of the cluster 
(compare Fig. 5-4G with 5-4E, F). A few insulin, glucagon, and double positive cells 
were detected in isolation away from other hormone positive cells (Fig. 5-4H). 
In stage 4 of the differentiation protocol, the cultures that contained pdx-1 
deficient cells were observed to have more neuronal structures than WT cultures (data not 
shown). The morphology of various cell types was examined by differential interference 
contrast (DIC) microscopy, however no differences between wt and pdx-T1' cells or the 
structures that they form were detected (Fig. 5-5A-D, data not shown). In contrast to wt, 
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Figure 5-6. Generation of pdx-1'1' ES cells, pdx-1-'- ES cells were produced 
by selection of pdx-1+/- ES cells in high concentration of G418. (A) Southern 
blot analysis of D N A samples digested with EcoRI from wildtype, pdx-1 
heterozygous, and pdx-1 null ES cells, pdx-1 targeted band is 3.8 kb and 
endogenous pdx-1 band is 3 kb (B) Western blot analysis of nuclear extracts 
generated from differentiated ES cells showing that no Pdx-1 proteins were 
produced in the null cell lines. TBP is the nuclear extract loading control 
showing equal loading in each sample. 
typically surrounded by hormone negative cells in the cluster (compare Fig. 5-5G to 5-
5E, F). In addition, cells that express insulin, glucagon, or both were scattered among 
hormone negative cells (Fig. 5-5H). These results revealed that the homeodomain 
transcription factor Pdx-1 is critically involved in organizing cells into clusters with islet 
like topology in vitro. Furthermore, Pdx-1 plays an important role in either generating 
pancreatic endocrine cells or maintaining their phenotype. 
Role of Pdx-1 in pancreatic endocrine cell function in vitro 
To assess the physiological effects of various cell intrinsic factors that are 
important for islet development, we differentiated wt, pdx-1*'', pdx-T'', hnf-3 a'1', hnf-3 fi'', 
and hnf-4 a'1' ES cells. Their insulin contents and secretory responses to different insulin 
secretagogues such as glucose, glucagon-like peptide (GLP)-l, and tolbutamide were 
determined. At the end of stage 3, only the insulin content of pdx-T'' cells were 
significantly lower than wt (28.9±4.4 vs. 53.1 ±3.5 ng/mg, /?=0.003) (Fig. 5-7). Even 
though cells of various genotypes at the end of stage 3 produced insulin, they were not 
responsive to any of the insulin secretagogues (Fig. 5-8, data not shown). 
The total insulin content at the end of stage 4 increased over stage 3 for wt and all 
mutants except for Pdx-1 null cells (wt 2.0 fold increase, pdx-1+1- 1.9 fold increase, hnf-
3a''\.l fold increase, hnf-3fi~'' 1.9 fold, and hnf-4a'' 2.0 fold) (Fig. 5-7). The 
intracellular insulin content of pdx-T1' cells were significantly lower than wt (36.4±2.3 vs. 
108.4±8.6 ng/mg, p=0.002) (Fig. 5-7). We did not observe any significant differences in 
total insulin levels between other mutants and wt. We found that wt cells could secrete 
insulin in response to different stimuli at the end of stage 4 (tolbutamide 2.4 fold 















• Stage 3 
| Stage 4 
Figure 5-7. Loss of Pdx-1 reduces insulin production. Wildtype, pdx-V'-, 
hnf-3a'-, hnf-3fi-'-, and hnf-4a'~ increased total intracellular insulin content with 
progressive differentiation. In contrast, pdx-1 null ES cells have diminished 
insulin content. Grey and black bars represent insulin content measured at 
stage 3 and 4, respectively. The results were reproduced in at least 3 
independent experiments for the wildtype and pdx-1+/- cells. At least 2 
independent null clones for each genotype were used. Insulin values for the 
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with the exception of pdx-1 null mutants, cells of various other genotypes also showed 
secretagogue-induced insulin secretion (Fig. 5-9). However, wt exhibited better insulin 
secretory response relative to cells with gene disruptions in pdx-1, hnf-3 a, and hnf-3 fi 
(Table 5-1). 
Insulin content and glucose stimulated insulin secretion (GSIS) were measured in 
isolated pancreatic islets and compared to insulin producing cells generated in vitro. We 
found that the total intracellular insulin content for pancreatic islets, of which 90% are 
insulin producing, was 115 /xg/mg. Wt cells at the end of stage 4 contain 0.1 ^g/mg of 
insulin, however not all of them are insulin producing. Using flow cytometry, we 
determined that approximately 20% of all cells at stage 4 express Pdx-1 (Fig. 5-12). 
Assuming that 50% of the Pdx-1 positive cells also express insulin, the total insulin 
producing cells is 10% of all cells at the end of stage 4. Since insulin producing cells 
account for only 10% of all cells, the actual insulin content per insulin producing cell 
may be 1.0 Mg/mg. This would mean that the insulin producing cells at the end of stage 4 
have approximately 100 times less insulin than pancreatic islets (1.0 Mg/mg vs. 115 
Mg/mg). GSIS was compared between pancreatic islets and insulin producing cells 
generated in vitro. We found that islets increased insulin secretion by 37.9 fold in 
response to glucose (Fig. 5-10), in contrast, wildtype cells at the end of stage 4 increased 
insulin secretion by 2.4 fold (Fig. 5-9). 
Our physiological assessments revealed that insulin positive cells undergo 
significant maturation between stage 3 and 4. We found that insulin content increased 
approximately 2 fold from stage 3 to stage 4 and that the insulin positive cells developed 
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Baseline 30 Minutes 
Figure 5-10 Glucose stimulated insulin secretion in isolated pancreatic 
islets. Insulin release in response to glucose challenge (16.6 m M ) was 
measured 30 minutes after induction in static incubations. Islets increased 
insulin secretion by 37.9 fold in response to glucose, approximately 15 times 
more responsive than wildtype differentiated cells at stage 4. Results were the 
average of 4 independent experiments. Data are shown as mean ± SEM. 
effects of various cell intrinsic factors that are important for pancreatic (3-cell 
development and function were also assessed in our in vitro system. We found that 
insulin production and secretion is critically dependent upon the homeodomain 
transcription factor, Pdx-1. In contrast, deficiencies in Hnf-3oc and Hnf-3(3 only mildly 
impaired insulin secretory responses but not insulin production. Finally, insulin 
producing cells generated by in vitro differentiation were compared to pancreatic islets. 
We showed that the insulin positive cells generated in this system contained about 1% of 
insulin compared to pancreatic (3-cells. In addition, differentiated ES cells were less 
efficient in releasing insulin in response to glucose challenge. 
Role of Pdx-1 in pancreatic endocrine cell formation in vitro 
The temporal and spatial expression patterns of the pdx-1 gene indicate that it is 
an ideal marker to identify pancreatic endocrine cells. Consequently, pdx-1*'' and pdx-T1' 
ES cells (generated by the LacZ gene knocked into the Pdx-1 locus) can be used as 
reporter cells to study pancreatic development in vitro. After differentiation of these 
reporter cells, (3-galactosidase ((3-gal) should be expressed in all the pancreatic cell 
lineages. A vital fluorogenic substrate for LacZ, 5-chloromethylfluorescein di-(3-D-
galactopyranoside (CMFDG), was used to label pancreatic endocrine cells. In LacZ 
positive cells, CMFDG is converted to a bright green fluorescent product. Because 
loading with CMFDG is based on osmolar shock, propidium iodide (PI) was used to 
identify dead cells by labeling them with a red nuclear fluorescence. These labeled 
pancreatic endocrine cells could then be quantitated by flow cytometry. 
pdx-1*1' and pdx-T1' ES cells were differentiated and stained with CMFDG at the 
end of stage 2, 3, and 4, and the proportion of LacZ/Pdx-1 positive cells was determined 
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by flow cytometry. Figure 5-11 shows the typical controls that were done for each flow 
cytometric measurement. We found that about 40% of the cells survived the CMFDG 
loading procedure as indicated by PI negative staining (Fig. 5-11 A). Only live cells (PI 
negative) were used to determine the percentage of cells that stained with CMFDG 
(fluorescein positive). The background fluorescein level was determined by using cells 
not stained with CMFDG and was used to set the region to detect LacZ/Pdx-1 positive 
cells. Less than 0.064% of the unstained cells were in the fluorescein positive interval 
(Fig. 5-1 IB). In wt cells (without the lacZ transgene), less than 0.87% of the cells are 
stained with CMFDG (Fig. 5-1 IC). To confirm that the LacZ/Pdx-1 positive cells were 
stained with CMFDG, we collected fluorescein positive and negative cells by 
fluorescence-activated cell-sorting (FACS) and analyzed them by microscopy and gene 
expression. We determined that fluorescein positive and negative cells were green and 
unstained respectively, under fluorescent microscope (Fig. 5-1 IE, F, and data not shown). 
In addition, there was selective enrichment of LacZ and/or Pdx-1 expression in 
fluorescein positive cells (Fig. 5-14). 
Figure 5-12 shows the representative CMFDG staining profiles of pdx-1*1' and 
pdx-T1' cells at the end of differentiation stages 2. 3, and 4. The percentages of LacZ/Pdx-
1 positive cells representing pancreatic endocrine cells (fluorescein positive/PI negative) 
were determined. We found that the proportions of LacZ/Pdx-1 positive cells at the end 
of stage 2 were similar between ES cells with one or no functional copies of pdx-1 (fig. 5-
12A, D, G). The number of pdx-1*'' cells that were fluorescein positive and PI negative 
increased approximately 4-fold from stage 2 to stage 3 (Fig. 5-12A, B). In contrast, this 
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Figure 5-11 Flow cytometry controls to isolate lacZ+/Pdx-1 +population. (A) The 
propidium iodide (PI) negative cells represent the live cells and approximately 4 0 % of the 
cells are PI negative after staining with the vital fluorogenicsubstrate for lacZ, 5-
chloromethyifluoresceindi-(3-D-galactopyranoside ( C M F D G ) . T h e PI negative population 
w a s gated and their fluorescein content (representing lacZ expression) w a s determined. 
(B) This figure shows the fluorescein intensity of unstained cells. Typically, less than 
0.064% of the unstained cells exhibit fluorescein stain. (C) In wildtype cells (without the 
lacZ transgene), less than 0.87% of the cells were stained with C M F D G . (D) T h e purity 
of the fluorescein containing cells were determined at the conclusion of the cell sort. 
Typically, about 9 0 % purity w a s achieved from the sorting protocol. (E) & (F) Cells after 
sorting for fluorescein were examined by microscopy under transmission light in (E) and 
U V light in (F). 
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Figure 5-13. X-gal stain of pdx- 1+lm and Pdx-7_/- differentiated E S cells, pdx-
1+/- (A) and pdx-1'1' (B) E S cells were differentiated and stained with X-gal at the 
end of stage 4. Numerous X-gal positive (blue) cells (representing endocrine 
cells, LacZ/Pdx-1 positive) were observed in hormone positive cell clusters of 
differentiated pdx-1+/- cells (A). In contrast, few X-gal positive cells were detected 
scattered among X-gal negative cells (B). 
functional Pdx-1 protein (Fig. 5-12D, E, G, and H ) . The percentage of this population 
remained stable from stage 3 to stage 4 in both the pdx-1*1' and pdx-T'' cells (Fig. 5-12B, 
C, E, F, H, and I). The decreased number of LacZ/Pdx-1 positive population in 
differentiated pdx-T1' cells were also confirmed by X-gal staining (Fig. 5-13A, B). 
Overall, these results showed that the homeodomain transcription factor Pdx-1 is 
important to generate cells committed to the pancreatic fate. In addition, differences in 
the rate of proliferation and apoptosis during phase 3 of stage 3 differentiation were ruled 
out as possible mechanisms that caused decreased pancreatic population in pdx-T'' cells. 
Isolation and Molecular Characterization of LacZ/Pdx-1 Positive Cells 
By staining pdx-1*1' and pdx-T'' cells with the vital fluorescent P-gal substrate 
CMFDG and analyzing by flow cytometry, we identified a population of cells 
(fluorescein positive) that may have committed into pancreatic fate. Furthermore, in the 
absence of Pdx-1, there were less putative pancreatic cells and that they had significantly 
lower total insulin content along with an inability to secrete insulin in response to 
secretagogues. To study the molecular mechanisms that are responsible for these 
differences, we isolated these putative pancreatic cells by fluorescence-activated cell 
sorting (FACS) and analyzed their steady-state mRNA levels. 
At least 200,000 LacZ/Pdx-1 positive cells were isolated from pdx-1*'' and pdx-T'' 
cells at the end of stage 2, 3, and 4 for expression analysis. In addition, LacZ/Pdx-1 
negative cells were also isolated and used as controls. At the end of each FACS 
experiments, we determined the purity of our isolated cells. Only isolated cells with over 
90% purity were used for gene expression profiling (Fig. 5-1 ID). The cDNA of pdx-1 
heterozygous cells were generated from two independent differentiations and the pdx-T1' 
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cDNAs were synthesized from two different pdx-1 null clones. W e measured expression 
of different pancreatic developmental markers as well as genes shown to be important for 
pancreatic development and function in order to characterize LacZ/Pdx-1 positive cells 
from with one or no functional pdx-1 allele. 
Hypoxanthine phosporibosyltransferase (Hprt) expression levels were determined 
to show that each sample contained equivalent amounts of mRNA (Fig. 5-14). No 
products were amplified in the absence of reverse transcriptase (Hprt-RT), indicating the 
absence of genomic DNA in the mRNA samples. The expression of LacZ and Pdx-1 
were additional controls confirming the genotype and the enrichment of the desired 
population (Fig. 5-14). The expression pattern of nestin showed that nestin positive cells 
were indeed selected during stage 3 and that as differentiation progressed (stage 4), 
downregulation of nestin occurs (Fig. 5-14). We observed that LacZ/Pdx-1 positive cells 
expressed many pancreatic markers including Ngn-3, Hnf-3(3, P48, Isl-1, NeuroDl, 
Nkx2.2, Nkx6.1, Pax6, Pax4, insulin, and glucagon. These pancreatic markers can be 
subdivided based upon their requirement in the pathway of pancreatic development (Fig. 
5-1). We observed that the expression of Hnf-3(3 in pdx-1*1' cells was decreased with 
differentiation. In contrast, the expression of Hnf-3(3 was maintained in pdx-T1' cells. 
mRNA levels of the pro-endocrine gene, Ngn3, increased with differentiation and was 
not regulated by Pdx-1. The expression of P48, the pro-exocrine gene, was not regulated 
by Pdx-1 but its expression was enriched in LacZ/Pdx-1 cells. These results indicate that 
Pdx-1 does not affect early pancreatic development and specification of exocrine and 

































































Figure 5-14. Gene 
expression profile of 
isolated pancreatic 
endocrine cells. RT-PCR 
analysis of pancreas 
developmental markers 
and genes important for 
pancreatic function was 
performed on LacZ/Pdx-1 
positive cells isolated by 
FACS. cDNAs were made 
from at least 200,000 
LacZ/Pdx-1 positive cells 
isolated from pdx-1+/- and 
pdx-1-'- cells at the end of 
stage 2, 3, and 4. Each 
differentiation stage 
contained the following 
samples: one sample of 
LacZ/Pdx-1 negative 
population from pdx-1+/-
cells, two samples of 
LacZ/Pdx-1 positive 
population from pdx-1+/-
cells from 2 independent 
isolations, and finally 2 
samples of LacZ/Pdx-1 
positive population from 2 
different pdx-1-'- clones. 
Transcript levels were 
measured in the isolated 
cell population by RT-PCR 
using [a-32P]dCTP- PCR 
products were separated 
by PAGE, and bands were 
visualized by 
autoradiography. 
W e observed that Pdx-1 is critically important for the subsequent differentiation 
of pancreatic endocrine cells after the initial fate specification. Pdx-1 regulated the 
expression of several transcription factors that are important to determine the lineage of 
islet cells including Nkx2.2, Nkx6.1, Pax6, and Pax4 (Fig. 5-14). Lack of Pdx-1 function 
does not affect the expression of Isl-1 and NeuroDl (Fig. 5-14), suggesting that in pdx-T1' 
cells, the arrest of pancreatic differentiation occurred after the requirement for Isl-1 and 
NeuroDl. As expected, the expression of insulin and glucagon were drastically reduced 
in the absence of Pdx-1. 
Overall, our results showed that pancreatic endocrine cells can be generated in 
vitro and be isolated to over 90% purity by FACS. In addition, we showed that the 
phenotypic defects in pdx-T1' cells might be caused by an arrest of pancreatic endocrine 
development downstream of the requirement for Isl-1 and NeuroDl. 
Generation of pdx-1-EGFP Transgenic Mice. 
To generate an in vivo mouse model to study pancreatic (3-cell development, a 
mouse transgene was constructed in which the pdx-1 promoter drives enhanced green 
fluorescent protein (EGFP). A transgenic approach was selected because an EGFP 
knocked into the pdx-1 locus would result in diabetic mice and may compromise 
pancreatic development and gene expression in these mice. During murine 
embryogenesis, Pdx-1 is initially expressed throughout the pancreas and parts of the 
stomach and duodenum. Its expression becomes progressively restricted to pancreatic [3-
cells by birth. Therefore both pancreatic precursors as well as (3-cell of the transgenic 
mice can be selected by the presence of EGFP and studied subsequently. 
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Figure 5-15. Generation of Pdx-EGFP Transgenic Mouse. (A) A 
schematic diagram showing the pPdx-1-pEGFP transgenic construct. In 
mice carrying this transgene, the expression of G F P was found in the 
adult pancreatic islets (B and C) as well as in periductal cells (D and E). 
The pdx-1 promoter was isolated by screening a mouse genomic library. A 4.5 kb 
pdx-1 promoter was cloned upstream of the EGFP to generate the mouse transgene (Fig. 
5-15A). This transgene was transfected in an insulinoma cell line HIT-T15 and 
functionally confirmed that EGFP is expressed (data not shown). The pPdx-1-pEGFP 
construct was used to generate 19 founder mice. The pancreas from the progeny of these 
founders were examined and only one exhibited EGFP expression in pancreatic [3-cells 
(Fig. 5-15B-E). In addition, we observed that isolated cells next to pancreatic ducts 
expressed EGFP (Fig. 5-15D, E), which may represent adult endocrine precursor cells or 
ductal cells (198). We are currently checking whether the transgenic EGFP expression 
exactly mimics Pdx-1 expression both spatially and temporally during development. 
We have generated mice carrying EGFP under the control of pdx-1 promoter. In 
the adult, we found EGFP expression in pancreatic (3-cells as well as in periductal cells 
which may be adult endocrine precursors. This transgenic mouse is an important reagent 
for the lab in the future. 
Discussion: 
Despite the minute size of the pancreatic islets, the endocrine pancreas is a critical 
organ for maintaining glucose homeostasis and plays a key role in the etiology of type 1 
and type 2 diabetes mellitus. Diabetes is one of the most costly chronic disease of 
children, adolescents, and adults and frequently lead to microvascular and macrovascular 
complications (1). Replacement of functional pancreatic (3-cell mass through islet 
transplantation may be a cure for type 1 and in some cases type 2 diabetes mellitus. 
However, problems such as paucity of doners and immunosuppressive therapy limited the 
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success of islet transplantation. Therefore, a major goal in the treatment of diabetes is to 
generate alternative sources of (3-cells that can maintain glucose homeostasis in 
transplanted host. Because ES cells are capable of both self-renewal and can differentiate 
into a variety of lineages, they may represent one such unlimited source of pancreatic (3-
cells. We utilized the developmental similarities between neurons and islets to generate 
insulin producing cells from ES cells. Even though the pancreas (endoderm) and neurons 
(ectoderm) are derived from different embryonic germ layers and are functionally 
distinct, comparable signaling pathways, inductive molecules, and cell intrinsic factors 
control their development and function. These similarities suggest that methods that were 
used to generate neurons could also be adopted to produce pancreatic endocrine cells. 
Recently, promising results have demonstrated that pancreatic hormone producing cells 
can be generated from ES cells in vitro by using strategies that were established for 
neural differentiation (160, 166). To generate cells expressing insulin and other 
pancreatic islet specific markers, we have adopted a modified neural differentiation 
protocol and developed a differentiation scheme that would direct the differentiation of 
ES cells into pancreatic endocrine cells. Figure 5-2 summarizes the differentiation 
scheme. 
There are several critical steps in the differentiation protocol. The first important 
step is in the generation of EB. EB may be the first in vitro differentiated structure to 
contain cells from different germ layers (ie endoderm) and to provide conditions such as 
polarized cell contact, cell-cell interactions, and production of growth factors necessary 
to generate and maintain cells of different lineages. To achieve this state, EB must be 
metabolically active and as a result, the media should turn quite yellow everyday. Since 
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differentiation is promoted in less than optimal growth conditions (ie upon growth factor 
withdrawal and in limiting resources), media is changed at most once a day. If EB are not 
metabolically active, then differentiation should be restarted. 
Stage 3 contains several critical steps in the differentiation procedure. In phase 1 
of stage 3, at least 50% of dissociated EB should attach to tissue culture plates to ensure 
that the cells which have initiated into pancreatic fate are selected and enriched in 
subsequent steps of differentiation. We have tested different coating reagents including 
laminin, collagen, fibronectin, gelatin, poly-D-lysine, and poly-L-lysine and found that 
tissue culture plates coated with the combination of poly-D-lysine, fibronectin, and 
gelatin are the most favorable for cell adherence. Recent studies have shown that there 
are pluripotential stem cells in the brain that are capable of differentiating into neuronal 
cells (160, 193, 199). These cells have in common with hormone negative pancreatic 
endocrine precursors in that they both express nestin, an intermediate filament protein 
(191, 200). The nestin-positive hormone negative cells isolated from adult pancreas can 
differentiate ex vivo into insulin and glucagon expressing cells (192). We therefore 
hypothesized that pancreatic endocrine cells may be generated in vitro by first 
differentiating ES cells into nestin positive cells. This is achieved by growing dissociated 
EB in serum free ITSF medium to select for nestin positive cells (160, 166). Pancreatic 
ductal cells, which may represent adult pancreatic stem cells, are also differentiated into 
insulin positive cells by culturing in serum free ITSF medium (198, 201). The resulting 
nestin positive cells are then expanded and directed into pancreatic fate using bFGF, 
(3NGF, nicotinamide and B27. bFGF and (3NGF were used as mitogens over other growth 
factors because they were shown both in vitro and in vivo to be essential for pancreas 
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development (60, 170, 194-197). Nicotinamide and B27 supplement were used because 
they were shown in vitro to promote the generation of pancreatic endocrine cells (166, 
167, 202, 203). Despite the "propancreatic" reagents used for differentiation, the cells at 
the end of stage 3 differentiation are morphologically heterogeneous, although 2 major 
cell types predominate: small rounded cell clusters and large neuronal cells. Consistent 
with a previous report that used a similar differentiation strategy, the cell clusters formed 
at the end of this stage express insulin and glucagon (166). The hormone producing cells 
in the cluster organize into islet-like topology with majority of glucagon positive cells 
located at the periphery of the cluster. In contrast to the report by Lumelsky et. al., we 
found that there are numerous insulin and glucagon double positive cells. Although not 
conclusive, our data suggest that (3- and a- cells arise from a common progenitor in vitro. 
Differentiated cells at the end of stage 3 were tested for their ability to use 
physiological signaling pathways to regulate insulin release. The insulin secretagogues 
used are glucose, tolbutamide, and GLP-1. Glucose targets the first step of GSIS and is 
used to check if the insulin positive cells developed machinery for glucose sensing. 
Tolbutamide an anti-diabetic drug that targets the sulphonylurea receptor (Surl) induces 
the closure of ATP sensitive potassium channel which leads to membrane depolarization 
and insulin release (204). GLP-1 stimulates insulin secretion by an ATP-sensitive 
potassium channel-independent pathway by targeting cAMP/protein kinaseA (205). We 
found that the insulin positive cells at the end of stage 3 are unable to secrete insulin in 
response to these secretagogues, suggesting that in vitro, cells committed to the panceatic 
P-cell fate produce insulin before developing machinery that would couple physiological 
signal to insulin secretion. 
136 
The pancreatic hormone producing cells undergo a maturation process during 
stage 4. Growth factors are withdrawn to induce further differentiation. In addition. 
glucose levels are gradually lowered from 25 mM to 6 mM in the culture medium. Low 
glucose concentration is used at stage 4 because elevated glucose level alters gene 
expression and the phenotype of pancreatic P-cells in vitro (167, 206, 207). Recently, 
chronic hyperglycemia was shown to trigger loss of P-cell differentiation in a rat model 
of diabetes (208). The morphology of cells at the end of stage 4 is similar to that at stage 
3 with numerous large neurons and small, rounded cells that aggregated into clusters. The 
hormone positive clusters continue to organize into structures with islet-like topology 
with insulin or insulin/glucagon double positive cells surrounded by glucagon expressing 
cells. Even though cells that co-express insulin and glucagon were also observed in stage 
4, the proportion of double positive cells are less than in stage 3. In contrast, the number 
of insulin positive cells increased in stage 4 suggesting that differentiation of double 
positive precursors into insulin producing cells had occurred. The functional 
characteristics of stage 3 and 4 islet like clusters were compared by their insulin content 
and their insulin secretory response. We found that the total cellular insulin content is 
increased. Furthermore, stage 4 cells are responsive to different insulin stimuli indicating 
that significant functional maturation also occurred between stage 3 and 4. 
The "holy grail" in ES cell transplantation for treating diabetes is to reconstitute 
all of the biochemical, molecular, and physiological functions of pancreatic P-cells in 
differentiated ES cells. Morphologically, we have generated islet like structures that 
express pancreatic hormones. A series of experiments were performed to compare the 
functional characteristics of stage 4 islet like clusters and pancreatic islets. We found that 
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the insulin content of in vitro hormone positive cells is 1 % of pancreatic islets. In four 
independent experiments with 25 islets each, we found that stage 4 cells were about 15 
times less efficient in their GSIS response than pancreatic islets (2.4 fold induction vs. 
37.9 fold induction). These data showed that although the in vitro cells have similar 
insulin secretory response to physiological cue as pancreatic islets, the signaling 
pathways to regulate insulin release may not be fully developed. The hormone positive 
cells generated by our procedure may represent pancreatic endocrine precursors and that 
additional refinements in culturing condition are necessary to further differentiate and/or 
mature these cells to have the same functional capabilities as pancreatic islets. Additional 
conditions may be to culture cell clusters from stage 4 on Matrigel, a commercial 
preparation of murine basement membrane, with keratinocyte growth factor (KGF), and 
GLP-1 since these components were required to differentiate pancreatic ductal tissue into 
glucose responsive islet tissue ex vivo (201, 209). 
Spatial and temporal modifications of gene expression by different cell intrinsic 
and extrinsic factors direct the process of development from endoderm precursors to 
differentiated P-cells in vivo. To determine if ES cells in combination with our 
differentiation protocol can be used as a model system to study endocrine development, 
we differentiated WT, pdx-1*'', pdx-T'', hnf-3a'', hnf-3fi'' and hnf-4a''' ES cells and 
compared their functional efficacy with respect to insulin content and physiologically 
relevant insulin secretion pathways. Three classes of phenotype can be catagorized: (1) 
reduced insulin content and complete lack of insulin secretion response {pdx-T1'), (2) 
impaired insulin secretion response (pdx-T1', hnf-3a''', hnf-3 fi'1' ), and (3) similar 
functional response as differentiated WT cells (hnf-4a1'). Based upon the observed 
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defects, the function of Pdx-1 may lie upstream of Hnf-3a, Hnf-3P, and Hnf-4a in the in 
vitro pathway of pancreas development. Differentiated pdx-1*1', hnf-3a'\ and hnf-3 fi1' 
cells exhibited milder defect than pdx-1 null cells and may represent endocrine precursors 
unable to complete functional maturation. The phenotype of Hnf-4a suggests that it may 
either be dispensible or lie downstream of Hnf-3a and Hnf-3P in the pathway of in vitro 
pancreas development. 
Since Pdx-1 deficiency severely impairs the development and/or function of 
insulin producing cells in vitro, pdx-T1' cells were further characterized by microscopy 
and flow cytometry. We observed that although the morphology of differentiated cells are 
similar, there are significantly less insulin producing cells in pdx-T1' cell clusters. 
Furthermore, cells in the middle of the pdx-T1' islet like clusters are hormone negative 
suggesting that these cells may have lost their pancreatic endocrine phenotype. Flow 
cytometry quantitatively confirmed our microscopy results. The mechanism of decreased 
pancreatic endocrine cells was addressed by measuring the rate of proliferation and 
apoptosis during expansion phase of stage 3. Stage 3 was selected because the 
quantitative difference in pancreatic precursors occurred during this period. No 
differences in proliferation or apoptosis were observed between WT or pdx-T1' pancreatic 
endocrine cells. However, an increased rate of apoptosis and/or decreased rate of 
proliferation in may still be one of the mechanisms that lead to reduced proportion of 
pdx-T'' pancreatic endocrine cells since only one time point in stage 3 were checked. 
Alternatively, Pdx-1 may be required to sustain its own expression either directly or 
indirectly by maintaining the differentiation state of pancreatic endocrine cells. Such an 
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autoregulatory role in sustaining expression is a common feature shared with other 
transcription factors involved in differentiation (80, 210-213). 
To gain insight into the characteristics of pancreatic endocrine/Pdx-1 positive 
cells and well as to study the molecular mechanisms of pdx-T1' phenotypes, we isolated 
these putative pancreatic precursors by FACS and analyzed their steady-state mRNA 
levels. Markers of pancreatic development such as Ngn-3, Hnf-3P, P48, Isl-1, NeuroDl, 
Nkx2.2, Nkx6.1, Pax6, Pax4, insulin, and glucagon are expressed in these cells, 
suggesting that the endocrine precursors generated in vitro developed molecular 
characteristics of an islet. The expression profiling results further support the notion that 
these islet-like clusters use physiological signaling pathways to regulate insulin release. 
Previous reports have shown that development and differentiation of the pancreas 
requires the coordinate activation of different cell intrinsic as well as cell extrinsic 
factors. The pancreatic markers that were used for expression analysis can be grouped by 
their requirement in development. The function of Hnf-3P and Pdx-1 may be required the 
earliest followed by Ngn-3 for endocrine fate and P48 for exocrine fate (54, 55, 91, 92, 
94, 178, 180, 181). Isl-1, NeuroDl, Pax-6, and Nkx2.2. lie more upstream than the 
homeobox genes Pax4 and Nkx6.1 in the development of endocrine pancreas (71, 144, 
152, 187-189). Insulin and glucagon are differentiated markers for P- and a- cells 
respectively. PDX-1 deficiency does not lead to reduced expression of Hnf-3P, Ngn3, 
P48, Isl-1, and NeuroDl. These results suggest that lack of Pdx-1 function does not affect 
the early steps of in vitro pancreas development such as specification of endocine vs. 
exocrine fate. In contrast, the expression of Nkx2.2, Nkx6.1, Pax4, Pax6 are drastically 
decreased in the absence of Pdx-1. Since the function of Nkx2.2 is required more 
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upstream in endocrine development (144, 152, 188, 189), arrest of pancreatic 
development in pdx-T1' cells caused by decreased Nkx2.2 expression may also contribute 
to decreased Nkx6.1, Pax6, and Pax4 expression. Nkx2.2 is a member of the NK2 
homeobox transcription factor that is expressed in a-, P-, and PP- cells of the islet (214). 
In Nkx2.2 deficient mice, there is an arrest in the development of the endocrine pancreas 
that results in a large population of islet cells that do not produce any of the four 
endocrine hormones (152). Interestingly, the phenotype observed in nkx2.2 KO mice 
share a remarkable similarity to pdx-T1' islet-like clusters in vitro. Together, our results 
show that in vitro, Pdx-1 is important in the specification or maintenance of different 
pancreatic endocrine cell types and its deficiency may not lead to a block in cell type 
differentiation (since insulin and glucagon positive cells are present, but at reduced 
numbers). In addition, the phenotypes observed in pdx-T1' cells may be due to a block in 
pancreas development at the stage when the function of Nkx2.2 is required. 
We have demonstrated the feasibility of isolating pancreatic precursor cells by 
FACS. Purifying insulin producing cells is critical since a mixed cell population is not 
suitable for transplantation. The disadvantage of our system is that we used a reporter 
gene inserted into the pdx-1 locus. Disruption of even one allele of pdx-1 was shown in 
both in human and mice to impair glucose homeostasis. Therefore, a better method to 
mark pancreatic cells must be established. One such way is to put the reporter gene under 
the control of a (3-cell specific enhancer element (ie. pdx-1 promoter or insulin promoter). 
We have cloned a 4.5 kb pdx-1 enhancer element and shown in transgenic mouse that this 
element mediates (3-cell and periductal cell specific expression. A reporter construct 
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using the pdx-1 promoter is therefore a viable way to mark ES cells that have committed 
into the pancreatic endocrine fate for isolation. 
Another major problem in transplantation therapy to treat diabetes is host versus 
graft disease (HVGD). Immunosuppressants such as glucocorticoids and steroids can 
minimize HVGD, however it also lead to many unwanted side effects (158, 215, 216). 
Nuclear transfer technology may be used in combination with ES cells to reduce HVGD 
in transplantated P-cells. The transfer of the nucleus into an enucleated donor oocyte will 
result in a clone with the same genetic information as the donor. This technique was used 
to clone dolly the sheep (217). Recently, the feasibility of nuclear transfer technology has 
been demonstrated in ES cells (218). In theory, customized ES cells can be generated to 
carry the genetic material of any diabetic patient. Our differentiation protocol can then be 
adopted to differentiate the customized ES cells and the resulting insulin producing cells 
isolated by FACS. Thus, another potential advantage of an ES cell based differentiation 
system is that insulin producing cells with a patient's own genetic information can be 
generated to avoid graft rejection and immunosuppressive therapies. 
It is generally assumed that all islet cell types develop from a common endocrine 
precursor that undergo progressive stages of differentiation to give rise to different 
endocrine cell types (152). However, due to the complexity in studying pancreas 
development in vivo, no endocrine precursor cells have been identified nor are their 
molecular properties characterized. In addition, no direct lineage tracing has been done in 
the pancreas to follow the development of various islet cell types. ES cells represent a 
genetically tractable model system to study pancreas development. Null mutation in 
different cell intrinsic or inductive factors can be generated in ES cells and its effect 
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studied. W e showed that pdx-T1', hnf-3 a1', hnf-3 fi'1', and hnf-4 a1' cells arrest at distinct 
stages of pancreatic endocrine development in vitro. These cells may represent various 
intermediate endocrine precursors and its molecular characteristics can be studied and 
compared. Similar studies can be done with other factors involved in pancreas 
development. The information gathered from these studies may contribute to our 
understanding of pancreatic development in vivo and may one day generate a molecular 
fate map where each step of pancreatic development can be identified by a particular set 
of gene expression code. 
In summary, we have developed an ES cell system to generate pancreatic islet like 
clusters that expresses insulin as well as physiological signaling pathways to regulate its 
release. Using FACS, we were able to isolate the pancreatic endocrine cells to over 90% 
purity. Purified endocrine cells represent a much safer mean for transplantation purposes. 
Finally, the feasibility of using an ES cell based system as a model to study pancreas 
development were illustrated by differentiating pdx-T'', hnf-3a~'', hnf-3 fi''', and hnf-4a'' 
ES cells. Similar studies can be done with other factors that are known to be important 
for pancreas development. The data from these studies may one day lead to a molecular 
blueprint where scientists can engineer sufficient amounts of functional insulin producing 
cells for cell replacement therapy in both type 1 and type 2 diabetes mellitus. 
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C h a p t e r 6: H e p a t o c y t e N u c l e a r F a c t o r l a is a n Essential 
Regulator of Bile A c i d a n d P l a s m a Cholesterol M e t a b o l i s m . 
Introduction 
Hepatocyte nuclear factor la (HNF-la, TCF1) is a homeodomain containing 
transcription factor that is critical for diverse metabolic functions in pancreatic islets, 
liver, intestine and kidney (115). Mutations in TCF1 cause maturity-onset diabetes of the 
young type 3 ( M O D Y 3 ) that is characterized by an autosomal dominant mode of 
inheritance, an age of onset usually before 25 years of age and defects in insulin secretion 
(5). In chapter 4, we showed that mice with null mutations in tcfl have multiple 
metabolic abnormalities including defects in glucose and amino acid homeostasis. Loss 
of Tcfl function in mice also results in hypercholesterolemia but normal plasma 
triglycerides levels (36, 37). The role of Tcfl in cholesterol homeostasis has not been 
elucidated. 
Cholesterol homeostasis is achieved through the coordinated regulation of dietary 
cholesterol absorption, de novo biosynthesis, and disposal in the form of bile acids 
(summarized in Fig. 6-1). Within the intestinal lumen, dietary cholesterol is presented to 
the brush border of mucosal enterocytes as a micelle formed by the action of bile salts, 
cholesterol, and fatty acids. Cholesterol is principally absorbed in the duodenum and 
jejunum, whereas bile acids are absorbed in the ileum via specific bile acid transporters at 
the apical surface that include apical sodium-dependent bile acid transporter (Asbt, 
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bile salts from the basolateral surface of enterocytes into the portal circulation has been 
attributed to an anion-exchange protein (219), however the transporter is yet unknown. 
Circulating bile acids are taken up from portal blood by 2 major class of hepatic 
basolateral transportes: sodium-dependent and sodium-independent organic anion 
transporter polypeptide family of transporters. At the apical surface of hepatocytes, 
conjugated bile acids are actively extruded into the canalicular space by members of the 
ATP-binding cassette (ABC) superfamily of proteins (220) that include bile salt export 
pump (Bsep, Abcbll) and multidrug resistance proteins (MRP) -1 (Abccl). Elevated 
intracellular bile acid levels in the hepatocyte activate the nuclear receptor Fxr and 
modulates further bile acid uptake by decreasing the levels of influx bile acid transporter 
(SlclOal) and increasing the level of efflux transporter (Abcbll). Bile acids are then 
transported in the canalicular space to the gall bladder where they are concentrated 
against a 1000-fold concentration gradient. About 5% of the bile acid pool (0.5g/day) are 
lost and are excreted in the stool. The lost bile acids are replaced by de novo synthesis in 
the liver. 
The conversion of cholesterol into bile acids and the biliary excretion of 
cholesterol are important mechanisms for the removal of cholesterol from the body. The 
degradation of cholesterol occurs principally by conversion to bile acids in the liver 
through two main pathways: the classic pathway and the acidic pathway (221). The 
classic pathway, responsible for >50% of biosynthesis of bile acids, starts with a 7a-
hydroxylation of cholesterol by the cytochrome P450 hydroxylase Cyp7al and occurs 
only in the liver. The transcription of Cyp7al is subject to both feedforward and feedback 
regulation (222). Expression of cyp7al is activated by the orphan receptor Lrh-1. In 
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addition, feedforward activation by oxysterols, mediated by the liver X receptor a 
(Lxra, NR1H3) along with its dimerization partner retinoid X receptor (Rxr) also 
regulate the expression of Cyp7al (223, 224). Feedback repression of cyp7al is 
mediated by the farnesoid X nuclear receptor (Fxr) through a complex molecular 
mechanism that involves the coordinated regulation of several liver-enriched nuclear 
receptors. Bile acids are physiological ligands of Fxr, and its binding to Fxr leads to the 
transcription of small heterodimer partner (shp, NR0B2) (225, 226). Shp then 
heterodimerizes with Lrh-1 and inhibit its activity, which leads to promoter-specific 
repression of cyp7a 1 (227-230). 
The acidic pathway starts with a 27 hydroxylation of cholesterol by the 
cytochrome P450 hydroxylase Cyp27al to generate oxysteroids. Since all the primary 
bile acids carry a 7a-hydroxyl group, this group is added to the oxysteroids by a specific 
hydroxylase Cyp7bl at a later step in bile acid formation. Cyp7bl is completely specific 
for oxysterols and has no significant activity for cholesterol. Humans with mutations in 
the cyp7bl have severe neonatal cholestasis, cirrhosis, and liver failure even though the 
cyp7al gene is intact (231), thus highlighting the importance of the acidic pathway in 
early life. 
In this study we used Affymetrix® oligonucleotide microarrays to identify Tcfl-
regulated genes involved in cholesterol and bile acid metabolism. We then studied the 
physiological consequences of these molecular defects in tcf'~ mice. We show that Tcfl 
is a key regulator of multiple pathways that are essential for the maintenance of normal 
plasma cholesterol levels, including bile acid synthesis, bile acid uptake by the liver, 
intestines and kidney, and HDL-cholesterol metabolism. 
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Results 
Liver Gene Expression in tcfl"'" Mice 
To study the molecular basis of hypercholesterolemia in tcfl null mice, we used 
the murine Affymetrix® oligonucleotide microarrays to compare gene expression between 
tcfl"'" and wildtype (wt) littermate animals. Gene expression was measured in the liver, 
the principal organ that regulates cholesterol homeostasis. Several distinguishable 
clusters of genes involved in lipid, glucose, and amino acid metabolism, as well as 
detoxifying enzymes, transporters, secreted proteins and transcription factors were 
differentially expressed (Table 6-1). Of the 37,820 gene sequences surveyed, 165 known 
genes and 279 EST sequences displayed a greater than two-fold decrease in expression in 
tcfl"'" and 415 genes were increased in tcfl"'" compared to wt livers. Upregulation of 
genes in adult tcfl"'" mice are most likely secondary events and were not found in 
newborn mice, an observations that is in agreement with Tcfl being a transcriptional 
activator (115). 
Regulation of Bile Acid Transporter Genes by Tcfl 
Genes involved in bile acid metabolism and cholesterol synthesis were identified. 
In the liver, we found that the steady state mRNA of sic 10a 1 (ntcp), the gene encoding 
the principal sodium-dependent bile acid transporter for conjugated bile acids (232, 233), 
and slc21a6 (oatp-Q, slc21all (oatp-D) and slc21a5 (oatp2), three distinct genes of the 
sodium-independent organic ion transport family (234-236), were either absent or 
markedly downregulated in tcfl"'' mice (Fig. 6-2A). All proteins encoded by these genes 
are known to mediate the uptake of bile acids across the basolateral (sinusoidal) 
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livers using western blot analysis. The expression of Sic 10a 1 was reduced to 4 % of wt 
animals in tcfl"'" mice. Furthermore, we were unable to detect Slc21a6 protein in the 
livers of rc/7~Amice (Fig. 6-3B). 
Since tcfl"'" mice develop hepatomegaly and central lobular hypertrophy at 5-7 
weeks of age which may lead to secondary changes in hepatic gene expression, we 
studied mRNA levels in newborn animals with no morphological or biochemical 
evidence of liver diseas (36, 37). We found that the decrease in gene expression of 
basolateral bile acid transporters was already apparent shortly after birth, suggesting that 
loss of Tcfl function rather than chronic liver disease is the primary cause of the defect 
(Fig. 6-2A). Together, these results indicated that Tcfl is essential for bile acid transport 
across the basolateral (sinusoidal) hepatocyte membrane. 
Regulation of Bile Acid biosynthesis by Tcfl 
Conjugated bile acids exist as anions at physiological pH and consequently, 
require carrier for transport across the membranes of enterohepatic tissues. Efflux of bile 
acids at the apical surface of the hepatocytes is mainly mediated by ATP-binding cassette 
(ABC) superfamily of proteins that include including Abcbll (Bsep), Abcc2 (Mrp2), 
Abcbl (Mdrl), and Abcb4 (Mdr2) (220). ABC proteins share common structural motifs 
including a conserved intracellular domain that binds ATP and couples primary active, 
unidirectional export of a broad range of compounds (xenobiotics, bile acids, etc) to ATP 
hydrolysis. 
To investigate whether Tcf-1 similarly regulates bile acid transporters that are 
located at the apical (canalicular) membrane, we measured mRNA levels of transporters 
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transporters, the expression of bile acid carriers such as Abcbll, Abcc2 and Abcbl, that 
are located at the canalicular membrane of the hepatocytes, were indistinguishable 
between tcfl*'* and tcfl"'" animals (Fig. 6-2B, 6-3). The expression of Abcb4 (Mdr2), a 
transporter protein that is mutated in progressive familial intrahepatic cholestasis (PFIC) 
(237, 238), is also normal in Tcfl null mice (Fig. 6-2B). 
Regulation of Bile Acid Biosynthesis by Tcfl 
To study the role of Tcfl in bile acid biosynthesis, we determined the steady-state 
mRNA levels of genes that are involved in the classical and the acidic pathway of 
cholesterol catabolism in tcfl'' mice. Gene expression studies showed that the expression 
of cholesterol 7a-hydroxylase (Cyp7al), but not oxysterol 7a-hydorxylase (Cyp7bl), 
was increased in adult tcfl~'~mice. Furthermore, the biochemical measurement of Cyp7al 
activity showed a 5-fold increase in tcfl"'" mice (35.1 vs 177.5 pmol/mg microsomal 
protein/min tcfl*'* vs. tcfl"'", respectively, n=10, P <0.001) (Fig. 6-3A, 6-4A, B). To 
study the molecular basis of the upregulation in bile acid synthesis, we analyzed the 
expression levels of Lxr-a, Lrhl, Shp-1, and Fxr in the liver. Lxroc, Rxr, and Lrhl 
expression levels did not differ significantly in wt and tcf 1"'"mice (Fig. 6-4A). In contrast, 
the DNA array data and northern blot analysis revealed a significant decrease in Shp-1 
and Fxr expression, due to the loss of the Fxr-1 specific isoform (Table 6-1, Fig. 6-3A). 
Two Fxr-isoforms, Fxr-1 and Fxr-2, exist in mice and differ in their 5'-untranslated and 
coding regions. These transcripts are expressed in approximately equimolar quantities in 
liver and intestine (Fig. 6-3A). The selective loss of expression of the Fxr-1 isoform was 
confirmed in adult and newborn livers of tcf 1"'" mice by RT-PCR analysis using specific 
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mice is the result of decreased feedback repression of Fxr, mediated by reduced 
expression of Shpl and possibly diminished intracellular bile acid concentrations. 
To further study the transcriptional regulation of Fxr by Tcfl, we cloned 0.7 kb of 
the 5'-flanking promoter region of the murinefxr gene and linked it to a luciferase 
reporter gene (pGL2-pFxr-l). Cotransfection of this reporter plasmid with a Tcfl 
expression vector (pcDNA3-pHNF-la) showed an approximately six-fold dose-
dependent activation of the Fxr-1 promoter (Fig. 6-5A). Sequencing analysis of the Fxr-1 
promoter identified a high affinity Tcfl binding site at -201 to -217 bp. Electrophoretic 
mobility shift assays were performed with mouse liver nuclear extracts to study the 
binding properties of this Tcfl binding site. A major DNA/protein complex was detected 
with a 32P-labeled oligonucleotide that contained the Tcfl binding site (Fig. 6-5B, lane 2). 
This binding activity could be competed by an unlabeled excess of an oligonucleotide 
containing a known high-affinity Tcfl binding site of the insulin growth factor binding 
protein-1 (igfbpl) promoter (239) (Fig. 6-5B, lane 3). To test directly for the interaction 
of Tcfl with the oligonucleotide probe, we analyzed whether a Tcfl-specific antibody 
affected the protein-DNA complex. A supershift of the complex was observed after 
preincubation of extracts with Tcfl antiserum, but not with anti-STAT-1 antibodies, 
demonstrating that Tcfl can bind to the Tcfl site in the Fxr-1 promoter (Fig. 6-5B, lane 4 
and 5). Together, these data indicate that Tcfl is a transcriptional activator of Fxr-1 and 
that loss of Tcfl function reduces the feedback inhibition of ligand-activated Fxr target 
genes, and thereby activating bile acid synthesis. 
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Ileal and Renal Bile Acid Absorption in tcfl"1" Mice 
We next investigated the physiological effects resulting from the impaired 
expression of genes encoding hepatic bile acid uptake and the enhanced de novo 
synthesis of bile acids in the liver. From our expression data, we predicted that bile acids 
in the serum may be elevated and that de novo synthesized bile acids would be secreted 
normally into the canalicular system and ultimately into the intestine. Serum bile acid 
levels in tcf 1~'~ mice were indeed elevated to =250 jttmol/L and five-fold higher than in 
WT control littermates (Fig. 6-6A). Interestingly, fecal bile acid concentrations were 
approximately six-fold elevated in the stool of mice that lacked expression of Tcfl 
compared to normal littermates (Fig. 6-6B). We also found increased bile acid 
concentrations in the urine of Tcfl null mice (Fig. 6-6C). 
The incomplete absorption of bile acids from the distal ileum and the renal 
proximal tubule of tcfl"'" mice suggested that Tcfl might also be a transcriptional 
activator of genes involved in intestinal and renal bile acid uptake. The apical sodium 
dependent bile acid transporter (Slcl0a2, Asbt, Ibat) is expressed at the apical surface of 
enterocytes in the terminal ileum and on the apical membrane of the renal tubule and 
biliary epithelia (240, 241). Measurements of steady state mRNA of sic10a2 by RT-PCR 
in the terminal ileum and kidney showed that expression was practically absent in tcfl 
null mice (Fig. 6-7A, B). Furthermore, we were not able to detect any Slcl0a2 expression 
in tcf 1"'" mice of intestinal protein extracts using immunoblot analysis or in tissue sections 
of the terminal ileum using immunohistochemistry (Fig. 6-7C and D, respectively). 
To study whether Tcfl is a direct activator of slclOa.2 gene transcription, we 
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regulatory region. An 1854 bp promoter region was cloned upstream of a luciferase 
reporter and cotransfected with a Tcfl expression vector. Transient cotransfections of 
Tcfl with the slclOa.2 promoter led to a dose-dependent 40-fold activation of luciferase 
activity (Fig. 6-8A). When the Tcfl site in the slcl0a2 promoter was selectively mutated, 
transcriptional activation was reduced 50-80% (Fig. 6-8A). Gel mobility shift assays 
were performed using double stranded 32P-labeled oligonucleotides containing the wt and 
mutated Tcfl binding site using mouse liver nuclear extracts. A DNA-protein complex 
was detected (Fig. 6-8B, lane 2). The specificity of protein binding to this site was 
determined by competition assays using cold wt and Tcfl-binding defective 
oligonucleotides. The competitor wt sequence, but not the mutant binding site, effectively 
competed for protein-DNA complex formation (Fig. 6-8B, lanes 3 and 4). Furthermore, 
Tcfl antiserum supershifted the DNA-protein complex, demonstrating that Tcfl protein 
is a component of the binding activity (Fig. 6-8B, lane 5). These data suggest that Tcfl is 
a potent activator of slcl0a2 transcription in vivo and in vitro. 
Cholesterol Metabolism in tcfl"'" Mice 
Mice lacking Tcfl expression have normal cholesterol levels at birth but develop 
hypercholesteremia (=300 mg/dl) at 6 to 8 weeks of age (Fig. 6-9A). We examined the 
cholesterol distribution in plasma lipoproteins of tcfl"'", wt, and LDL receptor knockout 
animals (Idlr"'" mice accumulate cholesterol predominantly in LDL particles) (242). 
Fasting plasma lipoprotein composition was analyzed following FPLC fractioning. As 
shown in figure 6-9B in the ldlr~'~ mice, cholesterol was eluted mainly in the LDL but was 
also present in the VLDL and HDL fractions (Fig. 6-9B; the positions at which VLDL, 
LDL, and HDL elute are indicated). In contrast, almost all of the cholesterol in the 
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Figure 6-9. S e r u m lipoprotein profiles of control andhnf-1cc'- mice. (A) Hnf-1a 
deficient mice have normal cholesterol levels at birth but develop progressive 
hypercholesteremia. (B) and (C) Plasna (0.5 ml) from wt, hnf-1cc'- and low-density 
lipoprotein receptor-deficient {Idlr'-) mice were separated by F P L C , which w a s run 
with P B S as elutant. T h e fractions (0.5ml) of the eluate were assayed for Cholesterol 
(B) and Phospholipids (C). A n "abnormal" lipoprotein particle with intermediate 
buoyancy between H D L and L D L peaks is seen in hnf-la;1- mice. 
plasma of tcf 1"'~ mice was carried by the H D L fraction and an "abnormal fraction" with 
intermediate buoyancy between HDL and LDL peaks (Fig. 6-9B, fractions 23 to 29). 
Phospholipids in the plasma of tcf 1~'~ mice was also carried mainly by the HDL fraction 
and by the "abnormal" lipoprotein particle (Fig. 6-9C). 
Three lipoprotein particles may account for this abnormal lipoprotein fraction: 
Lp-X, small dense LDL or large HDL (HDLC). Lp-X is a lamellar particle that contains 
mainly unesterified (free) cholesterol (FC) and has been identified in the plasma of 
patients with obstructive jaundice and in familial lecithin cholesterol acyltransferase 
deficiency (243-247). Small dense LDL is a spherical particle that contains mainly 
esterified cholesterol (EC) (248). Large HDL has been described in mice lacking hepatic 
lipase or increased activity of Lcat and may be caused by a defect in HDL phospholipids 
hydrolysis or increased choesterol esterification, respectively (249, 250). To distinguish 
between the three possibilities, we characterized the abnormal lipoprotein fractions in the 
plasma of tcfl null mice. The analysis of the cholesterol content in the abnormal 
lipoprotein fraction by gas liquid chromatography revealed that this particle contains 
mostly esterified cholesterol (62% EC vs. 38% FC) and in that respect was similar to that 
of LDL of Idlr"'" mice (62%EC vs. 38% FC). To further rule out the existence of Lp(X) 
in the plasma of tcfl"'" mice, we examined these particles by electron microscopy (Fig. 6-
9A). Negatively stained samples revealed structures with diameters ranging from 40-100 
nm. The abnormal lipoprotein particles from tcfT'~ mice were smaller than LDL particles 
of ldlr~'~ mice and lacked the lamellar (hollow spherical) structures that characterize Lp-X 
(Fig. 6-10A) (246). We also determined the concentrations of Apo Al and Apo B48/100, 
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Figure 6-10. Characterization of large buoyant H D L \uhnf-1a'- mice. (A) Electron 
microscopy is shown of the abnormal lipoprotein and LDL factions in the plasma of 
H n M a deficient and Ldlr deficient mice. Negative staining of a sample from fractions 
16 and 17 of ldlr1' mice and fractions 23 and 24 of hnf- 1a'- mice. The particles in 
hnf-la1' mice lacked lamellardiscoid structures that are typical of Lp-X. Bar, 200 
nm. (B) Measurements of ApoA1 (top) and ApoE levels (bottom) in fractions 20 to 34 
of hnf-1ah and ldlr1- mice using immunoblotanalysis. (C) Immunoturbitrometric 
measurements of ApoB48/100 concentrations in FPLC gel filtration fractions of ldlr'-
(green line) and hnf-la'- (red line) mice. 
immunoturbometric analysis. In tcfl''" mice the abnormal fraction contained ApoAl (Fig. 
6-10B, fractions 21-27). In contrast, apolipoproteins B48/B100 were detected mainly in 
the LDL fractions (14 to 24), and were only seen in small amounts at the beginning of the 
abnormal lipoprotein peak (fractions 21-24)(Fig. 6-10C). These findings strongly suggest 
that the abnormal lipoprotein fraction consist mainly of large HDL particles. Large 
ApoE-enriched HDL particles have been shown in high cholesterol fed animals (251). 
We therefore measured the ApoE levels in the FPLC fractions and found ApoE enriched 
in the buoyant HDL fractions (21-27) of tcf 1~'~ mice (Fig. 6-10B). These results suggest 
that the abnormal lipoprotein fraction is similar to HDLC. 
To begin to investigate the molecular mechanisms for the formation of large, 
buoyant HDL in tcfl~'~ mice, we measured the mRNA levels of HDL modifying enzyme 
including lecithin.cholesterol acyl transferase (Icat), sterol acyltransferase (soatl and 
soat2) and hepatic lipase (lipc) genes. Previous reports have shown that transgenic mice 
overexpressing lcat and lipc-deficient animals have moderately elevated plasma 
cholesterol levels and large HDL (249, 250). We did not find down regulation of Soatl or 
Soat2. However, consistant with the animal models that exhibit large buoyant HDL 
particles, we found that the expression of lcat is significantly increased in adults and that 
of lipc is reduced in newborn and adult tcfl"'" mice (Fig. 6-11 A). Moreover, Lipc activity 
was reduced in tcf" and tcfl"'" mice compared to wt animals (Fig. 6-1 IB). These findings 
suggest that tcfl"'" mice may have enhanced HDL cholesterol esterification and impaired 
HDL phospholipids hydrolysis that may account for the large HDL particles in the 
plasma of these animals. 
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than in wt mice (1.61 vs 1.87 mg/g, respectively, n=12, p=0.01) and was associated with 
increased expression of key regulators and enzymes of cholesterol synthesis, including 
Srebpl, squalene synthase (fdftl), and (HMG)-CoA reductase (hmgcr) (Fig. 6-12A). The 
activity of this Hmgcr, the rate limiting enzyme of cholesterol synthesis, was also 
increased =3-fold in livers of tcfl-/- vs. tcfl+/+ animals (460 vs. 162 pmol/mg 
microsomal protein/min, respectively, n=10, P <0.001), indicating that cholesterol 
synthesis is increased in mutant tcfl mice (Fig. 6-12B). However, it is important to note 
that increased expression of these genes is absent immediately after birth and develops 
only secondary to chronic intestinal bile acids malabsorption (Fig. 6-12A). 
Discussion 
The presence of functional consensus recognition sites for Tcfl in the promoters 
of numerous genes encoding metabolic enzymes suggests that Tcfl fulfill an essential 
role in cellular metabolism. Consistant with this notion, we found that Tcfl is 
indispensable for the expression of several key genes involved in bile acid and 
cholesterol metabolism. Tcfl deficiency in mice leads to profound bile acids loss in the 
stool and urine, increase in bile acids levels in the plasma, increase in cholesterol and bile 
acid synthesis, and formation of large buoyant HDL particles. 
Our results demonstrate that Tcfl regulates bile acid metabolism and cholesterol 
homeostasis by at least three mechanisms: First, Tcfl appears to be a transcriptional 
activator of bile acid transporters that are located at the apical plasma membrane of ileal 
enterocytes and renal tubule cells as well as the basolateral side of the hepatocyte. The 
entry of bile acids into hepatocytes at the basolateral surface (in contact with the blood 
sinusoids) occurs by two processes. The major uptake system is sodium-dependent and 
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driven by the transmembrane N a + gradient maintained by Na+/K+-ATPase. The major 
member in this transporter family for bile acid influx into hepatocytes is SlclOal, a 
glycoprotein of 362 amino acid residues (233). A second sodium-independent uptake 
system in the liver is mediated by several members of the organic anion transporter 
polypeptide (OATP) family of transporters, which function as anion exchangers. In the 
liver, the sodium independent bile acid uptake is predominantly mediated by Slc21a6 and 
to a lesser extent by Slc21all and Slc21a5 (234, 236, 252, 253). Impaired Tcfl function 
leads to reduced expression of the major sodium dependent (SlclOal) and sodium 
independent (Slc21a6, Slc21all, and Slc21a5) transporters resulting in marked elevation 
in plasma bile acid levels. Some bile acid up-take probably occurs in tcf-1 deficient 
animals by bile acid transporters not regulated by Tcf-1 including Slc21a3. Slc21a3 is not 
sufficient to compensate for the decreased expression of other bile acid transporters in 
tcfl"'" mice because it is expressed at low levels and have low affinity for bile acids (Km 
of Slc21a3 and Slc21a6 for taurocholate are 60 mmol/1 and 14mmol/l, respectively) (252-
254). An efficient intestinal re-uptake of bile salts and delivery to the portal blood for re-
entry at the basolateral surface of hepatocytes is important to maintain bile acid 
homeostasis. Reabsorption mechanisms exist mainly in the distal ileum which expresses a 
sodium-dependent carrier, Slcl0a2, for the re-uptake of both primary and secondary 
conjugated and unconjugated bile acids (255). Unlike its liver counterpart SlclOal which 
is expressed basolaterally, Slcl0a2 is expressed at the apical surface in the ileum. 
Mutations in SLC10A2 that result in a clinical syndrome of diarrhoea, malabsorption of 
fat and malnutrition and primary bile acid malabsorption have been identified in humans 
(256), further underscore the importance of this ileal bile acid transporter. The absence of 
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Slcl0a2 in the enterocytes of the terminal ileum is responsible for reduced bile acid 
reabsorption and fecal loss in tcfl"'" mice. In the kidney, downregulation of the same 
transporter is responsible for impaired reabsorption in the proximal and distal renal 
tubules and loss of bile acids in the urine. 
Second, Tcfl is a transcriptional activator of Fxr-1. Intracellular and extracellular 
cholesterol and bile acid levels are tightly maintained within a narrow physiological 
range by a transcriptional control network. In the liver, Lxr-a and Lrh-1 are the 2 major 
transcriptional activator of cyp7al, the rate-limiting step in bile acid synthesis. Expansion 
of the bile acid pool activates the nuclear receptor Fxr. Fxr mediates bile acid-dependent 
repression of the cyp7al gene by inducing the transcription of shp (225, 257). Elevated 
Shp protein levels inactivate Lrh-1 by forming a complex that leads to the repression of 
cyp7al (228, 229). Therefore, impaired Fxr-1 expression in tcfl"'" mice results in 
decreased levels of Shp, leading to increased Cyp7al activity and bile acid synthesis. In 
addition, the absence of the hepatic bile acid binding protein (Akrlc2) (258) in tcfl"'" 
mice suggests a role for Tcfl in determining the intracellular bile acid pool that may 
contribute to defective sensing of the bile acid stores in hepatocytes. 
Third, Tcf-1 is involved in HDL metabolism. A number of epidemiological 
studies have shown that serum HDL-cholesterol levels are negatively correlated with the 
incidence of coronary heart disease (259). Furthermore, patients with a genetic deficiency 
of HDL are often accompanied by atherosclerotic cardiovascular diseases (260). Thus, 
HDL plays an essential role in the protection of blood vessels from atherosclerosis. HDL 
serves as a shuttle, delivering excess cholesterol from peripheral tissues to the liver for 
excretion into the bile. This pathway was named "reverse cholesterol transport" (261). 
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Plasma H D L particles are continuously modulated by various enzymes including 
cholesterol ester transfer protein (Cetp), Lcat, and hepatic lipase. Hypercholesteremia and 
the accumulation of large buoyant HDL in the plasma of tcfl"'" animals probably reflect a 
combined increase in HDL cholesterol esterification by Lcat and decreased hepatic lipase 
expression with decreased HDL phospholipid hydrolysis. Finally, the marked 
upregulation in Srebpl, (HMG)-CoA reductase, and squalene synthase expression and the 
increased activity of (HMG)-CoA reductase suggests increased hepatic de-novo 
cholesterol biosynthesis. This is most likely secondary to impaired cholesterol absorption 
from the intestines and/or stimulated bile acid synthesis in the liver. 
Cholesterol homeostasis is maintained by a series of complex transcriptional 
program including Fxr that control the acquisition of cholesterol from endogenous and 
exogenous sources and elimination cholesterol through conversion to bile acids and 
biliary excretion. In this study we have identified Tcfl as a novel regulatory pathway for 
bile acids and cholesterol homeostasis in addition to its role in pancreatic P-cells to 
maintain glucose metabolism as shown in chapter 4. In the pancreas, it is part of an islet 
enriched transcription factor network that controls the expression of genes involved in 
glucose stimulated insulin secretion. In extra-pancreatic tissues however, it is a key 
player in the control of many aspects of cholesterol homeostasis including bile acid re-
uptake, bile acid and cholesterol biosynthesis, and HDL metabolism. In addition, Tcf-1 is 
a major in vivo regulator of Fxr, a nuclear receptor that was shown to integrate multiple 
pathways for cholesterol homeostasis. In view of the profound physiological implications 
of bile acid metabolism in man and its link to cholesterol homeostasis, further analysis of 
this model that may identify novel molecular mechanisms that govern these process and 
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may uncover new target for pharmacological interventions in a variety of metabolic 
disease. 
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C h a p t e r 7: G e n o t y p e / P h e n o t y p e Relationships in H N F -
4 a / M O D Y l a n d H N F - l a / M O D Y 3 Diabetes: 
Associations with Reduced Apolipoprotein and Triglyceride Levels 
Introduction 
The M O D Y 1 gene is encoded by HNF-4oc, a transcription factor that belongs to 
the steroid/thyroid hormone receptor superfamily. It was first identified by its interaction 
with cis-regulatory sequences of liver-specific gene promoters (262). HNF-4oc plays a 
critical role in development, cell differentiation, and metabolism and is essential for the 
normal functioning of visceral endoderm, liver, intestine, kidney, and pancreatic (3-cells 
(24, 25, 77). H N F - 4 a also regulates the expression of transcription factor HNF-la, 
thereby defining a transcriptional hierarchy responsible for these phenotypically 
indistinguishable forms of early-onset type 2 diabetes (29, 80, 120). 
The first HNF-4oc7MODYl mutation was found to be a nonsense mutation in 
codon 268, Q 2 6 8 X (4). This mutation generates a truncated protein containing an intact 
D N A binding domain but lacking part of the A F 2 region. Functional studies of this 
mutation have shown that the cause of diabetes is a loss-of-function mutation, rather than 
by a dominant-negative or gain-of-function mechanism (25). 
Clinical studies have shown that H N F - 4 a and H N F - l a mutations are associated 
with impaired pancreatic (3-cell function characterized by abnormal insulin secretion (27, 
29, 120). These studies indicate that M O D Y is a primary genetic disorder of the (3-cells 
and that the M O D Y genes form crucial links in the cascade of islet enriched transcription 
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network that control the appropriate expression of (3-cell specific genes. However, with 
the exception of the insulin gene, target genes of both HNF-4a and HNF-la are also 
expressed in other tissues including the liver, kidney, and intestine. Therefore, mutations 
in the MODY1 and MODY3 genes could result in pleiotropic phenotypes such as 
impairment in cholesterol and lipoprotein metabolism in the liver. Recently, a mutation 
in the HNF-4a gene has been shown to affect triglyceride metabolism (263). Patients 
with HNF-la mutation have a reduction in the renal threshold for glucose, resulting in 
glucosuria, which suggests that kidney function may be abnormal in MODY3. Mice that 
are deficient for either Hnf-la or Hnf-4a also exhibit extra-pancreatic abnormalities. 
Hnf-la null mice have renal Fanconi-like syndrome, glycogen storage disease lb and 
defects in bile acid and plasma HDL-cholesterol metabolism (Chapter 6) (36-39). Mice 
with targeted inactivation of the hnf-4 a gene specifically in the liver accumulate lipid in 
the liver, exhibited greatly reduced serum cholesterol and triglycceride levels, and 
increased serum bile acid concentrations (264). Together, these data suggest that HNF-la 
and HNF-4a are also major in vivo regulators of genes involved in liver function. 
The liver is a major organ that performs many functions that are essential for 
metabolic homeostasis including plasma protein synthesis and cholesterol metabolism. 
Apolipoproteins are plasma proteins synthesized by the liver that are important for 
cholesterol and lipid homeostasis. In blood, apolipoproteins form lipoprotein particles 
that are composed of a nonpolar lipid core (containing cholesterol ester and triglycerides) 
surrounded by relatively polar coat that consist of phospholipid, free cholesterol, and 
apolipoproteins (265). The major plasma lipoprotein particles are defined according to 
the densities at which they are isolated and include: chylomicrons, very low density 
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lipoproteins, low density lipoprotiens, and high density lipoproteins. Lipoproteins 
function both to keep lipids soluble as they transport them in the plasma, and to provide 
an efficient mechanism for delivering their lipid contents to the tissues. The 
apolipoproteins associated with lipoprotein particles perform a number of diverse 
functions including serving as structural components of the particles, providing 
recognition sites for cell-surface receptors, and serving as cofactors for enzymes involved 
in lipoprotein metabolism (265). The presence of HNF-4a and HNF-la binding sites in 
the promoters of apolipoproteins have been identified (265). In addition, several 
apolipoproteins are down-regulated in Hnf-4a deficient mouse livers (264). These data 
suggest that HNF-la and HNF-4a may regulate several key plasma proteins synthesized 
in the liver that are involved in lipid transport and metabolism and thus, may contribute to 
MODY3 and MODY1 phenotypes respectively. 
To gain a better understanding of the physiological consequences of HNF-la 
mutations, we followed up on Hnf-la target genes in the liver that were identified 
through Affymetrix® oligonucleotide microarrays (see chapter 6). In particular, we have 
begun to characterize a recently identified apolipoprotein, apoM, that is associated with 
high density lipoprotein (266). In addition, we used a genetic screen to identify liver-
secreted target genes of HNF-4a in genetically manipulated embryonic stem (ES) cells. 
We then measured the serum levels of these proteins in subjects with HNF-4a 
haploinsufficiency and control groups. Our results indicate that a reduction in HNF-4a 
activity in humans manifests as a unique gene expression profile, affecting apolipoprotein 
and triglyceride concentrations. 
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Results 
Hnf-la is an Essential Transcriptional Regulator of Apolipoprotein M 
In the previous chapter, we demonstrated that Hnf-la is an essential regulator of 
bile acid and cholesterol homeostasis, and HDL metabolism. In view of the profound 
physiological implications of these metabolic defects and its possible association with the 
MODY3 phenotype, we are currently investigating expression sequence tags (ESTs) that 
are regulated by Hnf-la identified from Affymetrix® oligonucleotide microarrays. 
Characterization of Hnf-la regulated ESTs may identify new molecular components of 
existing metabolic pathways as well as novel pathways that may govern cholesterol 
homeostasis. These ESTs may also provide surrogate markers that could be used for the 
diagnosis MODY3. 
Six ESTs (Accession #: ai256288, aa866766, ai645500, ai574068, ai527381, 
aa791426, aa655303) that were regulated more than 10 fold by Hnf-la were reconfirmed 
by RT-PCR (data not shown). We also hybridized these ESTs in a Northern blot analysis 
of multiple tissues and shown that they are indeed enriched in the liver (data not shown). 
During the course of our analysis, one of the ESTs (aa655303) was identified as a novel 
HDL associated apolipoprotein, ApoM. In light of the abnormalities of HDL metabolism 
in hnf-la''' mice, we have begun to further characterize this apolipoprotein. 
Hybridization of apoM probe on a multiple tissue Northern blot revealed an 
approximately 750 bp message that is enriched in the liver and the kidney (Fig. 7-1 A). 
Rabbit antibodies were raised against 2 synthetic ApoM peptides 113-132 and 140-159. 
These antisera were used to reconfirm the tissue expression pattern on Western blot (Fig. 
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lipoprotein classes (Fig. 7-ID). Consistent with the previous observation (266), we found 
that ApoM is predominately associated with the HDL particle (Fig. 7-1C, data not 
shown). In addition, ApoM is completely absent in the HDL fractions of hnf-la'' mice 
(Fig.7-lC). 
Using the Celera database, we analyzed the promoter of ApoM to study its 
transcriptional regulation. We identified a consensus Hnf-la binding element at position 
-117 to -131 bp in the mouse ApoM promoter. This binding site was also evolutionary 
conserved at similar location in the human ApoM promoter (Fig. 7-2A). Electrophoretic 
mobility shift assays (EMSA) were performed to determine if the Hnf-la binding site is 
functional. A major DNA/protein complex was detected with a 32P-labeled 
oligonucleotide that contained the Hnf-1 binding site (Fig. 7-2A, lane 2). This binding 
activity could be competed by an unlabeled excess of cold Hnf-1 binding oligonucleotide 
(Fig. 7-2A, lane 3). Furthermore, a supershift of the complex was observed after pre-
incubation of extract with a polyclonal anti-Hnf-la antiserum, but not with anti-STAT-1 
antibodies (Fig. 7-2A, lanes 4 and 5) demonstrating that Hnf-la can bind to the Hnf-1 
site in the apoM promoter. 
Next, we addressed the question whether Hnf-la can act as a direct 
transcriptional activator in co-transfection assays by cloning a 610 bp of the 5'- murine 
apoM promoter containing the putative HNF-1 binding site and linked it to a luciferase 
reporter gene (pGL2-pAPOM). Co-transfection of pGL2-pAPOM with a Hnf-la 
expression vector (pcDNA3-pHNF-la) showed an approximately 3- and 27- fold dose-
dependent activation of the apoM promoter in HepG2 (liver) and Cos7 (kidney) cells, 
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promoter, we mutated the Hnf-1 binding site in the reporter plasmid pGL2-pApoM (Fig. 
7-2B). The basal transcription activity of pGL2-pApoMmut is 95% lower than pGL2-
pApoMwt in HepG2 cells (HepG2 cells have endogenous Hnf-la expression). In 
addition, the transcriptional activation of HNF-la on the pGL2-pApoMmut was 
abolished (Fig. 7-2B), indicating that the HNF-1 binding site in the ApoM promoter is 
functionally important for its expression. 
We have shown that Hnf-la is an important transcriptional regulator of ApoM 
expression. In the absence of Hnf-la, apoM is essentially missing in liver, kidney, and 
blood. To determine if Hnf-la haploinsufficiency reduces ApoM expression, we 
determined plasma ApoM levels in wt, hnf-la*'', and hnf-la'' mice. We showed that 
Hnf-la has a dose-dependent effect on plasma ApoM levels in mice (Fig. 7-1C). 
Therefore it represent a strong candidate surrogate marker for the early diagnosis of 
MODY3. 
Identification of Liver-Enriched HNF-4a Target Genes 
To gain a better understanding of a possible extra-pancreatic defect in HNF-4a 
haploinsufficient (MODY1) patients, we used a genetic screen to identify HNF-4a target 
genes in the liver. At the time of this study, only the complete knock-out of hnf-4a mice 
were generated. Hnf-4 a null mice die during development prior to formation of the liver 
and cannot be used to identify Hnf-4a regulated genes. Heterozygous hnf-4a mutant 
mice have normal glucose tolerance and do not mirror the human MODY1 disease. We 
therefore studied the loss of Hnf-4a function on target gene expression in embryoid 
bodies (EBs) that were derived from embryonic stem cells in vitro (267). EBs contain 
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Figure 7-3. Regulation of 
liver-specific genes by Hnf-
4a in embryoid bodies. Hnf-
4a target genes were 
identified using genetically 
manipulated EBs. They 
included oc1 -antitrypsin (a1-
AT), a1-antichymotrypsin (a1-
A C H T ) , alpha fetal protein 
(AFP), ceruloplasmin 
(CERULO), insulin growth 
fator binding protein (IGFBP-
1), transferrin (TFN), and 
apolipoproteins (APO) Al, All, 
B, and Clll. RT-PCR analysis 
of Hnf-4a regulated genes in 
wildtype, hnf-4a+/-, and hnf-
4aA EBs shows that steady 
state m R N A levels of these 
genes are either reduced or 
absent in hnf-4a null EBs. 
visceral endoderm (VE), a tissue that displays many characteristics of the liver, including 
the expression of hepatocyte nuclear factors and their target genes (25, 267). 
A candidate gene approach in which genes that are primarily synthesized and 
secreted by hepatocytes were analyzed in EBs containing two, one or no functional hnf-
4a allele. Using this approach, we identified alpha fetal protein (AFP), insulin growth 
factor binding protein-1 (IGFBP-1), al-antitrypsin (al-AT), al-antichymotrypsin (al-
ACHT), ceruloplasmin (CERULO), transferrin (TFN), and apolipoproteins (apo) AI, All, 
B, and CIII (Fig.7-3). 
Genotype/Phenotype Analysis in HNF-4a/MODYl Diabetes 
Hnf-4a is a key regulator of hepatocyte-specific gene expression. Therefore, it 
might be anticipated that loss of function by hnf-4a mutations could manifest in a 
pleiotropic MODY1 phenotype that results not only in pancreatic islets but also liver 
dysfunction. To test this hypothesis, we obtained serums of the RW/MODY1 family. 
MODY1 in the RW diabetic individuals is caused by Q268X mutation in the HNF-4a 
gene (4). This mutation results in a truncated HNF-4a protein with no transcriptional 
activity (25). Our study groups were composed of 12 diabetic patients with HNF-4a 
mutation (D-HNF4+/-). 6 non-diabetics with HNF-4a mutation (N-HNF-4+/-), 12 normal 
matched controls (N-HNF4+/+). and 12 matched diabetic (MODY-X) patients (D-
HNF4+/+). These study subjects were matched with respect to ethnicity, gender, age, and 
body mass index (BMI). The clinical characteristics of the different study groups are 
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W e measured the protein levels of HNF-4a-regulated genes in the study subjects' 
serum including a 1-antitrypsin, ceruloplasmin, transferrin, IGFBP-1, and apo AI. All, B, 
Oil and Lp(a). In addition, we also measured total triglyceride serum concentrations. 
The results of our measurements are shown in table 7-2. Serum concentrations of al-AT, 
ceruloplasmin, transferrin, and apo AI, and B showed no significant or consistent 
differences among the various study groups. However, we found that subjects who carry 
aHNF-4a mutation have a significant reduction in serum ApoAII (26.9 ±1.4 vs. 37.4 
±1.6 mg/dL; p=1.3E-5), ApoCIII (19.8+1.5 vs. 26.5±2.0; p=0.01), Lp(a) (12.1±3.5 vs. 
45.2± 6.3 mg/dL; p=5.9E-5), and triglyceride levels (72.1+6.3 vs. 124.2±7.3 mg/dL; 
p=3.1E-6) when compared to individuals without the HNF-4a mutation (Table 7-2). (In 
1989, mean serum concentrations of triglycerides for 14 diabetic subjects of the RW 
pedigree (D-HNF4+/-) was 77.7±7.3 mg/dl). Moreover, no significant differences were 
observed when diabetic and nondiabetic subjects with or without the MODY1 mutation 
were compared (D-HNF4+/- vs N-HNF-4+/- and D-HNF-4+/+ vs. N-HNF4+/+, 
respectively) (Table 7-2. Fig.7-4). This indicates that HNF-4a haploinsufficiency rather 
than secondary effects due to impaired glucose homeostasis is the primary cause of 
decreased serum ApoAII, ApoCIII, Lp(a). and triglyceride concentrations. To exclude the 
possibility that the reductions we observe could be due to genetic (other than HNF-4a) or 
environmental factors, we compared serum factors of HNF-4a+/+ individuals from the 
RW-family and unrelated control subjects (Nfam. vs Nunrl.). No significant differenes 
between these two groups were observed, indicating that familial aggregation of 
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To identify novel pathways that may contribute to the MODY3 and MODY1 
phenotype, we performed genetic screens to identify Hnf-la and Hnf-4a target genes in 
the liver. ApoM was initially identified from Affymetrix® oligonucleotide microarrays as 
a strong target gene of Hnf-la. To better understand the molecular basis of apoM gene 
regulation, we studied its promoter. The 5'-regulatory sequence of apoM contained an 
evolutionary conserved Hnf-la binding site. Biochemical characterization of this site and 
in vitro transactivation studies indicate that Hnf-la is a direct transcriptional activator of 
the apoM gene. In vivo expression studies revealed that Hnf-la is necessary for the 
expression of ApoM and that its expression is directly correlated with the allelic dose of 
Hnf-la. These properties make ApoM an ideal candidate as a plasma surrogate marker 
for the possible diagnosis of MODY3. We are currently studying serum ApoM levels in 
MODY3 patients and control subjects. We are also developing an ELISA assay for high 
throughput measurement of serum ApoM levels. 
The function of ApoM remains to be determined. ApoM is hypothesized to be 
linked to the HDL assembly and secretion from the liver (266). This possibility is 
unlikely since HDL particles are found in hnf-la'' mice that does not express ApoM. 
Hnf-la deficient mice however have abnormal HDL metabolism by accumulating large 
buoyant HDL. Accumulation of large buoyant HDL in the plasma of hnf-la'' mice 
probably reflects a combined increase in HDL cholesterol esterification and decreased 
HDL phospholipid hydrolysis (39). In light of these findings, ApoM may be involved in 
the formation of large buoyant HDL by serving as activators or coenzymes for enzymes 
involved in lipoprotein metabolism. To better characterize the function of ApoM, we 
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have generated transgenic mice carrying the A p o M gene under the control of ApoAl 
promoter (ApoAl-ApoM). We will characterize the cholesterol and lipid profile of the 
ApoAl-ApoM mice as well as crossing them into Hnf-la deficient mice. 
HNF-4a is a transcription factor of the steroid hormone receptor superfamily that 
has an important role as a key regulator of pancreatic islet and hepatic gene expression. 
Genetic studies have shown that mutations in HNF-4a result in an autosomal dominant 
form of non-insulin-dependent diabetes mellitus characterized by defects in pancreatic (3-
cell function and glucose- and arginine-stimulated insulin release. Liver function has not 
been thoroughly assessed MODY1 patients. 
We have performed a genetic screen to identify hepatocyte enriched genes that are 
regulated by HNF-4a. We used the visceral endoderm (VE) of embryoid bodies that were 
derived from wt and hnf-4a null ES cells as a model system to identify HNF-4a target 
genes. The VE is functionally related to the liver and shares many molecular 
characteristics including the components of the hepatocyte nuclear factor network and 
their targets (25, 77, 267). This model also allows the analysis of transcriptional 
regulation of HNF-4a targets genes on a genomwide scale and in the context of native 
chromatin. Nine proteins that are encoded by genes that are predominantly expressed in 
the liver and secreted into the blood were strongly dependent on the expression levels of 
Hnf-4a in visceral endoderm (Fig. 7-3). We therefore tested if the serum concentrations 
of these proteins were reduced in subjects with HNF-4a haploinsufficiency as compared 
to normal control individuals and, thereby, serve as serum markers for MODY1. In order 
to differentiate between changes in gene expression that are caused by the genotype and 
effects that are due to the phenotype of the study participants, we included 4 groups in 
our study design: 1. diabetic patients with HNF-4a mutations (D-HNF4+/-), 2. non-
diabetic subjects with HNF-4a mutations (N-HNF4+/-), 3. normal matched controls (N-
HNF4+/+) and 4. matched, early-onset diabetic subjects that do not have defects in the 
MODY 1-5 genes (D-HNF4+/+). 
We found that subjects who carry a HNF-4a mutation have a significant 
reduction in serum apoAII, apoCIII, Lp(a), and triglyceride levels when compared to 
normal controls. We also observed that this reduction still holds when various genotypic 
and phenotypic comparisons were made, indicating that HNF-4a haploinsufficiency 
rather than confounding effects due to family aggregation or diabetes is the primary cause 
of the defect in lipoprotein metabolism. Our findings are in agreement with a recent study 
(263) that observed a significant reduction of triglyceride plasma levels in individuals 
carrying a MODY1 mutation. In contrast to two other reports (268, 269), we found that 
the serum levels of apoAII and Lp(a) were significantly decreased in individuals with a 
heterozygous HNF-4a mutation. We believe that one of these discrepancies can be 
explained by the fact that the HNF4(R127W) mutation in these individuals is not a 
functional mutation but rather a rare polymorphisms and therefore does not lead to 
altered HNF-4a-dependent gene expression (269, 270). The other study, reporting a 
family with a HNF-4(R154X) mutation found elevated Lp(a) and no significant 
differences in ApoAII, Oil and triglyceride levels (268). However, this study used a 
small sample size, including only two normal control individuals that were not well 
matched with regards to age and BMI. Another explanation for the difference in Lp(a) 
levels may be confounding factors that were not ruled out. For example, Lp(a) shows 
wide quantitative variation among individuals, the variations in concentration are 
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heritable and the LPA gene itself accounts for almost all genetic variability in plasma 
Lp(a) levels (271, 272). Differences in Lp(a) concentrations between HNF-4a*'* and 
HNF-4a*'~ individuals may therefore also be due to genetic variation in the LPA gene 
itself. 
The serum levels of some HNF-4a-regulated genes including TFN, alAT, 
IGFBP-1, ApoAl and ApoB were not decreased in subjects with HNF-4a mutations. 
Several reasons may account for this finding. Insulin and glucose levels per se can alter 
gene expression and this effect may be stronger and mask differences between genotypes. 
For example, IGFBP-1 gene expression is known to be markedly upregulated in diabetic 
subjects and this may account for the elevated IGFBP-1 serum levels in D-HNF-4+/-
subjects (273). The lack of reduction in other HNF4-regulated serum factors may also be 
explained by compensatory posttranscriptional mechanisms. Lastly, differences in gene 
expression of HNF-4a target genes between human and mice may exist. 
The mechanisms by which HNF-4a regulates expression of the above genes are 
unknown but are likely to be both direct and indirect. Some of these genes, including Apo 
All and ApoCIII, are known to contain HNF-4a binding site and therefore may be 
directly regulated by HNF-4a (262, 274). HNF-4a may also mediate its regulation of 
these target genes through a transcriptional cascade involving HNF-la (77, 80). 
However, there may be a subset of genes that is regulated by HNF-4a but not by HNF-
la since the expression of the glycolytic gene aldolase B is decreased in the absence of 
HNF-4a but not in the absence of HNF-la (25, 36). Such a subset of genes could in 
theory serve as a molecular marker to be used to differentiate between MODY1 and 
MODY3. 
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Our data suggests that the decrease in apoAII, apoCIII, Lp(a) are caused by 
impaired transcriptional activation of these genes due to HNF-4a haploinsufficiency. 
These transcriptional changes in the liver lead to a decrease in the serum levels of these 
factors. Lowered triglyceride concentrations may be due to an increased lipoprotein 
lipase (LPL) activity since apoCIII is an inhibitor of LPL-activity in vitro (275) and 
transgenic mice overexpressing human apoCIII have elevated triglyceride levels in 
plasma due to the presence of enlarged triglyceride-rich lipoproteins with increased 
apoCIII levels (276). Low apoll levels may also contribute to decreased triglyceride 
levels since overexpression of apoll in transgenic mice leads to hypertriglyceridemia 
(277), and apoAII deficiency in knockout mice are associated with low free fatty acid 
(278). However, a 25% decrease in apoAII levels are unlikely to have a major effect on 
lipid metabolism, since human deficiency of apoAII has little influence on either lipid 
and lipoprotein profiles or the occurrence of cardiovascular disease (279). Subjects with 
HNF-4a mutations may have a slightly lower risk of developing cardiovascular 
complications since Lp(a) and triglycerides, two independent risk factors for 
cardiovascular diseases, are reduced. Our finding here were later corroborated by hnf-4a 
liver specific knock-out mice which also showed an atheroprotective serum lipid profile 
(264). 
Our data suggest that HNF-4a is a central regulator of glucose and lipid 
metabolism and that the development of HNF-4a-agonists and antagonists may be 
powerful drugs for the treatment of insulin secretion defects or dyslipoproteinemias, 
respectively. Ideally, any future therapeutic drug development that targets HNF-4a to 
improve B-cell function should increase HNF-4a activity and exhibit pancreatic (3-cell 
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tissue specificity whereas selective improvement of lipoprotein metabolism may be 
achieved with HNF-4a-antagonists in the liver and intestine. 
In summary, genotype/phenotype relationship studies can dissect primary and 
secondary defects of pancreatic 3-cell dysfunction and lipid/lipoprotein metabolism. 
Altered hepatocyte gene expression contributes to the phenotype of HNF-4a/MODYl 
diabetes. HNF-4a haploinsufficiency causes primary defects in lipoprotein metabolism 
and is independent of altered glucose metabolism. HNF-4a-dependent serum protein 
profiles may in the future serve as molecular markers that can be used for the differential 
diagnosis of MODY1 diabetes from type 2 diabetes or other forms of MODY. 
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C h a p t e r 8: Materials a n d M e t h o d s 
Vectors. 
The sequences of all the clones were confirmed by dideoxynucleotide sequencing 
at the Protein/DNA Technology Center (Rockefeller University, NY). 
pCMV-pHNF4a: The construction of expression vector pcDNA3-pHNF4a was 
generated by cloning a EcoRI hnf-4 a fragment from pCMV-pHNF-4a (25). 
pcDNA3-pHNF-la: The vector pcDNA3-pHNF-la was generated by cloning a 2.8 kb 
Notl/BamHl fragment from pBJ5-pHNF-la (a gift from G. Crabtree)(80) containing the 
entire rat HNF-la coding sequence into pcDNA3. 
pCDNA3-pSHP: The pCDNA3-pSHP expression vector was constructed by PCR 
amplification of an 850 bp mouse Shp fragment that contained the entire open reading 
frame using mouse liver cDNA as a template. This fragment was cloned into the EcoRI 
site of pcDNA3. 
pGL2-pSHP: The reporter plasmid pGL2-pSHP was constructed by PCR amplification of 
the human SHP-1 promoter (Genebank accession no. AF044316), using oligonucleotides 
SHP-Pm-1 (5' TCCTAGACTGGACAGTGGGCA-3') and SHP-Pm-2 (5' 
CTTCCAGCTCTCTG GCTCTGT-3") and subsequent cloning of the 582 bp fragment 
into plasmid pPCR2.1. A Kpnl/Xhol fragment from this plasmid was then subcloned into 
the pGL2, inserting the SHP promoter upstream of the luciferase reporter gene. 
pGL2-pSHPmut: Vector pGL2-pSHPmut was generated by PCR using oligonucleotides 
SHPmut-F (5'-TCCTAGACTGGACAGTAA AAAAAGCCT-3') and SHP-Pm-2, and 
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pGL2-pSHP as a template. This fragment, containing a mutated HNF-4 binding site, was 
cloned into pPCR2.1 prior to insertion into pGL-2. 
pGL2-pASBT: The reporter plasmid pGL2-pASBT was constructed by PCR 
amplification of the human SCL10A2 promoter using oligonucleotides ASBT1 (5'-
GGTTGCCCTGGAAGGAAATGG-3') and ASBT2 (5' 
GCCCTGGCTCTGCTGCTGGTTG-3') and subsequent cloning of the 1854 bp fragment 
into plasmid pCR2.1. A Spell EcoRV fragment from this pPCR2.1-pASBT was then 
subcloned into the pGL2 (pPGL2-pASBT), inserting the SCL10A2 promoter upstream of 
the luciferase reporter gene. 
pGL2-pASBTmut: Vector pGL2-pASBTmut was generated by PCR using 
oligonucleotides ASBTmutlA3 (5'-CAAACCCTCGAGGACAGGGGACAT-3') and 
ASBT2, using pCR2.1-pASBT as a template. This 308 bp fragment, containing a mutated 
Tcfl binding site, was cloned into pCR2.1. A 0.3 kb Xhol fragment from this plasmid 
was inserted into pGL2-pASBT Xhol fragment to create pGL2-pASBTmut. 
pBS-pFxr-1: To identify the Fxr-1 promoter, we screened a mouse (Svl29) genomic 
library in lambda Fix II (Stratagene). Three identical phage clones were identified that 
contained the Fxr-1 promoter. A 1.2 kb EcoRI Fxr promoter fragment containing the 
transcription start site was subcloned into pBluescript KSII to generate pBS-pFxr-1. 
pGL2-pFxr-l: pBS-pFxr-1 was used as a template to PCR amplify the Fxr-1 promoter 
using oligonucleotides T7 and FXR lpromR (5' 
GAGAAGGACTCGAGGTAAGAAGCGACAGG-3'). The PCR product was blunt-
ended with Klenow and then digested with Xhol, prior to cloning into a blunted Sacl and 
a Xhol site of pGL2. The resulting plasmid was named pGL2-pFxr-l. 
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HNF-3a Targeting Construct. 
The hnf-3 a gene was isolated from a XFIXII murine 129/Sv genomic library 
(Stratagene, CA). hnf-3a was mutated by targeted deletion of the DNA binding domain 
and the C-terminal transcriptional transactivation domains by homologous recombination 
in ES cells. To generate the hnf-3 a targeting vector, an approximately 2.0 kb Xhol/AlflU 
fragment (5' short arm) containing the first exon, intron, and part of exon 2 was inserted 
into the modified targeting vector pPNT with an in-frame fusion of the E.coli lacZ gene 
(93). The 3'-end of the targeting vector was generated by cloning an 8.0 kb NhellSacl 
fragment downstream of the neomycin resistance gene (Fig. 2-1). 
Generation of pPdx-1-pEGFP Transgenic Mice. 
To identify the pdx-1 promoter, we screened a mouse (Svl29) genomic library in 
lambda Fix II (Stratagene, CA). Two identical phage clones were identified that 
contained the pdx-1 promoter. A 4.5 kb pdx-1 promoter was cut using SacII and Smal 
(position 245 bp in the first exon) sites and was cloned into pBluescript KSII to generate 
pBS-pPdx-1. The promoter was then cloned into pEGFP-1 (Clontech, CA) to generate 
pPdx-1-pEGFP. A 5.8 kb pPdx-1-pEGFP fragment was cut out using SacII and DraRl 
and injected into pronucleus (The Rockefeller University Transgenic Service Facility, 
NY). Mice containing the transgene were confirmed by Southern blot and by PCR using 
the primers GFP-3, GGGGGTGTTCTGCTGGTAGTGGTC and GFP-5, 
ATGGTGAGCAAGGGCGAGGAG. 
Animals and Genotyping. 
The mice used for chapters 2, 3, and 6 were in a mixed background. The mice 
used in chapters 4 and 5 were bred and maintained in C57/B6 background and were 
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housed in Laboratory of Animal Research Center (LARC), a pathogen-free animal 
facility at the Rockefeller University. The animals were maintained on a 12 hours 
light/dark cycle and fed a standard rodent chow. Genotyping was performed on DNA 
isolated from 3 weeks old mice by PCR. The primer sequences of the wildtype and 
mutant alleles are available upon request. 
MODY Subjects. 
HNF-4a*'' (Q268X) and non-affected individuals of the RW pedigree were 
previously identified by sequencing analysis (4). 12 diabetic patients with HNF-4a 
mutations (D-HNF4+/), six non-diabetics with HNF-4a mutations (N-HNF4+/), 12 normal 
matched controls (N-HNF4+/+) and 12 matched early-onset diabetic (MODY-X) patients 
(D-HNF4+/+) were included in the study. The N-HNF-4+/+control group consisted of six 
N-HNF-4+/+ RW relatives and six nonrelated N-HNF-4+/+ matched control subjects. 
MODY-X patients and unaffected controls were of European descent and the majority of 
these subjects were referred to the Rockefeller University GCRC. Clinical diabetes was 
defined according to the new guidelines of the expert committee on the diagnosis and 
classification of diabetes mellitus (10). Individuals were classified as MODY-X when 
their pedigrees were consistent with an autosomal dominant form of inheritance, at least 
two subjects in a given pedigree were diagnosed < 35 years of age, in the absence of 
overt obesity, and in the absence of mutations in the genes encoding MODY1-5. Study 
groups were matched for gender, age and BMI. Fasting blood glucose and insulin levels 
in MODY-X subjects (D-HNF-4a+/+) was significantly higher than than the other groups. 
This is most likely due to the different ascertainment procedure of these subjects (see 
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above) and continued insulin treatment. The clinical characteristics of the four study 
groups are shown in Table 7-1. 
Mutation Analysis. 
M O D Y - X patients were screened for mutations in the HNF-4a, GCK, HNF-la, 
PDX-1 and HNF-1 fi genes by single strand conformational polymorphism (SSCP) 
analysis as described (280). In addition, haplotype analysis was performed in the majority 
of families using markers in the MODY 1-5 gene locations. Abnormal SSCP conformers 
were reamplified and sequenced using an Applied Biosystem DNA sequencer, model 
373A, a didioxynucleotide-cycle-sequencing protocol and fluorescent labeled 
dideoxynucleotide terminators as described by Applied Biosystems. 
Biochemistry Assays 
Plasma for insulin, glucagon, and Cortisol measurements were obtained by 
collecting whole blood in heparinized capillary tubes, immediate centrifugation, and 
storage at -20°C. Insulin and glucagon levels were measured using radioimmunoassay 
(RIA) kits with rat insulin and glucagon standards (Linco, MO). Glucocorticoid levels 
were measured with a Cortisol RIA kit (Diagnostic Systems Laboratories, TX). Growth 
hormone was assayed by using a 125I-GH assay system with magnetic separation 
(Amersham Pharmacia, NJ). Total catecholamine was measured by using catecholamines 
[3H] radioenzymatic assay (Amersham Pharmacia, NJ). Glucose was measured using an 
enzymatic (glucose oxidase) assay (Sigma, MO). Serum triglyceride levels were 
analyzed using colorimetric test (Sigma, MO). Liver glycogen contents were measured 
after homogenization in ice cold perchloric acid and glycogen hydrolysis with 
amyloglucosidase as described previously (281). Quantitation of amino acids were 
performed on a Beckman Model 6300 ion-exchange instrument. 
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Bile acid concentrations in feces were determined as previously described (282, 
283). In short, bile acids were extracted from each fecal sample with 80% methanol and 
chloroform-methanol. The two extracts were combined and taken to dryness. The extract 
was resuspended in 80% methanol by sonication and stored at -20 °C. [14C] cholic acid 
(New England Biolabs) was added to determine the relative recoveries of bile acids 
throughout the procedure. Plasma was obtained by collecting whole blood in EDTA 
treated 1ml syringe, immediately centrifuging, and storing at -20 °C. Bile acid content 
from stool, serum, and urine were determined enzymatically using Sigma Diagnostics 
Bile Acid reagents (Sigma, MO). Lipoprotein cholesterol profiles of control, Tcf 1~'~ and 
Ldlr"'" mice were determined by on line post-column analysis of Superose 6 gel-filtered 
mouse plasma (284). Samples (0.2 ml) of the Superose-column filtered LDL and HDL 
peaks were extracted and analyzed for total, free and esterified cholesterol using gas 
liquid chromatography as previously described (285). ApoB levels were measured by an 
automated immunoturbidimetric assay for mouse apoB (coefficient of variation: <5%) 
(286).Cyp7al and (HMG)-CoA reductase activities were measured as describes 
previously (285). Hepatic lipase activity was measured by a continuous fluorometric 
hepatic lipase select test (Progen): the kinetic increase in fluorescence intensity is 
measured at 342 nm excitation and 400 nm emission for 10 min using luminescence 
spectrometer LS50B (Perkin Elmer). 
Concentrations of Lp(a), apoAI and apoB were determined with 
immunoturbidimetric assays from (Roche Diagnostics, Germany) using a Hitachi 917 
autoanalyser. ApoC-III was quantified with a commercially available 
electroimmunoassay (Hydragel LpA-I, Sebia, Paris, France). The coefficient of variance 
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(CV(%)) of of Lp(a) and apoB are <6.4 and 2.7, respectively. ApoA-II was determined 
independently by the use of an immunoturbidimetric test from Immuno (Vienna, Austria) 
with a Cobas Bio analyzer (Roche Diagnostics, Germany) and an ELISA test. For the 
latter, mouse anti-human apo All monoclonal antibody (Perlmmune), diluted 1:100 in 
bicarbonate buffer, was applied to wells of Nunc Maxisorb ELISA plates and incubated 
overnight at 4°C. All subsequent incubations were performed at room temperature with 
gentle agitation. Wells were washed with PBS and blocked with casein blocker (Pierce) 
for one hour. Serum standards (Kamiya Biomedical) and serum samples, diluted 1:30,000 
in buffer A (casein blocker/0.5% tween20), were applied to the wells for 1 hour. Plates 
were washed with buffer B (PBS/0.5% Tween 20) and a biotinylated goat anti-human 
apoA-II polyclonal antibody (Biodesign), diluted 1:1000 in PBS/1% BSA, was applied 
for 1 hour. After washing, streptavidin-HRP (Pierce), diluted 1:1000, was applied for 1 
hour. HRP enzyme was detected by incubation with TurboTMB substrate (Pierce). The 
reaction was terminated with IM sulfuric acid, and the absorbance was measured at 450 
nm on a SpectraMax plate reader (Molecular Devices). The CV(%) of this test was <7. 
Serum concentrations of a 1-antitrypsin, ceruloplasmin, and transferrin were determined 
by rate nephelometry on a Beckman Array 360 (Beckman-Coulter, Brea, CA) using 
specific antibodies to each analyte. The system measures the intensity of light as it is 
scattered by particles in suspension when a beam of light is passed through a flow cell. 
The resulting antigen-antibody reaction is converted to a peak rate signal and is 
proportional to sample antigen (analyte) concentration. CV(%) were 4.2, 3.4 and 2,7, 
respectively. Serum triglyceride concentrations were determined using an enzymatic, 
colorimetric assay (GPO-Trinder, Sigma, MO). The coefficient of variance of this test is 
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<5%. Serum IGFBP-1 concentrations were measured by using an immunoradiometric 
assay and antibodies specific for human IGFBP-1 (DSL). 
Measurements of Pyruvate Kinase Activity. 
Pyruvate kinase enzyme activity was measured in extracts of islets isolated from 
four mice. Following overnight culture in RPMI 1640 containing 11.6 mM glucose, 
islets were hand picked, washed twice in PBS and transferred to a homogenization buffer 
consisting of 200 mM mannitol, 70 mM sucrose, 5 mM potassium HEPES buffer, pH 7.5 
and 1 mM dithiothreitol. The islets were washed twice in buffer containing 1 mM EGTA 
and then twice in the buffer without EGTA. The islets were then sonicated (Ultrasonics 
Sonicator Cell Disrupter, Model W 185 F, Heat Systems, Inc. Plainview, NY) and 
centrifuged at 105,000 x g for 60 minutes at 4C. The protein content of the islet extracts 
was measured (Biorad, #500-0006) and the activity was measured in equivalent amounts 
of protein from the different mice. Pyruvate kinase enzyme activity was measured in a 
reaction buffer consisting of 80 mM triethanolamine chloride buffer, pH 7.5, 5 mM 
MgS04, 100 mM KCI, 2.5 mM ADP, 0.14 mM NADH, 1 mM dithiothreitol and 7 mM 
phosphoenolpyruvate and 2.5 U of lactic dehydrogenase (all reagents were purchased 
from Sigma, St Louis, MO). Each reaction was carried out in a final volume of 1 ml and 
was started by the addition of the islet extract. NADH levels were measured as 
fluorescence emitted at 448 nm in response to excitation at 340 nm for ten minutes. The 
rates of consumption of NADH were similar in hnf-la*'* (n=4), hnf-la*'" (n=5), and hnf-
la~'~(n=A) mice. 
Generation ot pdx-T' ES Cells. 
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pdx-1 null ES cells were generated by culturing the pdx-1*1' ES cells (55) in either 
1.5 mg/ml or 2.0 mg/ml of G418 in ES medium. DNA from resistant ES cell clones were 
digested with EcoRI and the Southern blots were hybridized with the 3' external probe 
(55). The 3 kb and 3.8 kb bands on the Southern blot represent endogenous and targeted 
pdx-1 locus respectively. 
Maintenance of Undifferentiated ES Cells in vitro. 
ES cells were grown on 0.1% gelatin-coated tissue culture plates in ES cell 
medium supplemented with 1,000 units ml"1 of ESGRO (Chemicon International, CA) 
over a primary embryonic fibroblast feeder layer. ES cell media is composed of 
Dulbecco's Modified Eagle's Medium (DMEM) (Specialty Media, NJ) supplemented 
with 25 mM glucose, 15% fetal bovine serum (FBS) (Atlanta Biologicals, GA), non-
essential amino acids (NEAA), 110 mg/L sodium pyruvate, 365 mg/L L-glutamine, and 
0.55 mM P-mercaptoethanol (BME). 
Differentiation of ES Cells into Insulin-Producing Cells 
The differentiation protocol is composed of 4 stages. It begins with culturing ES 
cells on gelatin-coated tissue culture plates in ES cell media in the absence of primary 
embryonic fibroblast feeder layer and ESGRO to sub-confluency (stage 1). To induce 
embryoid bodies (EB) formation (stage 2), cells were dissociated in trypsin/EDTA (Life 
Technologies, NY) and plated onto non-adherent bacterial culture dishes at a density of 
2-3xl04 cells cm"1 in ES cell medium and cultured for 3 days. Differentiation must be 
restarted if EB are not metabolically active; media must turn yellow every day. Selection 
and expansion of endocrine/neural progenitor cells comprised stage 3 differentiation. It 
was initiated by trypsinizing EB for < 5 min and plated onto tissue culture dishes coated 
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for 3 hours (hrs) with 0.1% gelatin (Sigma, M O ) , 0.1% poly-D-lysine (Sigma, M O ) , and 
1 figlml fibronectin (Life Technologies, NY) dissolved in PBS. Differentiation must be 
restarted if less than 50% of the dissociated EB attach. The cells were maintained in ES 
medium until they grow to sub-confluence (< 3 days), after which the selection of 
endocrine/neural precursors were initiated by using serum-free ITSF medium. ITSF 
medium is composed of DMEM/F12 (Rockefeller Tissue Culture Service, NY), 
supplemented with 25mM glucose, NEAA, 55 mg/L sodium pyruvate, 365 mg/L L-
glutamine, 0.55 mM BME, ITSX (Life Technologies, NY), and an additional 45mg/L 
transferrin (Life Technologies, NY). After the cells were reduce to approximately 20% 
confluent, cell expansion was initiated by culturing in ITSF medium supplemented with 
B27 (Life Technologies, NY), 10 ng/ml basic fibroblast growth factor (bFGF) (R&D 
Systems, MN), and 100 ng/ml (3 nerve growth factor (NGF) (R&D Systems, MN). They 
were expanded until sub-confluent. If cells do not aggregate at the end of this stage, 
differentiation must be restarted. Terminal differentiation (stage 4) was comprised of 2 
phases. It started by culturing the cells in differentiation medium with 100 ng/ml (3NGF 
and 12.5 mM glucose for 2 days, and then with 6 mM glucose for 4 days. Differentiation 
medium was composed of RPMI medium supplemented with 2.5% FBS, NEAA, 110 
mg/L sodium pyruvate, 365 mg/L L-glutamine, B27, and lOmM nicotinamide (Sigma, 
MO). 
Detecting (3-galactosidase Activity in Living Cells. 
The presence of (3-galactosidase ((3-gal) was detected in LacZ/Pdx-1 positive cells 
by the vital fluorescent (3-gal substrate, 5-chloromethylfluorescein di-[3-D-
galactopyranoside (CMFDG) following manufacture's instructions with minor 
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modifications (Molecular Probes, OR). Briefly, cells were dissociated from the surface of 
tissue culture dishes by trypsin/EDTA. These cells were washed in medium and pelleted 
for 5 min at 500G. 50 million cells were gently resuspended (by tapping only) in 1 ml of 
loading medium containing 1 mM CMFDG and 50 /xM verapamil and incubated at 37°C 
for 10 mins. 150 ml of hypotonic lysis medium (6 parts medium without serum and 4 
parts deionized water) was added to the cell suspension, mixed by gentle inversion, and 
incubated at RT for 1 minutes. Cells were pelleted for 1.5 mins at 500G and resuspended 
in 50 ml of growth medium containing 1.5 /xM propidium iodide to facilitate the 
identification of dead cells incurred during the procedure. These cells were incubated at 
37°C for 30 minutes before examination. Data for flow cytometry was acquired on 
FACSCalibur™ (Becton Dickinson, CA). For FACS experiments, LacZ/Pdx-1 positive 
cells were isolated using Coulter Altra Cell Sorter™ (Beckman Coulter, CA), Cornell 
Sort-Stat Sort Stabilization Device© (Weill Medical College of Cornell University, NY) 
and a Coulter Sort Sense quartz flow cell tip (Beckman Coulter, CA) by C. Colon at the 
Cornell Weill Flow Cytometry Core Facility. Excitation of fluorescein and propidium 
iodide was accomplished with a Coherent Enterprise™ Argon laser 15 mw at 488nm. 
Sheath fluid used was Coulter Isoflow (Coulter, CA). 
Data for both flow cytometry and FACS were analyzed using FlowJo software 
(Tree Star, Inc., CA). 
BrdU Labeling and Staining for Flow Cytometry. 
BrdU staining was performed by using the BrdU Flow Kit (BD Pharmingen, CA) 
and following the manufacturer's protocol. Briefly, cells during day 2 phase 3 of 
differentiation stage 3 exposed for 6 hours to 0.01 mM BrdU and chased for 12 hours 
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with tissue culture media. Cells were then loaded with C M F D G (Molecular Probes, OR). 
Fixation and permeabilization was done with Cytofix/Cytoperm Buffer (BD Pharmingen, 
CA) for 30 minutes at room temperature and were washed in Perm/Wash Buffer (BD 
Pharmingen, CA). Cells were refixed in Cytofix/Cytoperm Buffer for 5 minutes at room 
temperature and washed again in Perm/Wash Buffer. Cells were then treated with 30 /xg 
of Dnase for every 1 million cells and incubated for 1 hours at 37°C. Cells were washed 
in Perm/Wash Buffer and stained with anti-BrdU antibodies for 20 minutes at room 
temperature. Data were acquired on FACSCalibur™ (Becton Dickinson, CA) and 
analyzed using FlowJo software (Tree Star, Inc., CA). 
Annexin V-PE Labeling and Staining for Flow Cytometry. 
Annexin V staining were performed using Annexin V-PE apoptosis detection kit I 
(BD Pharmingen, CA) following manufacture's instructions. After loading the cells with 
CMFDG (Molecular Probes, OR), the cells were resuspended in Annexin V binding 
buffer and stained with 1 test unit of Annexin V conjugated to the fluorochrome 
Phycoerythrin (PE) and 1 test unit of 7-amino-actinomycin D (7-AAD) (BD Pharmingen, 
CA) for every 1 X 105 cells. The cells were then incubated for 15 minutes at room 
temperature in the dark. Data were acquired on FACSCalibur™ (Becton Dickinson, CA) 
and analyzed using FlowJo software (Tree Star, Inc., CA). 
Tissue Culture, Transient Transfections and Luciferase Assay. 
Cos7 and HepG2 cells were grown on MEM supplemented with 10% fetal calf 
serum and DMEM supplemented with 15% fetal calf serum, respectively. HIT-T15 cells 
were grown in DMEM supplemented with 5% fetal calf serum and 10% horse serum. 
MIN cells were grown in ES cell media (See maintenance of undifferentiated ES cells in 
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vitro). A modified calcium phosphate precipitation procedure using calcium phosphate 
transfection system (Life Technologies, NY) was used for transient transfections. In 
short, 0.5 ml of the precipitate, containing 1 /xg of CMV-LacZ, 0.5 tig of luciferase 
reporter construct, the indicated amount of expression vectors and carrier DNA (up to 10 
/xg), were added per 60 mm dish. Luciferase was normalized for transfection efficiency 
by the corresponding (3-galactosidase activity (287). 
Nuclear Extract Preparation. 
In vitro cultured cells: cells were lysed in hypotonic buffer (20 mM Hepes, pH7.9, 10 
mM KCI, 0.1 mM Na3V04, ImM EDTA, 10% Glycerol, IX complete protease inhibitor 
(Roche, Germany), 20 mM NaF, and 1 mM DTT) with 0.2% NP40 on ice for 10 minutes. 
After centrifugation at 4°C (1200 G) for 2 minutes, the supernatants were collected as 
cytoplasmic extracts. The crude nuclei (pelleted) was washed in hypotonic buffer before 
resuspending in hypertonic buffer (hypotonic buffer with 20% glycerol and 420 mM 
NaCl), rocked for 30 minutes at 4°C, and the supernatants were collected after 
centrifugation at 4°C (1200 G) for 10 minutes. 
Animal Tissues: Tissues were removed and dounce-homogenized 15 times in 100:1 (v:v) 
of buffer A (10 mM KCI, 1.5 mM MgCl2, 10 mM Hepes pH 7.9, 1 mM DTT, 1 mM 
NaV04, lx complete TM protease inhibitor (Roche, Germany). After centrifugation at 
2,000xg for 10 min at 4 °C, the pellet was resuspended in 4 volumes of the same buffer, 
dounced 10 times and centrifuged again at 2,000xg. The nuclei containing pellet was 
resuspended in 2 volumes of buffer B (420 mM NaCl, 10 mM KCI, 20 mM Hepes pH 
7.9, 20% glycerol, 1 mM DTT, 1 mM NaV04, lx complete TM protease inhibitor) and 
extracted for 30 min at 4 °C on a shaking rotor. After centrifugation at 16,000xg, the 
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supernatant was diluted 10 fold in buffer C (10 m M KCI, 20 m M Hepes pH 7.9, 2 0 % 
glycerol, 1 mM DTT, 1 mM NaV04, lx complete TM protease inhibitor) and centrifuged 
for 15 min at 16,000xg. The supernatant was loaded onto a Biomax-50 filter unit 
(Millipore) and centrifuged for 2 h at 4,000xg at 4 °C. The protein concentration of the 
concentrated and desalted sample was determined by Bradford assay (BIO-RAD). 
Whole Cell Extract Preparation. 
Whole cell lysates were prepared in RIPA buffer (IX PBS, 1% NP40, 0.5% 
sodium deoxycholate, 0.1% SDS, and IX complete protease inhibitor) and rocked for 
4°C for 30 minutes, and supernatants were collected after centrifugation at 4°C (1200 G) 
for 10 minutes. Protein concentrations were determined using Bicinchoninic Acid Protein 
Assay Kit (Sigma, MO). 
Western Blot Analysis. 
20 /xg of nuclear extract, total cell extract, or total tissue extract was separated by 
10% SDS-PAGE and transferred onto a nitrocellulose membrane (Schleicher&Schuell, 
NH) by electroblotting (30 min, 15 V). Expression of organic anion transporter proteins 
on the basolateral (SlclOal, Oatpl) and canalicular (Abcbl 1) membranes of liver was 
analyzed in crude liver membranes (100,000 x g pellet) of WT, hnf-la*'' or hnf-la'' 
mice. The preparation of liver membranes have been described previously (288, 289). 
Pdx-1 was detected with rabbit anti-Pdx-1 antiserum (1:500). 
Tcfl was detected with rabbit anti-Tcfl (1:300) polyclonal antibody (Geneka 
Biotechnology Inc., Canada). 
Fxr was detected with goat anti-FXR (1:1000) polyclonal antibody (Santa Cruz, CA). 
Slcl0a2 was detected with rabbit anti-Slcl0a2 (1:2000) antibody. 
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Slc21a3 was detected with rabbit anti-Slc21a3 (1:1000) antibody. 
SlclOal was detected with rabbit anti-SlclOal (1:1000) antibody. 
Abcbll was detected with rabbit anti-Abcbll (1:2500) antibody. 
ApoAl was detected with mouse anti-ApoAl (1:1000) antibody (Biodesign 
International). 
GTP binding stimulatory protein (Gs) was detected with rabbit anti-Gs (1:1000) antibody 
(generous gift of T. Sakmar). 
Tbp was detected with rabbit anti-TBP (1:3000) antibody (generous gift of M. 
Teichmann). 
Goat anti-rabbit IgGs conjugated to HRP (Santa Cruz, CA) was used at 1:10,000. 
All antibodies were dissolved in 5% milk in TBS with 0.5% Tween-20. The blots 
were washed 3 times 15 min each between each antibody incubation. All the primary 
antibodies were incubated over night at 4°C and the secondary antibody incubation were 
done at RT for 1 hr. For visualization, the Renaissance chemiluminescence substrate 
(NEN, MA.) was used. 
Electrophoretic Mobility Shift Analysis. 
In vitro translated proteins, total cell extracts, or nuclear cell extracts were 
incubated with 32P-labeled ds-stranded oligonucleotide probes containing the 
transcription factor binding sites. The 15 /xl reaction mixture contained 20 mM Hepes 
buffer pH 7.9, 40 mM KCI, ImM MgCl2, 0.1 mM EGTA, 0.5mM DTT, 4% Ficoll and 2 
/xg poly(dldC) at 25°C for 20 min. Supershift analysis was performed by incubating the 
antibody with the protein or nuclear extracts for 5 min on ice before adding the probe. 
The reaction mixture was loaded on a 6% non-denaturating polyacrylamide gel 
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containing 0.25 x TBE buffer (0.023 M Tris-borate, 0.5 m M EDTA) and run at 4DC. The 
list of transcription factor binding site is listed below: 
Hnf-4a binding site in SHP promoter: sequences: 5' TGGACAGTGGGCAAAGTCC-
TCCC-3' and 5'-TGGACAGTAAAAAAAGTCCT CCC-3', respectively. 
Tcfl binding sites in the Slcl0a2 promoter: sequences: 5'-AGGACATTAAACATTAA-
CGTGGCTC-3' and5'-AGGACAGGGGACATTAACGTGGCTC-3', respectively. 
Tcfl binding site in the Fxr-1 promoter: sequence: 5'-GATGGGGGTTAATCAAGT-
AAACCACAC-3'. 
Tcfl binding site in the insulin growth factor binding protein: sequence: 5'-
ACTGGTTAATGATTGGCATGC-3' (239). 
Immunohistochemistry and Immunofluorescence Analysis. 
Immunofluorescent analysis was performed on differentiated ES cells grown on 
fibronectin coated coverslips (Becton Dickinson, CA). Cells were fixed for 30 minutes 
with 4% paraformaldehyde, washed with lOmM glycine in PBS, and permeabilized with 
0.1% Triton X (if detecting cytoplasmic protein). Cells were blocked for 30 min with 5% 
normal donkey serum in PBS. Primary antibodies used were guinea pig anti-insulin 
(1:600) (Linco, MO), rabbit anti-glucagon (1:300) (Linco, MO), and rabbit-anti-Pdx-1 
antibody (1:300). Secondary antibodies used were Rhodamine Red conjugated donkey 
anti-guinea pig (Jackson Immunoresearch, PA) and Alexa Fluor 488 conjugated donkey 
anti-rabbit (Molecular Probes, OR) at a dilution of 1:100 and 1:600 in PBS respectively. 
Hybridization with primary antibodies was done at 4°C overnight in a humidified 
chamber. Hybridization with secondary antibodies was done at room temperature for 1 
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hour. Sections or ccells were washed three times in PBS between each step and were 
mounted using Prolong Antifade Kit (Molecular Probes, OR). 
Glut 2 immunofluorescence was performed on 5 |im sections from 6 weeks old 
hnf-la*'*, hnf-la*'", and hnf-la~'~ mice which were prepared as previously described 
(41). Sections were blocked for 30 min with normal rabbit serum at a concentration of 
1:100, in PBS. Sections were stained with rabbit anti-mouse Glut2 antibody (Chemicon 
International Inc., Temecula, CA) in PBS at a dilution of 1:200. The secondary antibody, 
a TRITC-labeled guinea pig anti-rabbit IgG, was applied at a concentration of 1:100 in 
PBS. Sections were washed twice in PBS between each step and after the application of 
the secondary antibody, and were mounted in PBS:glycerol, 1:9. 
For Slcl0a2 immunohistochemistry, mice were perfused with 4% 
paraformaldehyde through the heart and ileum was post fixed in 4% paraformaldehyde 
for 15 min, dehydrated, and embedded in paraffin. Seven micrometer sections were cut, 
deparaffinized, rehydrated, and permeabilized in 0.2% TritonX-100 for 20 min, blocked 
with 0.3% H-,0-, for 20 min, and 4% normal goat serum for 1 h. Sections were stained 
with rabbit anti-Slcl0a2 antibody in PBS at a dilution of 1:200 for 1 hr (289). The slides 
were washed with PBS before incubation with a secondary biotinylated anti-IgG 
antibody. Sections were developed using the ABC kit and DAB substrate (Vector 
Laboratories) and counterstained with hematoxylin (Sigma, MO). 
Image analysis were performed using Zeiss LSM 510 confocal laser scanning 
microscope (Zeiss, Germany) with three detectors, differential interference contrast 
(DIC), and an argon-krypton (Ar/Kr) laser for simultaneous scanning of two different 
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fluorochromes and DIC microscopy. Images were acquired using L S M 510 software 
package (Zeiss, Germany). 
Morphometric Analysis 
The pancreata were fixed in paraformaldehyde and stained for insulin and 
glucagon as described above. Sections (7 u,m) through the entire pancreas were taken, 
and every sixth section was used for morphometric analysis. At least 288 nonoverlapping 
images (pixel size 0.88 \xm) were scanned using a confocal laser scanning microscope 
(Zeiss LSM 510, Germany). The morphometry parameters were analyzed by using the 
METAMORPH software package (Universal Imaging, PA). The areas covered by cells 
stained by insulin or glucagon were integrated by using stained objects that are greater 
than 3 pixels in size. 
Cryostat Sections. 
For cryostat sections, the animal were perfused in 4% paraformaldehyde, the 
tissue of interest were post-fixed in 4% paraformaldehyde for 30 minutes at room 
temperature, washed 3 times for 15 minutes each in PBS, and incubated overnight in 30% 
sucrose in PBS. Embryos were then mounted in Tissue-Tek (Miles Scientific, Naperville, 
IL). 7 /xm sections were cut in a cryostat, collected in Superfrost slides (Fisher, PA), and 
stored in -80°C until examination. 
X-gal Staining. 
Differentiated ES cells grown on fibronectin coated coverslips (Becton Dickinson, 
CA) were fixed in 0.2% gluteraldehyde, 5 mM EGTA, 2 mM magnesium chloride in 
sodium phosphate buffer (pH. 7.3) for 5 minutes. Cells were washed 3 times, 5 minutes 
each in wash buffer (2.5 mM magnesium chloride, 0.01% deoxycholate, 0.02% Nonidet-
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P40 in sodium phosphate buffer pH. 7.3) and stained overnight in I m M 5'-bromo-4-
chloro-3-indolyl-(3-D-galactopyranoside (X-gal) (Roche, Germany) in wash buffer. 
Electronmicroscopy 
For negative staining, the fractions were mixed with an equal volume of a 2% Na-
phosphotungstate solution at neutral pH. Samples were adsorbed onto a formvar-carbon-
coated 400-mesh grid for one minute. Excess fluid was removed with a torn filter paper 
and air-dried. Samples were studied and photographed in a JOEL 100CX at an 
accelerating voltage of 80 kV. Pictures were taken at magnifications ranging from 
x50,000 to x 100,000. 
Isolation of Pancreatic Islets and Newborn Pancreata. 
Pancreatic islets were isolated from 4 to 6 week-old mice. We used collagenase 
digestion and differential centrifugation through Ficoll gradients, with a modification of 
procedures previously described (290). Islets were cultured overnight in RPMI1640 
medium supplemented with 10% fetal calf serum and 11.1 mM glucose. Islets were then 
double hand picked the next day and then used for subsequent analysis. Whole pancreata 
were removed from newborn mice and immediately snap frozen in liquid nitrogen or 
homogenized in TRIzol reagent (Life Technologies, NY). 
Measurement of Total Intracellular Insulin Content. 
Insulin was extracted from pancreatic islets or differentiated cells with acid 
ethanol (10% flacial acetic acid in absolute ethanol), sonicated for 1 minute, and 
centrifuged 2 times at 4°C at 12,000 G for 10 minutes. Supernatants are collected and 
stored in -20°C for insulin determination by Ultra Sensitive Insulin Elisa Kit (Crystal 
Chem, IL). 
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Measurement of Insulin Release. 
For static measurements of insulin release: 20 size-matched islets or differentiated cells 
grown on 6 well plate were washed twice in D-PBS/BSA/HEPES (Dulbecco's PBS, 
supplemented with 2g/l bovine serum albumin and 20mM HEPES (pH7.4)). They were 
then preincubated in 1ml of D-PBS/BSA/HEPES with 3.3mM (for glucose and 
sulphonylurea induction) or 6.6mM glucose (for GLP-1 induction) at 37°C for 30min. D-
PBS/BSA/HEPES are collected at the end of pre-incubation for baseline values. After 
preincubation, islets or differentiated cells were washed twice in D-PBS/BSA/HEPES 
and incubated in 1ml of D-PBS/BSA/HEPES with 16.7mM glucose (for glucose 
induction), 3.3mM glucose and 500/xM tolbutamide (for sulphonylurea induction) 
(Sigma, MO), or 6.6mM glucose and lOOnM hGLP-l(7-36) (for GLP-1 induction) 
(Sigma, MO) at 37°C for 30min. After incubation, media was collected and kept at -20°C 
for insulin ELISA assay (Crystal Chem, IL). 
For in vivo measurement of insulin release: For in vivo insulin release, glucose (3 g/kg 
body weight) was injected IP. Venous blood was collected at 0, 2, 5, 15, 30, 60, 120 min 
in heparinized tubes, centrifuged, and the plasma stored at -20°C. Insulin levels were 
measured with an ultrasensitive ELISA assay (Crystal Chemical, IL). 
Glucose Tolerance Test 
On 3 days old mice: Glucose tolerance tests were performed by intraperitoneal or 
subcutaneous glucose injection (2g/kg body weight). Whole blood was obtained from 2-
3 days old mice by decapitation 1 hr after glucose injection. Blood glucose was 
measured using an enzymatic assay (Sigma, MO). 
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On adult Mice: Mice were fasted overnight for 12 hr followed by intraperitoneal (IP) 
glucose injection (2 g/kg body weight). Venous blood was obtained from the tail vein at 
0, 15, 30, 60, and 120 min after the injection. Blood glucose was measured using an 
automated glucometer (Encore, Bayer). 
Selective Amplification via Biotin- and Restriction-Mediated Enrichment (SABRE). 
SABRE subtraction was performed as described previously (291). Double 
stranded cDNA is produced from oligo(dT) purified mRNA and digested with Sau3AI. 
Linkers were annealed to the digested overhangs containing an BamHI restriction site. 
"Tester" cDNA, in which differential messages are to be detected, was PCR reamplified 
with a biotinylated primer containing the Bam HI site. "Driver" or reference cDNA was 
amplified with a non-biotinylated primer containing a mutant Bam HI site. 33-fold excess 
of driver was hybridized to biotin-labeled tester, after which tester-tester homohybrides 
(representing differentially expressed genes) are purified by paramagnetic beads and 
digestion with Bam HI (292). Three rounds of subtraction were completed to enrich 
differentially expressed cDNAs. 
Gene Expression Analysis using Affymetrix Oligonucleotide Arrays 
i. Preparation of hybridization samples. 
Newborn and four-week-old tcfl wildtype and null mutant mice were sacrificed 
by CO, asphyxiation and total RNA was isolated from livers using Trizol® (Life 
Technologies, NY). RNA was pooled from five animals of each genotype for each 
experiment. RNA sample integrity was assessed by running denaturing formaldehyde 
gels. cDNA synthesis was completed with 30 /xg of total RNA cleaned with RNeasy 
columns (Qiagen). cDNA synthesis was be carried out according to the Superscript 
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Choice c D N A Synthesis Protocol (Life Technologies, NY), except an HPLC purified T7-
Promoter-dT30 primer (Genset) was used to initiate the first-strand reaction. Biotin 
labeled cRNA was synthesized from T7-cDNA using the RNA transcript labeling kit. Bio 
Array (Enzo), supplemented with biotin 11-CTP and biotin-16-UTP (Enzo) as specified 
in the Affymetrix technical manual. The sample was cleaned with RNeasy columns 
(Qiagen) to remove free nucleotides and quantitated spectrophotometrically. Biotin 
labeled cRNA was fragmented in 40 mM Tris pH 8.1, 100 mM KOAc, 30 mM MgOAc 
for 30 min at 94 °C. Hybridization samples were prepared according to the Affymetrix 
manual with a final concentration of fragmented cRNA of 0.05 /xg//xl. 
ii. Hybridization, washing, staining, and scanning of probe arrays. 
Affymetrix Genechip® Mul IK and Mul9K probe arrays were prehybridized with 
100 mM MES (Sigma) pH 6.6, lM[Na+], 20 mM EDTA, and 0.01% Tween-20 (Sigma) 
for 10 min at 45 °C. Hybridization samples were heated to 99 °C for 5 min, equilibrated 
to 45 °C for 5 min and centrifuged at 14,000 x g for 5 min to sediment any particulate 
matter. The prehybridization solution was removed and the sample was added to the 
probe array and allowed to hybridize for 16 h, rotating at 60 rpm at 45 °C. Probe arrays 
were subsequently washed and stained according to the Affymetrix technical manual in 
an Affymetrix fluidics station. The arrays were scanned using a Hewlett Packard confocal 
laser scanner and visualized using Affymetrix Genechip 3.1 software (Affymetrix). 
iii. Control experiments 
Messenger RNA levels of differentially expressed genes were studied 
independently using semiquantitative RT-PCR (See next section). 
RNA Extraction and RT-PCR. 
214 
Total R N A was extracted using TRIzol reagent (Life Technologies, N Y ) and 
following the manufacturer's instructions. Contaminating genomic DNA was removed 
using 10U of RNase free DNase-I (Boehringer Mannheim, Germany) per 5/xg of RNA. 
cDNAs were synthesized using Moloney murine leukemia virus reverse transcriptase 
with dNTPs and random hexamer primers (Stratagene, CA). The cDNAs provided 
templates for polymerase chain reactions (PCRs) using specific primers at annealing 
temperatures ranging between 60 and 65°C in the presence of dNTPs, [a-32P]dCTP, and 
Taq DNA polymerase. PCR synthesis for each primer pair was quantified at 15, 20, 25, 
and 30 cycles in a test reaction to ensure that the quantitative PCR amplification was in 
the linear range. The primer sequences used for PCR are available upon request. 
Statistical Analysis. 
Data are means ± SEM unless otherwise indicated. The statistical analysis was 
performed using the Microsoft Excel 98 statistical package (Microsoft Inc., WA). 
Student's t -test for 2 tailed analysis and unequal variance as parameters was used to 
assess statistical significance and the null hypothesis was rejected at the 0.05 level. 
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